Locoregional immunotherapy with interleukin-2 in head and neck squamous-cell carcinoma: preclinical and clinical studies by Mattijssen, E.J.M.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/145770
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
Locoregional immunotherapy with 
interleukin-2 in head and neck 
squamous-cell carcinoma 
Preclinical'and clinical studies 
. * • - * * • * * . . * ' % . 
* ì 
In*·*. ι *•-.· 
E? # • - »., 
fili *» 
V Λ · i ' 
¡¡ 'M I»".»'.» ' : ν ·%:· ."Vi •'A'S 
•Л · ; Í í i 
Vera Mattijssen 

I 
Locoregional immunotherapy with interleukin-2 
in head and neck squamous-cell carcinoma 
Preclinical and clinical studies 
Drukkerij: De Kleijn, Wijchen. 
CIP-GEGEVENS KONINKLIJKE BIBLIOTHEEK, DEN HAAG 
Mattijssen, Everdina Johanna Maria 
Locoregional immunotherapy with intcrleukin-2 in head and 
neck squamous-cell carcinoma : preclinical and clinical 
studies / Everdina Johanna Maria Mattijssen. - [S.l. : 
s.n.]. - 111. 
Proefschrift Nijmegen. - Met lit. opg. - Met samenvatting 
in het Nederlands. 
ISBN 90-9006981-Х 
Trefw.: immunothérapie / interleukinen. 
Locoregìonal immunotherapy with interleukin-2 
in head and neck squamous-cell carcinoma 
Preclinical and clinical studies 
Een wetenschappelijke proeve op het gebied 
van de Medische Wetenschappen 
Proefschrift ter verkrijging van de graad van doctor 
aan de Katholieke Universiteit Nijmegen, 
volgens besluit van het College van Decanen 
in het openbaar te verdedigen op 
dinsdag 10 mei 1994, des namiddags te 3.30 uur precies 
door 
Everdina Johanna Maria Mattijssen 
geboren op 27 januari I960 te Bemmel 
IV 
Promotores: Prof. Dr. D.J.Th. Wagener 
Prof. Dr. DJ. Ruiter 
Prof. Dr. P. Van den Broek 
Co-promoton Dr. P.H.M. De Mulder 
The studies described in this thesis were performed in the Department of Medicine, 
Division of Medical Oncology (head: Prof. Dr. D.J.Th. Wagener), the Department of 
Pathology (head: Prof. Dr. D.J. Ruiter), and the Department of Otorhinolaryngology 
(head: Prof. Dr. P. Van den Brock), University Hospital Nijmegen, The Netherlands, and 
the Laboratory for Pathology (head: Dr. J.G. Vos), National Institute of Public Health 
and Environmental Protection, Bilthoven, The Netherlands. 
These studies were financially supported by the Dutch Cancer Society. 
Aàft Wtíjñ (Wem 
VI 
VII 
Contents 
chapter page 
1. General introduction. 1 
2. Immunotherapy of cancer with interlcukin-2 with emphasis on 7 
locoregional supply: rationale, and overview of the literature. 
3. Determination of HLA antigen expression in routinely processed 31 
head and neck squamous-cell carcinoma lesions. 
4. Perilymphatic administration of recombinant interleukin-2 in 45 
patients with locally far-advanced, nonpretreated head and neck 
squamous-cell carcinoma. 
5. Recombinant interleukin-2 and PEG-interleukin-2 in locoregional 57 
immunotherapy of established guinea-pig line-10 tumors. 
6. Histological and immunohistochemical analysis of line-10 tumor 73 
regression induced by intratumoral PEG-intcrlcukin-2 therapy. 
7. Intratumoral PEG-interleukin-2 therapy in patients with 91 
locoregionally recurrent head and neck squamous-cell carcinoma. 
8. Biodistribution of interleukin-2 and PEG-interleukin-2 in the 109 
guinea-pig following intratumoral injection. 
9. Summary and general discussion. 119 
Samenvatting 125 
Appendix: Jakobsson score 129 
Dankwoord 131 
Curriculum vitae 133 
Bibliography 134 
vin 
Chapter 1 
General introduction 
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Cancer is a major health problem in Western countries. About 50% of patients in whom 
cancer is diagnosed will die of this disease. As the second cause of death, it accounts for 
22% of all deaths in the United States [1] and for 27% in The Netherlands [2]. 
Surgery, radiotherapy and chemotherapy are the keystones of cancer treatment. Recently, 
as a result of increased knowledge on host defense mechanisms and advanced biotech­
nologie developments, immunotherapy emerged as a fourth treatment modality of cancer 
[3]. Immunotherapy aims at stimulation of the host immune system to detect and to 
eliminate cancer cells. The immune system encompasses a range of immune-competent 
cells, such as Τ lymphocytes, В lymphocytes, natural killer (NK) cells, monocytes, 
macrophages and granulocytes, whose natural functions are regulated by soluble protein 
products of mainly lymphocytes and monocytes, called cytokines. 
Interleukin-2 
One of the first cytokines recognized was interleukin-2 [4]. This IL-2 has a pivotal role in 
the generation and regulation of the immune response [5]. IL-2 is secreted by Τ lym­
phocytes upon antigenic stimulation of the Τ cell receptor. Subsequently, it induces clonal 
expansion of antigen-selected Τ cells and В cells, and promotes the secretion of additional 
cytokines and antibodies. This is the basis for a specific immune response and immune 
memory. In addition, IL-2 may augment antigen-nonspecific immune reactivity by 
activation of NK cells and monocytes. 
Because of its effects on a range of immune cells, IL-2 was supposed to be a valuable 
stimulant in anticancer immunotherapy. Immune cells might cause cancer-cell destruction 
in several ways, such as direct cell-mediated lysis, antibody-mediated lysis, and release of 
toxic mediators. At least two potential anticancer effector cells were identified in vitro 
using IL-2. By incubation of peripheral blood- or spleen lymphocytes with IL-2, lym-
phokine-activated killer (LAK) cells were generated, which were capable of lysing a broad 
range of fresh malignant, but not normal cells in vitro. On the other hand, expansion of 
tumor-infiltrating lymphocytes (TIL), isolated from solid tumors, with IL-2 in vitro 
resulted in cells with specific immune reactivity against the autologous tumor [3]. 
Experimental results concerning the anticancer immune-stimulating effects of IL-2 have 
been mainly translated into the development of clinical trials using high-dose intravenous 
IL-2 administration [6]. Objective responses were described in 15-30% of selected patients 
with metastasized melanoma or advanced renal cell carcinoma. The underlying mechanism 
of these IL-2-induced antitumor effects in vivo is not yet dear. 
It is questionable whether systemic administration of high doses IL-2 is the most beneficial 
way to induce an antitumor immune response. Endogenous IL-2 acts over short distances. 
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at the site of antigen presentation, as a paracrine or autocrine mediator. Exogenous IL-2 is 
rapidly cleared from the circulation through the kidneys. Lymphocytes at the tumor site, 
which presumably have been sensitized against autologous tumor antigens, therefore 
probably will not be affected by intravenously administered 1L-2. Furthermore, systemic 
high-dose IL-2 therapy is accompanied by serious toxicity. 
MHC molecules 
Major Histocompatibility (MHC) molecules are cell-surface glycoproteins which play an 
important role in antigen presentation towards Τ lymphocytes. In man, these MHC 
molecules are represented by human leukocyte antigens (HLA). Antigen-specific CD8* Τ 
lymphocytes recognize cell-surface antigens if they are presented together with MHC class 
I molecules, and CD4* Τ lymphocytes recognize antigens in combination with MHC class 
II molecules. In other words: immunorecognition by Τ lymphocytes is MHC-restricted. 
This means that direct interaction of specific Τ lymphocytes with tumor cells will depend 
upon the expression of MHC molecules by the tumor. It has been demonstrated that 
cancer cells may have altered MHC expression as compared to the originating normal 
tissue [7]. Both defective MHC class I expression and de novo MHC class II expression 
were found. Therefore, studying MHC expression by tumor cells in vivo is relevant in im-
munotherapeutical trials in which Τ lymphocytes are supposed to play a role. NK cells, 
LAK cells, and monocytes, on the other hand, interact with tumor cells in a MHC-
nonrestricted way. 
Head tend neck squamous-cell carcinoma 
Head and neck squamous-cell carcinomas (HNSCC) are derived from the upper 
aerodigestive tract, predominantly the oral cavity, larynx and pharynx. Most tumors occur 
in men over 50 years of age. They encompass about 5% of all malignant tumors in men, 
and about 2% in women [1]. HNSCC primarily metastasizes to the regional neck lymph 
nodes. Approximately one third of patients present with confined Tl and T2 lesions. Of 
these patients, more than 80% and 60%, respectively, will be cured by surgery or 
radiotherapy. Two thirds of the patients have locally or regionally advanced disease at 
presentation (ТЭ or T4, N1-3, MO). About 30% of them will be cured after extensive 
surgery and radiation therapy. The majority, however, will die of locally or regionally 
persistent, or recurrent disease [8]. Although induction chemotherapy in HNSCC results 
in very high response rates, a survival benefit of adding chemotherapy to standard surgery 
and radiotherapy has not been confirmed in randomized trials [9]. In recurrent HNSCC, 
chemotherapy has a palliative role only. This indicates that new treatment approaches are 
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desirable in this disease. In patients with HNSCC impaired systemic and regional 
immuno-reactivity is well documented [10]. Whether this dysfunction is pre-existing and 
causative, or tumor-induced is not dear. Depressed immunity in HNSCC patients has 
been correlated with poor prognosis [10]. Immunotherapy with IL-2 may be an alternative 
approach. Because of the locoregional rumor spread, accessibility to injection, and 
localization dose to extensive submucosal and nodal lymphatic tissue, HNSCC appears 
especially suitable to locoregional IL-2 administration. 
Outline of this study 
This study was directed at exploration of the optimal route, schedule, and formulation of 
IL-2 in locoregional immunotherapy, and its local and systemic antitumor effects, in order 
to be applied in HNSCC. Besides, the mechanism of the induced antitumor effect was 
studied by evaluation of MHC expression on tumor cells and composition of the 
mononuclear cell infiltrate at the tumor site with immunohistochemical methods. 
Chapter 2 oudines the biological and immune-stimulating effects of IL-2, and the 
rationale for low-dose locoregional administration in anticancer immunotherapy. Further-
more, an overview of the literature on locoregional IL-2 administration in experimental 
and clinical studies is provided. 
Chapter 3 describes a study on the distribution of MHC class I and II expression in 
HNSCC using immunohistochemical methods. The staining procedures and scoring 
system established here, were applied in the evaluation of tumor samples obtained from 
HNSCC lesions treated with IL-2 in subsequent studies. 
Our first clinical study (chapter 4) concerned low-dose perilymphatic IL-2 administration 
in patients with nonpretreated locally far-advanced HNSCC. The treatment protocol was 
based on the previously published preliminary results with local IL-2 injections in 
HNSCC [11]. Aims of this study were confirmation of these results, and evaluation of the 
local effects at the microscopical level. 
Subsequently, an experimental study (chapter 5) was performed to further explore the 
optimal route, schedule, and formulation of IL-2 in locoregional immunotherapy of 
established tumors. For this goal, IL-2 and polyethylene glycol-modificd IL-2 (PEG-IL-2) 
were applied in the guinea-pig line-10 carcinoma model, characterized by regional lymph-
node metastases, and thus bearine resemblance to human HNSCC. 
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The results of serial histological and immunohistochcmical analysis of line-10 tumor 
regression induced by intratumoral PEG-IL-2 injections are described in chapter 6. 
Based on the experimental results in the line-10 tumor, another clinical protocol was 
developed to study the feasibility and efficacy of intratumoral PEG-IL-2 injections in 
patients with locoregionally recurrent HNSCC. The clinical and histopathological results 
obtained are represented in chapter 7. 
We assumed that intratumoral injection of PEG-IL-2 might result in longer retention in 
the tumor and the tumor-draining lymph nodes than IL-2. To verify this, the fate of 
radiolabeled IL-2 and PEG-IL-2 following intratumoral injection was studied in the 
guinea-pig line-10 tumor (chapter 8). 
In chapter 9 the results are summarized and discussed. 
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Introduction 
An important question in tumor immunology is why overt spontaneous tumors are 
incapable of eliciting an immune response resulting in rejection of the tumor. Prerequisites 
for such a response would be the presence of specific tumor antigens, adequate presen­
tation and recognition of these antigens, and the generation of an effector reaction. This 
implies that the non- or low immunogenicity of tumors can be both tumor- and host-
related. 
The insight into potential tumor antigens has substantially increased since it was found 
that cytotoxic Τ lymphocytes (CTI) can recognize short intracellular peptides, which are 
processed and presented at the cell surface in combination with major histocompatibility 
MHC) class I molecules [1]. Endogenously synthesized peptide products induced by 
genetic alterations in tumor cells thus can provide new epitopes to generate specific CTL 
[2], as was demonstrated for point mutations in murine tumor cells [3]. In humans, the 
infiltration of lymphocytes observed in many solid tumors is suggestive of a host-tumor 
interaction. These tumor-infiltrating lymphocytes (TIL) provide a reagent for detecting 
cellular immune responses to tumor antigens. In selected tumors, immune recognition was 
confirmed in vitro by specific MHC class I-restricted cytolytic activity of TIL against the 
autologous tumor [4], and by specific release of cytokines by TIL after incubation with the 
autologous rumor [5]. In addition, expression of memory Τ cell markers by TIL [6], as 
well as specific localization in rumor deposits after re-infusion [7] are suggestive of 
recognition of tumor antigens. Evidence for specific tumor antigens was obtained recently 
with the identification of the MAGE gene family in human melanomas [8]. These genes 
are expressed by different tumors and not by most normal cells. The antigen encoded for 
by MAGE-1 is recognized by anti-melanoma human leukocyte antigen (HLA)-Al-
rcstricted CTL 
An effective tumor-host interaction also depends on a well-functioning host immune 
system. Impaired immune responsiveness has been demonstrated in tumor-bearing animals 
and cancer patients [9]. The origin and nature of the defects and the consequences for 
interaction with the tumor are incompletely understood. In mice progressive tumor growth 
is accompanied with further decreased cytotoxic activity of nonspecific immune cells and 
CTL [10,11]. 
Stimulation of the failing host immune system to detect and to eliminate tumor cells 
might provide a means of anticancer therapy. The Τ cell product interleukin-2 (IL-2) has 
a variety of immune-stimulating effects. Natural IL-2 plays an essential role in the 
initiation and amplification of an immune response. In experimental situations IL-2 
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promotes che proliferation and the antitumor cytolytic activity of specific and nonspecific 
immune cells. In this paper it will be discussed how these effects of IL-2 have been 
applied in the treatment of experimental and human cancer. With the biological function 
of IL-2 as a basis, especially locoregional administration will be outlined. 
Biological activity o f interleukin-2 
IL-2 is a 15-Kd protein produced by Τ lymphocytes. As the first of a series of lym-
phocytotrophic hormones to be recognized [12] and characterized [13], it has had great 
impact on understanding the regulation of the immune response, in which it plays a 
pivotal role [14]. Resting Τ lymphocytes do not produce IL-2, nor do they respond to 
exogenously added IL-2. However, upon antigenic activation of the Τ cell receptor, Τ 
lymphocytes start producing IL-2, and express IL-2 receptors on their cell-surface. IL-2 
promotes the clonal expansion, and enhances the secretory capacities of antigen-selected Τ 
cells [14] and В cells [15]. This is the basis for a specific immune response and immune 
memory. In addition, IL-2 augments antigen-nonspecific immune reactivity by activation 
of natural killer (NK) cells. Defective IL-2 production causes severe combined im­
munodeficiency disease [16,17]. 
Antigen presentation thus results in IL-2-mediated clonal proliferation of Τ cells and 
production of secondary cytokines. These cytokines are involved in the subsequent dif­
ferentiation of immune effector cells. There is increasing evidence that functional Τ cell 
subsets can be defined by the pattern of cytokines they produce [18,19]. CD4* helper Τ 
cells, which recognize antigens presented in conjunction with MHC class II molecules, 
have been divided into TH1 cells and TH2 cells. TH1 cells, secreting IL-2 and ¡nterferon-γ 
(IFN-γ), are involved in delayed-type hypersensitivity (DTH) reactions, and promote 
effector responses mediated by CTL, NK cells, and macrophages. TH2 cells, on the other 
hand, generate B-cell development, humoral responses, and eosinophilia by their produc­
tion of IL-4 and IL-5 [19,20]. This distinction recendy has been extended to MHC class 
I-restricted CD8* Τ cells. IFN-γ producing type 1 CD8* cells, with cytotoxic functions, 
are distinguished from IL-4 producing type 2 CD8* cells, which suppress antigen-
stimulated proliferation of CD4* Τ cells [21]. The selection of the Τ cell subset to be 
activated and the quality of the ensuing immune response may depend on a range of 
factors, such as the epitope of the antigen, the type of antigen-presenting cell, the MHC 
molecules and other accessory signals in antigen presentation, and the past immunologic 
history of the host as was demonstrated in Τ cell-mediated responses to infectious 
11 
pathogens [20,21]. 
IL-2 mediates its effect locally, in a paracrine or autocrine fashion, by binding to IL-2-
specifìc receptors. The IL-2 receptor encompasses three transmembrane protein chains. 
The 55 Ю α chain binds IL-2 with very rapid on/off rates, but with a low affinity (af­
finity constant Kd=10"* M). The association of the 75 kD β chain and the 64 kD γ chain 
binds IL-2 with intermediate affinity (Kd°=10~9 M), and is responsible for signal transduc­
tion to the cell by its large cytoplasmatic domain. The expression of all three chains results 
in the formation of the high-affinity heterotrimeric receptor, which binds IL-2 with a 100-
fold higher affinity (Kd=10-" M) compared with the βγ chain complex [22,23]. Τ cells 
and В cells express high-affinity IL-2 receptors upon antigenic activation. In contrast, the 
majority of NK cells constitutively express intermediate-affinity IL-2 receptors, and thus 
are immediately responsive to IL-2. A relatively high concentration of IL-2 is required for 
saturation of the intermediate-affinity receptor (10"*M vs. 10~10 M for saturation of the 
high-affinity heterotrimeric receptor). Activation of immune cells by IL-2 thus depends 
both on IL-2-receptor expression and IL-2 concentration. 
IL-2 and immune effector cells against cancer 
Several types of immune cells have been demonstrated to obtain antitumor cytolytic 
activity when cultured with IL-2. These observations in principle were the background for 
application of IL-2 in vivo. 
NK cells comprise 10-15% of peripheral blood mononuclear cells, and proliferate and 
exhibit enhanced non-MHC-restricted cytolytic activity in response to IL-2 [24,25]. Lym-
phokine-acrivated killer (LAK) cells are generated from NK precursors by stimulation of 
splenocytes or peripheral blood mononuclear cells from normal or tumor-bearing hosts 
with IL-2 for several days. These LAK cells are capable of lysing a range of fresh and 
cultured tumor cells but not normal cells in vitro [26], and mediate the regression of 
experimental metastases from murine tumors after adoptive transfer together with IL-2 
[27,28]. LAK activity can also be generated in vivo by repeated systemic administration of 
high doses of IL-2 [29]. 
Monocytes, like NK cells, constitutively express the intermediate-affinity IL-2 receptor 
[30]. Activation by IL-2 enables monocytes to lyse tumor cells in vitro [31]. 
TIL are observed in many experimental and human solid tumors. IL-2 enables expansion 
of these TIL in vitro. TIL from murine tumors mostly are CD8* Τ cells. They have been 
shown to specifically lyse the autologous tumor in vitro [32]. TIL are 50-100 fold more 
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effective than LAK cells in reducing experimental lung metastases in vivo when ad­
ministered together with IL-2 [33]. This does not prove that direct cytolysis of tumor cells 
by TIL in vivo occurs as also noncytolytic CD8* TIL mediate the eradication of lung-
metastases [34]. Moreover, in vivo effectiveness of TIL appears to correlate better with 
secretion of IFN-γ when coculrured with the autologous tumor than with cytolytic activity 
in vitro [34]. TIL can be grown from human cancers of variable histologic types [35.36] 
including melanoma [4], renal cell carcinoma [37], lung cancer [6], head and neck cancer 
[38], and glioblastoma [39]. The majority of these TIL are CD3* Τ cells, with variable 
CD4*/CD8* ratios. Freshly isolated human TIL have depressed proliferative [40] and 
cytotoxic [41,42] responsiveness in vitro. This might be due to rumor-derived suppressive 
factors [11,40]. After expansion with IL-2 TIL often exhibit nonspecific cytolytic activity 
in vitro [36]. Unique cytolytic activity against the autologous tumor has been 
demonstrated in 30% of human melanomas [4] and rarely in renal cell carcinoma [43]. In 
melanomas this specific cytotoxicity was proven MHC-restricted [4]. 
Since recombinant IL-2 became available in 1983 [13] a large number of studies has been 
performed in cancer patients to evaluate the clinical efficacy of IL-2. These studies were 
directed towards the induction, proliferation and activation of cytolytic cells, especially 
LAK cells [26-29]. IL-2 was mostly administered intravenously (i.V.), alone, with LAK cells 
[44-47], or with IFN-a [48], or subcutaneously (s.c.) [49]. Analogous to cytotoxic 
chemotherapy, mostly maximally tolerated doses were given, especially in the i.v. trials. 
The classical schedule described by Rosenberg et al [44] consists of 5-day courses with i.v. 
IL-2 bolus injections of 100,000 U/kg every eight hours. A dose- and schedule-dependent 
(rebound) lymphocytosis with enhanced circulating LAK activity occurred [50]. With 
high-dose IL-2-based treatment schedules objective tumor regression has been obtained in 
patients with selected tumors. Partial responses (PR) and sometimes durable complete 
responses (CR) are demonstrated in about 15-30% of patients with malignant melanoma 
and advanced renal cell carcinoma. Partial responses have also been described in patients 
with colorectal cancer and non-Hodgkin's lymphoma. Unfortunately, high-dose systemic 
IL-2 therapy is associated with serious and sometimes life-threatening toxicity, including 
fever, chills, general malaise, nausea and vomiting, hypotension, fluid retention, respiratory 
distress and neurologic dysfunction, requiring intensive medical intervention [51]. 
Adoptive transfer of TIL together with IL-2 is very laborious and expensive, and has been 
performed in a small number of clinical trials. Objective responses have been described in 
25-60% of selected patients with malignant melanoma [52-54] and 30% of patients with 
renal cell carcinoma [53]. 
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Rationale for low-dose and locoregional IL-2 administration 
Most clinical studies on immunotherapy with IL-2 consider high-dose systemic IL-2 
administration. This results in objective responses in selected patients only, by a still 
incompletely understood working mechanism. Yet it is questionable whether high doses of 
IL-2 on the one hand, and systemic administration on the other hand, are most beneficial 
to elicit an antitumor response in vivo. 
Endogenous IL-2 is produced at the site of antigen presentation. It mediates its effect 
locally at the cell-cell interaction level [14], and its activity normally is not detectable in 
the human serum [55]. Exogenous IL-2 is rapidly eliminated (rom the circulation by renal 
nitration. After i.v. bolus injection a high circulatory peak-level is obtained, which 
decreases initially with a half-life (ta) of 13 min, followed by a slower elimination phase 
with a half-life (tß) of 85 min [55]. Due to variable IL-2 receptor affinity, activation of 
circulating immune cells will depend, among other things, on the obtained serum IL-2 
concentration [56]. In the treatment of metastatic murine tumors a biphasic IL-2 dose-
response relation was demonstrated, with low-dose therapeutic activity being Τ cell-
mediated, and high-dose activity being mediated by NK or LAK cells [57]. Serum IL-2 
concentrations obtained with the common, i.e. high dose, clinical i.v. or s.c treatment 
schedules are high enough to activate a substantial percentage of the intermediate affinity 
IL-2 receptors [56,58], as constitutively expressed on NK cells. These treatment schedules 
are accompanied by serious systemic toxicity. Recently, it was shown that continuous 
infusion with low doses of IL-2 (І.5-4.5ХІ05 U/m2/day) is sufficient for selective 
saturation of high-affinity IL-2 receptors [58]. In patients with lepromatous leprosy such 
doses of IL-2 applied ¡ntradermally generated effective cellular immunity [59,60]. Whether 
systemic IL-2 administration at the same low doses can elicit an effective antitumor 
response in cancer patients remains to be proved [61]. 
Whereas it is doubtful whether TIL and regional lymph-node lymphocytes arc affected by 
systemically administered IL-2, they might be directly activated by locoregionally applied 
IL-2. Activation of TIL appears preferable above circulating lymphocytes, since TIL may 
display specific antitumor reactivity in vitro [32], and adoptively transfered TIL are far 
more effective in vivo than IL-2-activated peripheral-blood lymphocytes or splenocytcs in 
experimental studies [33]. Relatively low doses of IL-2 will probably be sufficient, which 
will diminish or avoid systemic toxicity. High local IL-2 concentrations might even be 
worse. Murine specific CTL clones were shown to develop nonspecific promiscuous lytic 
ability upon stimulation with high doses IL-2 [62]. Moreover, TIL from immunogenic 
and nonimmunogenic murine sarcomas, cultured with irradiated autologous tumor in low 
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levels of IL-2 (10 U/ml), showed increased in vivo therapeutic efficacy as compared to TIL 
cultured with high levels of IL-2 (1,000 U/ml) [63]. The most important motive for 
locoregional application of IL-2 is, however, that this might provide a more physiological 
stimulation of the immune system than systemic IL-2 administration. The latter aims at 
activation of cytolytic cells. Locoregional supply of IL-2, i.e. at the site of antigen 
presentation, might favor sensitization of host immune cells to the tumor and act on the 
induction phase of an immune response. This hypothesis is reinforced by observations in 
experimental tumor models, which are reviewed in the next sections. In an analogous 
situation, in patients non-responsive to hepatitis В vaccine, specific immune responsiveness 
was elicited by local application of IL-2 at the vaccine injection site [64]. 
Experimental studies 
The antitumor effects and mechanisms of peri- or intracumorally applied IL-2 have been 
studied in several animal tumors. Preferably syngeneic tumor models were used, because 
they provide hosts with an intact immune system. The following topic will be reviewed 
separately: 1. suppression of tumor-growth induced by peritumoral IL-2 injections started 
shortly after challenge; 2. immune reactions elicited in vivo by tumor cells transfected with 
the IL-2 gene; and 3. locoregional IL-2 therapy of established, macroscopic disease. 
Tumor-growth suppression by peritumoral IL-2 administration 
Several investigators have demonstrated that inhibition of tumor growth can be obtained 
by repeated peritumoral IL-2 injections started 0-3 days after s.c tumor challenge [65-69]. 
Vaage [68] evaluated the strength of this intervention in a series of mammary carcinomas 
in syngeneic C3H/He mice. He found that the response to peritumoral IL-2 injections 
was related to tumor immunogenicity, infiltration of mononuclear cells, and a limited 
growth rate of the tumor [70]. In the immunogenic MC2 tumor, complete suppression of 
local tumor growth was obtained in 40-80% of animals with 10-12 daily peritumoral in­
jections of 1,000-5,000 U IL-2 [68,70,71]. Furthermore, Vaage showed o a t peritumorally 
administered IL-2 in this tumor not only elicited a local, but also a systemic antitumor 
reaction, since the growth of uninjected MC2 tumors simultaneously growing on the other 
flank was suppressed as well [68,70]. 
Forni et al [65] used the poorly immunogenic methylcholanthrene-induced CE-2 sarcoma 
in syngeneic BALB/c mice. They described how daily very low-dose (10-20 U) peritumoral 
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IL-2 injections for 10 days caused complete tumor-growth suppression in 80-100% of 
animals. A prerequisite, however, was that the subcutaneous tumor challenge was admixed 
at 1:5 cell ratio with spleen lymphocytes from tumor-bearing mice. These lymphocytes 
themselves were nonreactive against CE-2 in vitro or in vivo. This approach showed the 
same results in several other murine tumors. Moreover, the combination of IL-2 and 
lymphocytes at the tumor site induced systemic antitumor immunity. Cured mice showed 
specific DTH reactions and rejected CE-2 rechallenges. Development of this reactivity 
depended on an intact host immune system, and involved NK cells and Τ helper cells. It 
was thought that the lymphocytes inoculated with the tumor cells acted as initiator cells 
which, after activation with exogenous IL-2, produced cytokines and recruited specific and 
nonspecific host immune effector mechanisms [72]. Production of IFN-γ played an 
essential role in the antitumor effect, as also was shown by Vaage in his model [73]. 
Sigali and Schaefer [66] studied the effects of peritumotal IL-2 injections in the nonim-
munogenic B16 melanoma, inoculated s.c at a lethal dose in syngeneic C57BL/6 mice. 
Repeated perilesional injections with 30,000 U IL-2, once daily, cured 65% of mice. In 
this model cured mice did not reject a tumor rechallenge. 
Dubinett et al [69] investigated local IL-2 therapy in the poorly immunogenic LI alveolar 
carcinoma, syngeneic to BALB/c mice. Twice daily peritumoral IL-2 injections (50,000 
U), started on day 3 following s.c inoculation, and given for 3 weeks, resulted in 
significant tumor-growth inhibition and increased survival, with a cure rate of 24%. Like 
in Fomi's model [72] both Τ cell-mediated and nonspecific immune mechanisms appeared 
to be involved in this therapeutic effect. In this study it was also shown that local IL-2 
administration enhanced nonspecific cytolytic activity of both TIL and splenocytes [69]. 
These studies have in common that the peritumoral administration route was essential for 
the obtained effect. When equal doses of IL-2 were given i.v. or i.p., tumor-growth 
inhibition was minor [66] or absent [65,69,73]. In Vaage's model the effect was already 
lost when IL-2 injections were given 2 cm away from the tumor [70]. Furthermore, low 
doses of IL-2 were most effective, since a 10- to 20-fold increment of dose did not en­
hance [72], or even diminished [68] the enea. Only Dubinett et al [69] needed high 
doses for optimal result. 
The use of unmodified IL-2 required repeated injections at short intervals [65,71]. In 
other studies it was shown that locoregional application of sustained-release formulations 
such as IL-2 suspended in agar gel [74], entrapped in liposomes [74-76], or coupled to 
polystyrene beads [77], resulted in equal or increased antitumor activity at less frequent ad­
ministration compared to unmodified IL-2. 
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Tumor ceto transacted with IL-2 cDNA 
The effect of continuous delivery of IL-2 at the tumor site -was studied using mouse and 
rat tumor cell lines in which the gene encoding for IL-2 was inserted with retroviral gene 
transfer methods [78-83]. These engineered cells consriturively secreted various amounts of 
IL-2 in vitro. They were especially developed to investigate whether the failure of tumors 
to elicit an effective immune response in vivo could be overcome by paracrine stimulation 
of the host antitumor response. The amount of IL-2 produced by these cells in vivo is 
hard to deduce from the in vitro characteristics, and proved to decrease in the only study 
where this was checked [80]. Nevertheless, after s.c inoculation in syngeneic mice, the IL-
2-producing tumors showed reduced or abrogated tumorigenicity as compared to the more 
or less immunogenic [78-81] or nonimmunogenic [82,83] parental tumors. This growth-
inhibiting effect was extended to admixed unmodified parental cells [79-81,83]. It was 
shown that the antitumor effect was caused by an immune response induced by the IL-2-
producing tumor, which involved CD8* Τ cells and NK cells [78,82,83]. The power of 
the induced immune response depended on the level of IL-2 production as measured in 
vitro [78-80,82,83] and, considering the various studies, apparendy on the im-
munogenicity of the parental tumor. In some models the IL-2-producing tumors induced 
systemic tumor-specific immunity, thereby protecting the animals against subsequent 
rechallenge with the parental tumor [78,79,81,82]. Whereas CD4* Τ cells were not 
required for the initial tumor-growth inhibition [78,82,83], they played an essential role in 
the induction of this immune memory [82]. 
Histologic examination of the s.c rumor-challenge site, either of IL-2-producing tumors or 
following peritumoral IL-2 injections, generally revealed enhancement of the naturally 
occurring lymphocytic infíltrate. Increased numbers of macrophages [78,84], neutrophilic 
and eosinophilic granulocytes [72,82], and fibroblasts [83] were also observed. Vaage 
described an increased fibrotic reaction, encapsulating the tumor [84]. 
These results support the concept that the host immune response to poorly or nonim-
munogenic tumors can be enhanced by protracted local supply of IL-2. It was suggested 
that the inability of the parental tumors to generate an effective immune response is partly 
due to failure of Τ cell help, which is bypassed by local IL-2 supply [78]. The technique 
of IL-2 gene transfection might be especially important for the development of new tumor 
vaccines [85]. 
Regression of grossly established tumors induced by local IL-2 application 
The therapeutic effects of locoregional IL-2 immunotherapy in macroscopic disease have 
been studied in s.c [68,86], i.p. [87] and metastatic [76] syngeneic tumor models, and in 
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a spontaneous bovine tumor [88]. 
Regression of large tumor masses was observed by Maas et oL [87] in the weakly im­
munogenic SL2 lymphoma, i.p. inoculated in syngeneic DBA/2 mice. Whereas untreated 
animals developed large tumor burdens and died within 20 days, 70% of the animals 
receiving i.p. injections with IL-2 on days 10-14 were cured. Systemic antitumor activity 
developed, since 50% of simultaneously inoculated s.c SL2 tumors were cured as well 
[87]. Furthermore, surviving animals rejected subsequent tumor rechallenges [89]. This 
systemic reaction was found to be a tumor-specific Τ cell-mediated effect. Both the IL-2 
application site and the time schedule proved to be critical in this model. I.p. IL-2 injec­
tions in animals without Lp. tumor only had marginal effects on s.c growing tumors. 
Furthermore, IL-2 injections in an earlier phase of i.p. tumor development (day 3-7) had 
no therapeutic effect [89]. It was suggested that IL-2 reinforces a specific immune response 
which takes about a week to develop. The same phenomenon was observed by others in 
the immunogenic murine myeloma Х556Э, which could be cured by repeated local IL-2 
injections started on day 7, but not on day 1 after intradermal inoculation [86]. However, 
in the earlier mentioned immunogenic MC2 mammary carcinoma, rumor growth was sup­
pressed completely with peritumoral IL-2 injections at 1,000 U started 1 day after implan­
tation, and cure was still obtained when IL-2 injections at 5,000 U were started in pal­
pable 9 day-old tumors [68]. 
Anderson et al [76] studied the antitumor effects of intrathoracic IL-2 injections on 5 
day-old experimentally induced pulmonary metastases of the weakly immunogenic MCA-
106 sarcoma in C57BL/6 mice. The number of lung metastases was significantly decreased 
by 3-5 daily intrathoracic IL-2 injections, whereas i.v. or i.p. administration had no effect. 
In a quite different animal, Rutten et aL [88] confirmed the potential therapeutic effects of 
local IL-2 therapy in established tumors. In 5 cows with spontaneous bovine ocular 
squamous-cell carcinoma, ranging from 1-4 cm in diameter, 10 combined intratumoral 
and perilymphatic injections with IL-2 resulted in 3 CR and 1 PR. A remarkable 
protracted tumor-regression time, ranging from 2-7 months, was observed in this study. 
These experimental studies show that locoregional injections with IL-2 alone can induce 
complete regression of palpable tumor masses. The daily dose of IL-2 in all these studies 
varied from 5,000-50,000 U, and therapy was well tolerated. The prevalence of 
peritumoral injection over systemic administration in established tumors was demonstrated 
in 2 models [76,89], and is also suggested when these experimental studies are compared 
to those of Rosenberg and colleagues using systemic IL-2 treatment. These investigators 
aimed at the generation of LAK activity in vivo by three times daily i.p. IL-2 ad­
ministration [27,28,90]. The effects on s.c growing tumors was studied using the weakly 
18 
immunogenic MCA 105 sarcoma. Complete regression of 3-10 day old tumors was 
obtained in 20-50% of animals at very high doses of IL-2 only (500,000-600,000 U/day 
¡.p.), which caused severe toxicity [90]. Most experiments with systemic IL-2 treatment 
were directed towards 3-10 day old experimental liver and lung metastases of syngeneic 
murine tumors. These metastases were inhibited, but not cured by high doses (60,000-
300,000 U/day) of IL-2 alone [27,90]. The antitumor effect in these studies was related to 
the immunogenicity of the tumor [90]. It was LAK-efTector mediated, but in im-
munogenic tumors also Τ cells were involved [28]. The efficacy of this treatment was en­
hanced when combined with i.v. LAK cell administration [27,90]. 
Clinical studies with locoregional IL-2 administration 
The therapeutical effects of Iocoregionally administered IL-2 in human cancer have been 
studied on a modest scale. Most clinical studies concern local recurrent or residual disease, 
or primary locally far-advanced disease for which no conventional treatment was available. 
IL-2 was given alone or combined with LAK cells. Access to the tumor was obtained by 
direct, endoscopic or ultrasound-guided intra- or peritumoral injection, perilymphatic 
injection, i.e. around the tumor-draining lymph nodes, selected intra-arterial infusion, or 
compartmcntal administration into localized body cavities such as the peritoneum, pleura, 
bladder, or leptomeninges. Especially in the studies with intracavitary IL-2 administration 
high doses were used, aiming at high and prolonged IL-2 levels sufficient to generate or 
maintain LAK activity. Published studies on locoregional IL-2 administration will be 
discussed by tumor site. Details are summarized in Table 1. 
Head and neck squamous-cell carcinoma (HNSCC) is characterized by locoregional tumor 
spread near extensive submucosal and nodular lymphatic tissue. The first therapeutical 
study with IL-2 in this disease was based on Fomi's experimental results [65]. In this 
study Conesina et cd. [91] gave patients with Iocoregionally recurrent HNSCC perilym­
phatic injections with low doses IL-2 in order to activate regional lymphocytes. They 
obtained 3 CR (duration 4-6 months) and 3 PR in 10 patients. Subsequent studies using 
perilymphatic treatment schedules did not equal this high response rate [92-95]. Responses 
were also described with peritumoral [96] and intra-arterial [97,98] IL-2 administration. 
Generally, fewer responses were seen in patients with large tumor masses. In perilymphatic 
treatment responses appeared unlikely in patients with bilateral lymph-node dissection 
[91]. No conclusions can be drawn on the most beneficial IL-2 dose or route. In the 3 
dose-escalation studies the objective responses occurred at the lowest IL-2 dose used [97], 
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at the highest [95]. or both [94]. Systemic toxicity varied from none [91-93] or mild fever 
only [95.96,98], to significant at high-dose levels in the dose-escalation studies [94,97]. 
Temporary moderate local swelling, redness, or pain appeared not to be dose related 
[91.95.97]. Histological examination of treated tumors showed increased lymphocytic 
infiltration, macrophages, giant cells, and fibrous changes at the tumor site, and 
degeneration of cancer cells [96,98]. 
In bladder carcinoma, immunotherapy has a longer history, and the intravesical application 
of the microbial immunostimulant bacillus Calmette-Guérin (BCG) has been proven effec-
tive in superficial tumors [99]. Pathological CR and PR were also described using intraru-
moral, intravesical or intra-arterial IL-2 administration [100-103]. As in HNSCC the 
occurrence of systemic adverse effects depended on the dose used. Immunohistochemical 
analysis of treated tumors revealed increased numbers of infiltrating activated Τ cells and 
macrophages [104]. 
In patients with recurrent or residual brain tumors, local adoptive immunotherapy with 
IL-2 and LAK cells has been applied [105-107]. Few tumor regressions were found. Sys­
temic side effects including fever and chills, and neurological side effects related to 
increased cerebral edema [106,107] occurred in most patients. Increased intracranial 
pressure was also described in 2 case reports on high-dose intraventricular IL-2 im­
munotherapy for leptotneningeal melanoma metastases [108,109]. After intraventricular 
injection IL-2 is cleared from the cerebrospinal fluid with a half-life of 4-8 h [110]. Treat­
ment-induced secondary cytokines, soluble IL-2 receptor and neutrophilic leukocytes, 
sustained presence of lymphocytes, and decrease of malignant cells were shown in the 
cerebrospinal fluid [110]. 
Ultrasound-guided intratumoral IL-2 administration was described in few patients with 
small hepatocellular carcinomas (<3.5 cm) [111,112]. One PR was recorded. Transient 
fever and chills occurred. Repeated tumor biopsies from patients with stable disease (SD; 
duration 3-8 months) showed decreased numbers of neoplastic cells, tumor necrosis, 
fibrosis, and infiltration of lymphocytes and granulocytes [112]. 
Intrapleural administration of IL-2 was studied in patients with malignant pleural effusion. 
In one study it was shown that intrapleural injection with 1,000 U of IL-2 resulted in a 
local level of IL-2 gradually decreasing from 28 U/ml at 30 min to 4 U/ml at 24 h, while 
serum levels of IL-2 were <0.01 U/ml [113]. Increased numbers of intrapleural lym­
phocytes and eosinophils, disappearance of malignant cells, and subsequent disappearance 
of the pleural effusion occurred after repeated injections in 9 out of 11 patients, enabling 
surgical treatment of the primary tumor in 6 [113]. Objective tumor regression was 
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Table 1. Clinical studies with locvregionaJ lL-2 immunotherapy. 
Tumor, 
Reference 
HNSCC 
Connina et al [91] 
Cortesina ti al [92] 
Mactijocn et al [93] 
Vloek tt al [94] 
Squadrelli et al [95] 
Saito et al [96] 
Gore et al [97] 
Ishikawa et al [98] 
Bladder carcinoma 
Ρίτα et al [100] 
Fujiokartdt [101] 
Huknd et al [102] 
Tubato et al [103] 
Malienant brain tumors 
Yoshidartdl [105] 
Barbarti«/ [106] 
Merchant et al [107] 
LeptomcninEcal metastases 
Treatment with IL·2 
Route 
perilymphatic inj. 
perilymphatic inj. 
perilymphatic inj. 
perilymphatic 
+ peritumoral inj. 
perilymphatic inj. 
+ peritumoral LAK cells 
peritumoral inj. 
cone intra-arterial inf. 
intra-arterial inf. 
+ LAK cells 
intratumoral inj. 
intratumoral inj. 
cont. bladder perfusion 
cont. intra-arterial inf. 
intratumoral inj. 
+ LAK cells 
intratumoral inj. 
+ LAK cells 
intra- or peritumoral 
inj. + LAK cells 
Schedule* 
10 days 
lOdays 
10 days 
2x5 days 
10 days 
9-38 days 
5-10 days 
4-15 times 
2-3 times 
3days 
5 days 
2x5 days 
2-3 days/wk 
5 days 
4 days 
Daily dose 
(χΙΟΊί) 
0.2· 
1-5 
0.2-0.4 
0.2-4,000 
2.4-1,800 
800 
30-30,000 
1 
2-іь 
500 
3.000* 
l8-18,000/m2 
0.05-0.4 
10-60/kg 
1,000 
Patients 
η 
10 
10 
15 
36 
14 
20 
12 
6 
10 
12 
5 
12 
23 
9 
13 
Response 
3 CR, 3 PR 
7 MR' 
none 
2 PR 
3 PR, 3 MR 
2CR.1PR.1MR 
2 PR 
6 regression, 
not quantified 
3 CR, 2 PR 
1 CR, 2 PR 
1 CR 
2 CR, 3 PR 
6 regression, 
not quantified 
1 PR 
none 
Melanoma, lung carcinoma: 
List et al [110] intraventricular inj. 
Hepatocellular carcinoma 
Sturai etal [111] intratumoral inj. 
Gmdoiñ et al [112] intratumoral inj. 
+ LAK cells 
2 days/wk 1,000-12,000 11 8 responses' 
2-4 times 450-900 5 1 PR. 1 MR 
3-20 times 10-30 5 none 
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Table 1, continued 
Tumor, Treatment with IL-2 
Reference Route 
Malienant pleural effusion 
Lung carcinoma: 
Yasumoto et tL [113] intrapleural inj. 
Schedule* 
10-28 days 
Daily dose 
(»KCU) 
1 
Patients 
η Response 
11 9 effusion 
disappeared 
Mesothelioma, carcinomai: 
Asmul et tL [114] com. intrapleural inf. 
Intraperitoneal malignancies 
Ovarian, colon carcinoma: 
Steis et ai [115] intraperitoneal inj. 
+ LAK cells 
5 days 3,000-24,000 22 1 CR, 9 PR 
5 days 75/lcg 24 7 PR 
inj., injection; inf., infusion; cont, continuous. 
* Indicated are either the duration of 1 treatment course (in days; daily treatment; mostly 1-2 courses were 
given) or the total number of administration· (times). 
k
 Natural IL-2 was used 
' 6 additional responses recorded in 10 additional patients are identical to the previous publication [91]. 
d
 Defined as complete clearing of cerebrospinal fluid tumor on 2 sequential weekly lumbar punctures. 
described in patients with pleural carcinoma metastases and early-stage mesotheliomas 
[114]. Fever and transient increase of pleural effusion were recorded in both studies, while 
serious systemic toxicity occurred at the highest dose levels only. 
Intraperitoneal immunotherapy with high doses IL-2 and LAK cells has been applied in 
patients with malignancies limited to the peritoneal space, such as ovarian and colorectal 
cancer. Laparoscope- or laparotomy-documented PR were obtained [115]. A special and 
major problem encountered with this approach was intraperitoneal fibrosis, limiting 
repeated IL-2 administration. Systemic side effects were similar to chose reported in i.v. 
high-dose IL-2 treatment. 
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Conclusion 
In several experimental tumor models it has been shown that repeated or sustained supply 
of low doses IL-2 direcdy at the tumor site can dicit a systemic antitumor immune 
response in poorly immunogenic tumors. Both specific Τ cells and nonspecific immune 
mechanisms appear to be involved. The induced immune response mediates inhibition or 
regression of local and distant tumor sites. In this respect, local IL-2 administration is 
clearly superior to systemic IL-2 therapy. Whether local IL-2 supply is beneficial in human 
cancer remains to be proved. While several thousands of patients have been treated with 
high-dose systemic IL-2 therapy, there is only limited clinical experience with locoregional 
IL-2 application. Since various schedules, doses, and administration routes have been used 
in a variety of clinical situations, it is difficult to draw conclusions. Objective local tumor 
responses have been described especially in head and neck cancer and bladder cancer. The 
required access to the tumor might limit the application of locoregional IL-2 therapy. On 
the other hand, the absence of serious toxicity is advantageous. Clinical responses arc 
unlikely to occur in patients with large tumor masses. This might be related to depressed 
host immune responsiveness. The recently described structural and functional alterations in 
the Τ cell antigen receptor of advanced tumor-bearing mice and cancer patients might be 
the basis for depressed Τ cell responsiveness [116]. The future challenge will be to define 
the conditions and the mechanisms of beneficial effects of local IL-2 administration. 
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Chapter 3 
Determination of HLA antigen expression 
in routinely processed 
head and neck squamous-cell carcinoma lesions 
This chapter has been published as: 
Mattijssen V, De Mulder PHM, Schalkwijk L, Mann i JJ, Van 't Hof-Grootenboer B, 
Ruiter DJ. HLA antigen expression in routinely processed head and neck squamous-cell 
carcinoma primary lesions of different sites. Int J Cancer 1991; Suppl 6:95-100. 
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Summary 
Background: Since CD8* and CD4' Τ lymphocytes recognize antigens only in combination 
with, respectively, class I and class II human leukocyte antigens (HLA), the latter are 
supposed to play an important role in host-tumor interactions. Because of that we explo­
red the expression of HLA class I and II antigens by head and neck squamous-cell 
carcinomas (HNSCC). 
Methods: Paraffin-embedded samples from 66 HNSCC and 7 verrucous carcinomas were 
studied immunohistochemically using anti-HLA class I monoclonal antibodies (MAbs) 
HC10 and HCA2, and anti-HLA-DR rabbit serum. Percent stained tumor cells were 
scored in 1 of 5 categories. The scores of 40 tumors were compared to the staining results 
obtained on frozen sections of the corresponding lesions, including those of the anti-class I 
MAb W6/32. 
Results: High percentage-matched scores for paraffin and frozen sections were obtained, 
with HC10 vs. HC10, HC10 vs. W6/32, and anti-HLA-DR vs. anti-HLA-DR showing 
the best correlations. HLA class I expression in HNSCC was high {i.e. in 49/66 lesions 
>50% cells were stained), and correlated with the degree of differentiation, and inversely 
with the modified Jakobsson score {i.e. high expression was observed in well and 
moderately differentiated carcinomas). HLA class II expression (>5% cells stained) was 
found in 21/66 HNSCCs and correlated inversely with the degree of differentiation. From 
4 HNSCC subsites, oral cavity carcinomas showed the highest HLA class I expression. 
Conclusions: Routinely processed paraffin-embedded tumor samples are sufficient for 
immunohistochemical detection of HLA class I and II expression. In HNSCC a high level 
of HLA class I expression was observed especially in tumors from the oral cavity, which 
suggests susceptibility to CD8* Τ cells. 
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Introduction 
H LA antigens are supposed to play a role ¡η the host's immune response towards 
neoplastic cells. On a variety of cancer cells both defective HLA class I and dt novo class II 
expression have been described, mostly using immunohistochemistry on frozen tissue 
samples [1]. Low expression of HLA class I antigens correlates with poor differentiation in 
colorectal cancer [2] and in larynx carcinoma [3], and with poor prognosis in patients with 
locoregional melanoma metastases [4]. HLA class II expression in primary melanoma is 
associated with shorter disease-free survival [5]. The significance of HLA expression on 
tumor cells in relation to immunotherapy is mainly speculative, and has seldom been 
investigated. High HLA class II expression in regressing melanoma lesions following 
recombinant interleukin-2 (IL-2)-based immunotherapy has been described [6]. 
Immunohistochemical analysis of HLA antigen expression is largely restricted to fresh 
frozen tissue. Routine tissue processing, i.e., formaldehyde-fixation and paraffin-
embedding, denatures the antigens, and as a result the reactivity of most antibodies is lost. 
HCA2 and HC10 MAbs, however, were prepared against free denatured HLA-A and -B 
locus heavy chains, respectively, and found to be reactive in paraffin sections of normal 
tissues [7]. For detecting HLA class II antigen expression in frozen and paraffin sections 
rabbit polyclonal anti-class II sera have been developed (H.L. Ploegh, Amsterdam). 
Our first aim was to evaluate the immunohistochemical detection of HLA antigen 
expression on tumor cells using these antibodies on routinely processed tissue, by 
comparing results on frozen and paraffin sections of the same tumor. Such detection 
method proved feasible on paraffin sections of HNSCC. The sanple group was thus 
enlarged to include the distribution of HLA antigens in HNSCC in relation to primary 
site, stage of disease and histological grade. We arc at present studying local IL-2 
immunotherapy as a new treatment approach for HNSCC [8]. Answering these questions 
might be of relevance for the design and interpretation of such clinical studies. 
Materials and methods 
Patients and tumor specimens 
Routinely processed paraffin-embedded tissue samples of the primary tumor from 73 
patients with squamous-cell carcinoma (SCC, n=66) or verrucous carcinoma (n-7) of the 
head and neck were used. Eighteen samples were decalcified according to standard 
procedures. The samples were taken either at surgical tumor excision (n=50) or from 
34 
tumor biopsies (n=23). At the same time, a fresh tumor sample from 40 of the patients 
was also deep frozen and stored into liquid nitrogen until use. 
The SCC patients were selected to compose 4 site-specific groups (oral cavity, oropharynx, 
hypopharynx, and larynx) which were matched for stage of disease and histological grade 
(Table 1). All patients came from the Departments of Otorhinolaryngology and Maxillo-
Facial Surgery, University Hospital Nijmegen, between 1974 and 1990. The group 
consisted of 58 men and 15 women, with a mean age of 61 years (range 33-81 yean). 
They were not previously treated, except for 4 patients who had prior radiotherapy. The 
tumors were staged according to the TNM classification and scored in stages I to IV 
according to UICC (1987). 
The pathological diagnosis and grading was assessed on the paraffin sections. All tumors 
were scored according to the modified Jakobsson system for SCC [9]. In this semi­
quantitative grading scheme, 6 parameters on the tumor cell population and the tumor-
host interface are scored in a 1 to 4 point scale. 
Table 1. Clinical and histopathologic^ characteristics of the head and neck squamous-celi carcinomas 
according to site 
Site 
Oral cavity 
Oropharynx 
Hypopharynx 
Larynx 
Total 
η 
19 
15 
7 
25 
66 
T(TNM)· 
1+2 
10 
5 
1 
12 
28 
3+4 
8 
9 
6 
11 
34 
I+II 
6 
4 
1 
9 
20 
Stage* 
III+IV 
12 
10 
6 
14 
42 
Histopathological grade 
well mod. poor undif.' 
1 
0 
0 
1 
2 
15 
11 
4 
16 
46 
3 
3 
3 
7 
16 
0 
1 
0 
1 
2 
Jakobsson score' 
¿12 
9 
6 
1 
9 
25 
13-15 2=16 
6 3 
5 3 
3 3 
11 5 
25 14 
' Four tumors represent recurrent disease, and were not classified. 
" Well, moderately, and poorly differentiated squamous-celi carcinomas and undifferentiated carcinomas. 
' Two cases were not scored because tumor surrounding tissue lacked in the samples. 
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Table 2. Antibodies usai for immunohiitochemial analysis ofHlA antigen expression on tumor celli. 
Antibody 
MAbW6/32 
МЛЬНСЮ 
МАЬНСЛ2 
RaHC rabbit serum 
DR rabbit scrum 
Specificity 
HLA-A.B.C heavy chains, 
ß2-microglobiilin bound 
HLA-B.C heavy chain» 
HLA-A heavy chains 
HLA-A.B.C heavy chains 
HLA class II. DR mainly 
Dilutions 
frozen sect. 
1:5000 (2-step) 
1:2500 (2-step) 
1:80 (3-step) 
not done 
1:1200 (2-step) 
Dilutions 
parafi", sect. 
not applicable 
1:400 (2-step) 
1:80 (2-step) 
1:80 (3-step) 
1:40 (3-step) 
Source 
Seralab 
H.PIoegh 
H.PIoegh 
H.PIoegh 
H.PIoegh 
Ref. 
[14] 
[15] 
[7] 
[15] 
personal 
communie 
Irnmunobistotbemtstry 
To evaluate HLA antigen expression on tumor cells a 2- or Э-stcp immunoperoxidase 
procedure on 4 um thick frozen or paraffin sections was performed. The antibodies used, 
their specificity, dilution, and source are summarized in Table 2. Beside the newly 
developed anti-class I MAbs HC10 and HCA2, the W6/32 MAb was used on frozen 
sections as a standard, and the rabbit RaHC serum, reactive with all 3 class I heavy chains, 
was added to evaluate the paraffin sections. The anti-HLA-DR serum used was raised in 
rabbits against intact purified HLA-DR. 
Cryostat scaions were air-dried and fixed in 100% acetone. For staining with the 
polyclonal anti-HLA-DR serum sections were prc-incubated with 20% normal swine 
serum (NSwS) for 10 min to prevent non-specific binding of the secondary antibody to 
the tissue. For paraffin sections the procedure was as follows: they were deparaffinized with 
xylene, hydrated in graded alcohols, and immersed in 3% H 2 0 2 in phosphate buffered 
saline (PBS) for 30 min to block endogenous peroxidase activity. Then they were prc-
incubated with 20% normal rabbit serum (for staining with HC10 and HCA2), or with 
20% NSwS (for RaHC), or 100% NSwS (for anti-HLA-DR). Cryostat or paraffin sections 
were incubated with the primary antibody for 60 min. This was followed by incubation 
with the second, and in case of a 3-step method also with the third peroxidase labeled 
antibody for 30 min each. Between all steps the slides were washed in PBS. The 
peroxidase label was visualized by incubation with a 3,3' diaminobenzidine 
tetrahydrochloride solution as a substrate for 5 min. Sections were counterstained with 
Harris hematoxylin, dehydrated and mounted. The whole procedure was performed at 
м> 
room temperature. From all samples negative controls were obtained by skipping 
incubation with the primary antibody. 
Evaluation 
All slides were read by 2 observers. The staining intensity of the tumor cells was scored as 
negative (-), weak (+), moderate (++) or strong (+++). Expression of antigens on the 
tumor cells was estimated as a percentage of the total number of tumor cells in the slide, 
and scored in one of the following categories: 0-5%; 6-25%; 26-50%; 51-75%; and 76-
100%. Necrotic or keratinized areas of tumor tissue were not taken into consideration. 
Well differentiated keratinizing tumors, however, were scored in the highest category if the 
basal non-keratinizing layers were completely positive. 
Statistical analysis 
Correlations between staining results on paraffin and frozen sections from the same tumors 
were assessed by calculating kappa coefficients [10]. This is a parameter of agreement, 
which takes chance agreement into account A kappa value of 0 represents only chance 
agreement, and the more kappa approximates 1, the better the agreement. Staining results 
of decalcified and non-decalcified paraffin sections were compared with the Wilcoxon rank 
test. Non-parametric tests (Wilcoxon rank test and Kruskal-Wallis test) were used to find 
possible differences in dinico-pathological parameters for the 4 site-specific groups. 
Correlations between tumor Η LA antigen expression and clinical and pathological 
parameters were evaluated by calculating Pearson or Spearman correlation coefficients. 
Results 
Quality of staining 
Staining properties will be given for each antibody. The W6/32 MAb showed very strong 
and homogeneous staining with almost all tumors. In several sections normal mucosa was 
present, which always revealed HLA class I expression, especially in the basal layers. The 
HC10 MAb gave moderate to strong intensity in most paraffin and frozen sections. 
Heterogeneous expression of HLA class I was observed in several tumors. HC10, like 
W6/32, showed mainly membranous, but also cytoplasmatic HLA dass I expression on 
tumor cells (Figs. 1 and 2). The staining patterns of the RaHC serum resembled very 
much those of HC10, however the intensity was markedly lower, and the number of 
tumor cells stained with RaHC was equal or lower than with HC10. The HCA2 MAb 
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exhibited a homogeneous, diffuse cytoplasmatic saining pattern which was less dear than 
with HC10. Some non-specific background staining was seen. 
The staining intensity of the anti-HLA-DR serum was moderate in both paraffin and 
(rozen sections. In the lymphatic tissue surrounding some tumors a typical follicular HLA 
class II distribution was seen. In several tumors a heterogeneous, mainly cytoplasmaric 
expression of HLA class II antigens was observed (Fig. 3). 
Decalcification of paraffin sections did not influence the quality of staining, nor the 
scoring. This was confirmed by comparing statistically the results on decalcified and non-
decalcified sections. 
Comparison of results m frozen and paraffin sections of the same tumor 
These results are based on 40 tumors from which both paraffin and frozen sections were 
available. The percentage positive tumor cells was scored in 1 of 5 categories as described 
above. Comparing the results of 2 slides, scores in the same and also in an adjacent 
category were considered acceptable. In this way, percentage-matched scores for paraffin 
and frozen sections were calculated, and found to be high (>80%). The kappa correlations 
indicate fair to good levels of agreement for HC10 as compared to HC10, and for anti-
HLA-DR as compared to anti-HLA-DR (Table 3). 
Table Э. Immunohistoehemicaüy detected HLA antigen expression on tumor ctUs: comparison of result 
in paraffin (par) and frozen (fr) sections of the same tumor (n=40). 
Antibodies/sections % match' kappa' f % match* kappa' p* 
HC10 par vs. W6/32 fr 51 0.15 0.04 81 0.35 0.004 
HCA2 par vs. W6/32 fr 68 0.10 n.s. 92 0.09 n.i. 
HC10 par vs. HC10 fr 50 0.30 <0.001 83 0.56 <0.001 
HCA2 par vs. НСЛ2 fr 70 0.27 0.005 90 0.35 0.007 
HC10 par vs. RaHC par 40 0.22 <0.001 74 0.45 <0.0001 
HLA-DR par vs. HLA-DR fr 60 0.29 0.002 90 0.60 <0.001 
The estimated percentage stained tumor celli in each slide ¡s scored in 1 of 5 categories. 
* Scores in the same category accepted. 
' Scores in the same or an adjacent category accepted. 
n.s.. not significant. 
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Table 4. HLA antigen expression on tumor ceUs in primary head and neck sauamous-ceU carcinomas of 
différent sites. 
Site η 
Oral cavity 19 
Oropharynx 15 
Hypopharynx 7 
Larynx 25 
Total 66 
S5 
0 
0 
0 
2 
2 
HLA ciani ' 
6-25 
1 
3 
0 
5 
9 
26-50 
0 
2 
2 
2 
6 
51-75 
6 
3 
4 
5 
18 
76-100 
12 
7 
1 
11 
31 
S5 
12 
9 
5 
19 
45 
HLA das II» 
6-25 
4 
3 
2 
3 
12 
26-50 
1 
1 
0 
1 
3 
51-75 
2 
2 
0 
1 
5 
76-100' 
0 
0 
0 
1 
1 
ImmunohistochcmJcaUy detected in paraffin sections with MAb HC 10* and anti-HLA-DR rabbit scrum'. 
Percentage tumor cells stained scored in 1 of 5 categories'. 
HLA class I and Π expression on SCC 
Table 4 contains the results of the evaluation of paraffin sections of 66 squamous-cell 
carcinomas stained with MAb HC 10 and anti-HLA-DR rabbit serum. Overall, HLA class 
1 antigens were expressed on more than 50% of the tumor cells in 49 tumors (74%). Only 
2 tumors were completely negative. A moderate but significant correlation was found 
between the level of HLA class I expression and the degree of differentiation (Pearson corr. 
coeff. 0.26; />=0.04), and also inversely with the Jakobsson score (Spearman corr. coeff. 
-0.26; p=0.03), i.e., high class I expression was observed in well and moderately 
differentiated carcinomas, and in tumors with a low Jakobsson score. 
HLA class II antigens were expressed on more than 5% of the tumor cells in 21 tumors 
(32%), including 9 tumors (14%) with more than 25% tumor cells stained. HLA class II 
expression was inversely correlated with the degree of differentiation (Pearson corr. coeff. 
-0.27; p=0.03) i.e., high class II expression was more frequently observed in poorly 
differentiated carcinomas. 
No correlation was found between HLA dass I or II expression and TNM classification or 
stage of disease. 
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HLA antigen expression on tumors of the 4 different subsites was compared independently 
of the other parameters, as no significant differences were found for the distribution of the 
TNM classification, stage, histological grade, and Jakobsson score over these 4 groups 
(Table 1). The tumors from the oral cavity (mostly oral tongue and floor of the mouth) 
showed a significantly higher HLA class I expression as compared to the larynx carcinomas 
(Table 5, Chi square test, ^=0.04). No differences in HLA class II expression related to 
tumor site were found. 
Table 5· HLA class I expression in relation to tumor site. 
Site 
Oral cavity 
Larynx 
η 
19 
25 
% cells stained* 
550% >50% 
1 IB 
9 16 
Ch? =4.19; df=l¡ ^.0.04. 
' Immunohistochemically detected in paraffin sections with MAb HC10. 
HLA class I and Π expression on verrucous carcinoma 
Seven verrucous carcinomas were evaluated, 2 from the oral cavity and 5 from the larynx. 
They had a mean Jakobsson score of 7. All had a very high HLA class I expression (76-
100% of the tumor cells stained) as detected with MAb HC10 in paraffin sections (Fig. 
4). HLA class II was expressed on >5% of the tumor cells in 5 (71Ή), and on >25% in 1 
tumor (14%). 
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Figure 1. Moderately differentiated SCC of the oral tongue, paraffin section, stained with MAb 
HC10. Heterogeneous HLA class I expression on the tumor cells is illustrated. The normal mucosa 
(on the right) showes staining in the basal layers. Bar = 20 pm. 
Figure 2. Moderately differentiated SCC of the larynx, paraffin section, stained with MAb HC10, 
showing homogeneous, mainly membranous staining pattern of tumor cells. Bar = 20 pm. 
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Figure 3. Paraffin section of moderately differentiated SCC of the oropharynx, stained with anti-
HLA-DR serum. Staining of tumor cells with heterogeneous intensity is locally seen. Bar = 60 pm. 
Figure 4. Paraffin section of verrucous carcinoma of the larynx, stained with MAb HC 10, scored 
in the highest category for HLA class I expression. Bar = 60 pm. 
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Discussion 
A panel of recently developed anti-HLA antibodies was tested on paraffin sections of 
HNSCCs. For H LA class I detection on paraffin sections the HC10 and HCA2 MAbs 
were compared with the W6/32 MAb on (rozen sections of the same tumors. Although a 
high percentage of matched scores (81% and 92%, respectively) was found, the kappa 
correlations were moderate or, in case of HCA2 even not significant. Several explanations 
are possible for these findings. Statistical calculations are highly influenced by the distorted 
distribution of H LA class I expression detected with W6/32 in this group, which was 
found in the highest category in almost all cases. Furthermore, W6/32 has a somewhat 
broader reactivity than other anti-HLA class I MAbs [4]. We performed additional 
staining with the anti-HLA class I MAbs BRL [4] and B9 [5] in 14 of the 40 frozen 
tumor sections and found a somewhat lower class I expression as compared to W6/32 as 
well (results not shown). Besides, W6/32, НСЮ and HCA2 are directed against different 
antigenic determinants of HLA class I. Immunohistochemical staining with the anti-HLA-
OR rabbit serum gave quantitatively and qualitatively comparable results on frozen and 
paraffin sections. 
We conclude that immunohistochemical detection of HLA antigen expression with these 
antibodies on conventionally processed tumor tissue samples is reliable. For HLA class I 
expression the MAb HC 10 is preferred to HCA2 and RaHC because of the best 
correlation with W6/32 and the clearest staining pattern. Advantages of this method are 
the much higher availability and the bener preserved morphology of paraffin-embedded 
tissue as compared to frozen material. 
We used this technique to evaluate the HLA antigen expression on tumor cells in 66 
paraffin-embedded HNSCCs. Overall, high HLA class I antigen expression was found, 
especially in well and moderately differentiated carcinomas and in tumors with a low 
Jakobsson score, in agreement with the findings of Esteban et aL [3] in frozen sections of 
38 larynx and hypopharynx carcinomas. There was no evidence for selective H LA-A or -B 
loss when comparing the results of RaHC (anti-HLA-A,B,C), HCA2 (anti-HLA-A) and 
HC10 (anti-HLA-B.C). However, only immunohistochemical and no molecular biological 
techniques were used. 
HLA class II antigen expression on tumor cells was locally observed in a minority of the 
SCCs. An inverse correlation between class II expression and degree of differentiation has 
also been found by Houck et aL [11], evaluating frozen sections of 30 HNSCCs. In a 
separately analyzed group of verrucous carcinomas, however, which are a highly 
differentiated variant of SCC, we found relatively high HLA class II expression, as 
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compared to the SCC Although topological correlation between H LA class H-expressing 
tumor cells and infiltration of lymphocytic cells was observed in some tumors, both 
verrucous and non-verrucous, this could not consistently explain HLA class II staining 
pancrns. Our results on HLA class II expression do not indicate independent prognostic 
relevance of this factor, and are not in accord with those of Esteban et al [12], who found 
far more restricted class II expression in a group of 69 SCCs of the larynx. Differences in 
results of immunohistochemical studies, however, may be related to differences in 
techniques, antibodies and lesions used, and interpretation of staining patterns. 
Head and neck squamous-cell carcinoma represents a heterogeneous group of diseases. 
Their biological behavior and prognosis are related to stage of disease and primary tumor 
site. It thus appears reasonable to compare different subgroups when evaluating possible 
prognostic parameters. We did not find stage-related differences in HLA class I and II 
expression. However, dear site-related class I expression was observed, and high HLA class 
I expression was observed especially in the carcinomas of the oral cavity. 
When using local IL-2 immunotherapy in an animal tumor model, the tumor response 
highly depends on the presence of peritumoral lymphocytes [13]. In this respect, the well 
developed lymphoid tissue in the oral mucosa may be important. The high HLA class I 
expression in carcinomas of the oral cavity implies susceptibility to interaction with CD8' 
cytotoxic Τ cells. Tumors of the oral cavity arc also easily accessible to local injections and 
to clinical observation. This suggests that the subgroup of oral cavity carcinomas might be 
well suited for local immunotherapy among HNSCCs. 
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Chapter 4 
Perilymphatic administration of recombinant 
interleukin-2 in patients with locally far-advanced, 
nonpretreated head and neck squamous-cell carcinoma 
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Roy S, Ruiter DJ. Clinical and immunopathological results of a phase II study of 
perilymphatically injected recombinant interleukin-2 in locally far-advanced, nonpretreated 
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Summary 
Background: In experimental tumor models specific and nonspecific host effector 
mechanisms were recruited by local low-dose interleukin-2 (IL-2) injections and the 
presence of otherwise nonreacting lymphocytes at the tumor site (ƒ Immunol 1985; 
134:1305). This approach was applied in head and neck squamous-ccll carcinoma patients 
(HNSCC), and the first study reported 6 objective tumor responses in 10 patients {Cancer 
1988; 62:2482). 
Patients and methods: In 15 patients with locally far-advanced, nonpretreated HNSCC 
daily low-dose (200-4,000 U) perilymphatic IL-2 injections were given for 10 days. 
Tumor biopsies were taken before and after treatment for histopathological evaluation of 
the mononuclear cell infiltrate and immunohistochcmical detection of human leukocyte 
antigen (HLA) expression on tumor cells. 
Results: No advene effects were recorded. There were no objective responses. HLA class I 
and II antigen expression was detectable in 9/10 and in 2/10 tumors, respectively. As 
compared to pretreatment biopsies, no changes in the mononuclear cell infiltrate or in 
HLA expression were found following treatment. 
Conclusions: Low-dose perilymphatic IL-2 therapy is not effective in locally far-advanced 
HNSCC. The discrepancy with the previously published clinical study might be related to 
tumor size. 
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Introduction 
The potential of systemically administered interleukin-2 (IL-2) in cancer immunotherapy is 
presently being explored in many centers. High doses of IL-2, alone or in combination 
with lymphokine-activated killer cells, induce tumor regression in a number of patients 
with metastasized melanoma and renal cell carcinoma [1]. However, this treatment is 
accompanied by serious toxicity. Locoregional administration of IL-2, on the other hand, 
has had less attention, but may have important advantages in certain tumor types [2]. 
Forni et αϊ [3-5] described the effects of locoregional injections of very low doses of IL-2 
in a CE-2 sarcoma in syngeneic BALB/c mice. In the presence of otherwise non-reacting 
lymphocytes from tumor-bearing mice, ¡mmunorecognition of tumor cells was enhanced 
and specific and nonspecific host effector mechanisms were recruited. This resulted in 
almost complete tumor-growth inhibition and the development of a specific immunologic 
memory. Higher doses of IL-2 did not improve the effect. 
Based on these results, a clinical study was started by Cortesina et αϊ [6] in patients with 
recurrent head and neck squamous-cell carcinoma (HNSCC). In ten patients, treated with 
repeated perilymphatic injections of 200 U of Jurkat-IL-2, three complete responses 
(duration of 4-6 months) and three partial responses were recorded. No tumor regression 
was seen in the two patients who had prior bilateral lymph-node dissection. 
Local IL-2 immunotherapy appears to be highly suited for the treatment of locally 
advanced HNSCC with its superficial location (making it accessible to injection) and 
juxtaposition to an extensive lymph-node network (and thus a pool of lymphocytes). With 
current surgical, radiotherapeutic, and chemotherapeutic treatment rrethods, the prognosis 
for these patients is poor [7-12]. Besides this, in HNSCC patients, immune reactivity is 
frequently depressed [13,14]. IL-2 might help to overcome this. The addition of IL-2 to 
in vitro cultures restores the diminished lymphocyte function and counteracts immune 
suppressive effects from the HNSCC patient's serum [15]. 
The present study was designed to verify the value of treatment with a low dose of 
recombinant IL-2 injected perilymphatically in HNSCC, as described by Cortesina et aL 
[6]. Contrary to them, however, we selected a nonpretreated patient group, because of the 
expected relevance of an intact lymph-node system {i.e., not damaged by prior therapy). 
Tumor biopsies for histopathological and immunohistochemical studies were taken before 
and after IL-2 treatment to obtain additional diagnostic prognostic, and biological 
information. 
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Matcriab and methods 
Patients 
Fifteen patients with histologically proven, locally far-advanced, nonpretreated HNSCC, 
not amenable to primary therapy with curative intent, gave their informed consent and 
entered into this study between July 1988 and January 1989. Eligible patients met the 
following requirements: a Kamofsky performance status of 70% or more, an expected 
survival of at least 3 months, normal hematologic parameters, adequate liver, kidney and 
cardiac function, no other significant medical conditions requiring ongoing therapy, no 
organ allografts, no distant metastases, and no second malignancies. Patient characteristics 
are summarized in Table 1. 
Table 1. Patient characteristics and treatment with perilymphatic injections ofIL-2 in 15 patients with 
hcally far-advanced HNSCC. 
Tumor IL-2 injections 
Pat. Age, TNM Performance Dose/ Response' 
no. sex Location stage' status* Site' site' Courses (day 28) 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
57.F 
48.M 
67,M 
55,M 
58,M 
74.F 
61,M 
78.M 
51,M 
43.M 
67.M 
65,M 
73.F 
50.M 
60.F 
Oropharynx 
Floor of mouth 
Floor of mouth 
Hypopharynx 
Hypopharynx 
Floor of mouth 
Hypopharynx 
Oropharynx 
Floor of mouth 
Oropharynx 
Oropharynx 
Oropharynx 
Oropharynx 
Oral cavity 
Oropharynx 
T3N2 
T4N3 
T4N3 
T4N3 
T4N3 
T4N1 
T4N3 
T4N3 
T4N3 
T4N1 
T4N3 
T4N0 
T2N3 
T4N3 
T4N2 
80% 
100% 
70% 
100% 
90% 
80% 
70% 
100% 
90% 
90% 
80% 
90% 
100% 
100% 
90% 
Ы 
uni 
uni 
uni 
Ьі 
uni 
uni 
ы 
ы 
uni 
Ьі 
uni 
bi 
Ы 
uni 
0.2 
0.2 
0.2 
0.2 
0.2 
0.2 
0.2 
0.2 
0.4 
0.4 
0.4 
0.4 
0.4 
0.4 
0.4 
1 SD 
2 SD 
1 PD 
2 SD 
1 SD 
1 SD 
1(8 days) -
1(9 days) -
1 PD 
1 PD 
1 SD 
1 SD 
1 SD 
1 PD 
1 SD 
' Indicates tumor sin at the start of IL-2 treatment. All were M0. 
' Kamofsky score. 
' uni, unilateral; bi, bilateral. 
' Dose in ug of IL-2. In cases of bilateral injections, twice this dose was administered. 
' SD, stable disease; PD, progressive disease. 
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Treatment 
Recombinant IL-2 was provided by Glaxo 1MB (Geneva, Switzerland). The specific 
activity was lOMO7 U/mg protein. IL-2 was diluted in saline, containing 10% human 
serum albumin. Perilymphatical bolus injections were given on 10 consecutive days 
ipsilateral to the side with the tumor, or bilateral in cases of midline or bilateral disease. 
The injection site (1.5 cm from the insertion of the sternocleidomastoid muscle to the 
mastoid tip at a depth of 1.5 cm) is based on lymphographic studies, as mentioned by 
Conesina et αϊ [6]. The first eight patients received IL-2 0.2 pg/site/day, and, as no 
response was seen in this group, the seven subsequent patients received IL-2 0.4 
pg/site/day. Patients who received bilateral injections got twice this dose. This course was 
scheduled to be repeated after 30 days in responding patients. The tumor response was 
evaluated on days 10 and 28 with physical examination and/or CT-scan, and determined 
according to WHO criteria. 
Tissue specimen 
Surgical biopsies from the primary tumor both prior to the start of treatment and on day 
18 were obtained from 10 patients. A fresh specimen from mosc of these biopsies was deep 
frozen and stored in liquid nitrogen until use. 
The histopathological analyses were centrally performed on paraffin sections, and included 
documentation of the pathological diagnosis and grading according to the modified 
Jakobsson system for squamous-cell carcinoma. In this semi-quantitative grading scheme, 
six histological parameters of the tumor cell population and the tumor-host interface are 
scored on a 1 to 4 point scale [16]. The cellular infiltrate in the tumor-surrounding tissue 
was examined for overall intensity of mononuclear cells and the intensity of particular 
subsets of cells (lymphocytes, plasma cells, neutrophils, eosinophils, macrophages). The 
intensity was scored as - (no or only very few cells), + (occasional patch), ++ (patchy rim), 
or +++ (continuous rim of infiltrating cells). 
Immunobistocbemieal analysis 
The expression of human leukocyte antigens (HLA) by tumor cells was determined using 
an indirect ¡mmunoperoxidase procedure with 4 pm thick cryostat sections. If these were 
not available, paraffin sections were used. The peroxidase label was visualized by 3,3'-
diaminobenzidine tetrahydrochloride and hydrogen peroxide. Sections were countcrstained 
with Harris's hematoxylin. The intensity of the staining was scored from negative (-) to 
highly positive (+++). Expression of HLA antigens by tumor cells was estimated as a 
percentage of the total number of tumor cells, and scored in one of the following 
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categories: 0-5%. 6-25%, 26-50%, 51-75%. and 76-100%. Phenotyping of the 
lymphocytic infiltrate was performed according to standard procedures on frozen sections. 
The slides were read by two different observers; agreement was above 90%. 
Antibodies 
The following panel was used for evaluating HLA antigen expression: the monoclonal 
antibody (MAb) W6/32, recognizing all ß2-microglobulin-bound HLA class I antigens 
[17]; a MAb against ß2-microglobulin (done B.11.G6, Dr. B. Malissen, Marseille, 
France); HCA2, a MAb recognizing mainly heavy (H) chains of class I HLA-A loci [18]; 
HC10, a MAb recognizing mainly H chains of class I HLA-B and С loci [18]; RaHC, 
anti-Η chain rabbit serum recognizing HLA-A, B, and С H chains [18]; and three rabbit 
sera recognizing HLA class II antigens, raised against HLA-DR, -DP, and -DQ, 
respectively (all provided by Dr. H.L. Ploegh, Amsterdam, The Netherlands). Except for 
W6/32 and anti-ß2-microglobulin, all antibodies are applicable to both cryostat and 
paraffin sections. In addition T i l (anti-CD2), Leu4 (anti-CD3), Leu3 (anti-CD4), WT82 
(anti-CD8), Bl (anti-CD20), Leu7 [natural killer (NK) cells], and anti-HLA-DR were 
used for phenotyping the infiltrate [19]. 
Results 
Clinical evaluation 
Thirteen patients completed the 10-day course. In patient 7, treatment was stopped after 8 
days because of progressive dyspnea due to tumor progression. Patient 8 was withdrawn 
from the study after 9 days because of the development of a double-sided pneumonia and 
an arterial embolism in the right femoral artery. This patient died of pulmonary failure 4 
weeks after starting IL-2 treatment. In patient 13, an increasing swelling and redness of 
the neck lymph-node mass during treatment resulted in a rupture with loss of necrotic 
material on day 11. There were no signs of infection. 
Thirteen patients were évaluable on day 28. None of them showed signs of tumor 
regression. Stable disease was determined in nine patients and progressive disease in four 
patients. Patients 2 and 4 had subjective improvement of symptoms. Both received a 
second treatment course, without inducing an objective response. 
The treatment was well tolerated. No side effects were recorded. 
Subsequendy, 11 patients received chemotherapy and/or radiotherapy. Patient 4 had a 
complete response after combined chemo- and radiotherapy, and was still free of tumor 17 
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months after the IL-2 treatment. For all other patients, the median survival from the start 
of the IL-2 treatment was 7 months. 
Histopatholopcal evaluation 
From ten patients (nos. 1,2,3.4,5,9,10,11,14,15), tumor biopsies from both before and 
after IL-2 treatment were available (Table 2). All had moderately differentiated squamous-
cell carcinoma. The mean of the Jakobsson score before treatment was 13, ranging from 
11 to 14, except in patient 1 who had a score of 20 points. 
A patchy rim of mononuclear cells (++) was observed in the tumor-surrounding tissue in 
seven out of ten pretreatment biopsies. No significant changes in the intensity of the 
mononuclear cell infíltrate were found following IL-2 treatment (Table 2). The 
composition of the mononuclear cell infiltrate also did not change significantly after IL-2 
treatment. Lymphocytes were the most frequently present cells, followed by plasma cells. 
Eosinophils were sparse, and their number did not increase after IL-2 treatment (data not 
shown). 
Additional immunohistochemical phenotyping of the lymphocytic infiltrate in two 
representative patients (nos. 9 and 11) showed the following profile. The large majority of 
the lymphocytes were Τ cells; the CD4/CD8 ratio was about 1:1; approximately 75% of 
the Τ cells were HLA-DR positive; В cells (Bl) and NK cells (Leu7) were sporadically 
observed. No differences between treated and nontreated lesions were found (data not 
shown). 
Expression ofHLA class I and Π antigens by tumor cells 
The levels of expression obtained using the different antibodies for HLA class I antigens 
agreed. W6/32 and HC 10 gave the most intense staining in cryostat and paraffin sections, 
respectively. The results for HC10 are presented in Table 2. In six of ten tumor biopsies, 
more than 50% of the tumor cells showed HLA class I antigen expression. Only one 
sample (no. 1), which also had a very high Jakobsson score, was negative for HLA class I 
antigens (0-5%). No selective loss of HLA-B was seen. After IL-2 treatment, no significant 
changes in HLA class I expression could be detected. 
Equal levels of expression were obtained with the antibodies against HLA-DR, -DP, and -
DQ. The results for anti-HLA-DR are presented in Table 2. Eight of ten samples were 
HLA class H-ncgative (0-5%), both before and after IL-2 treatment. Only two biopsies 
(nos. 9 and 10) had locally positive tumor cells before and after IL-2 treatment. These 
tumors both had a relatively low Jakobsson score. There was no striking intensity of the 
mononuclear cell infiltrate in the HLA class Il-positive tumors. 
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Table 2. Histopathological evaluation and HLA antigen expression ση f re- and past-treatment tumor 
biopsies from ¡0 patients with HNSCC, treated with perilymphatic injections afIL-2. 
Par. 
no.« 
1 
2 
3 
4 
5 
9 
10 
11 
14 
15 
Histopathological feature» 
Giade' 
Moderately 
Moderately 
Moderately 
Moderately 
Moderately 
Moderately 
Moderately 
Moderately 
Moderately 
Moderately 
Jaki 
Pre-
20 
13 
13 
13 
12 
11 
11 
14 
14 
11 
юоге* 
Post-
18 
12 
12 
14 
15 
10 
17 
17 
11 
8 
Intensity of 
infiltrate' 
Pre-
+ 
+ 
++ 
•»·+ 
++ 
+• 
+•+ 
++ 
++ 
++ 
Post-
• 
++ 
+ 
+++ 
++ 
+ 
n.L 
+++ 
n.i. 
++ 
HLA antigen expression by tumor 
class 1 
Pre-
0-5% 
51-75% 
6-25% 
26-50% 
76-100% 
76-100% 
76-100% 
76-100% 
6-25% 
76-100% 
Post-
0-5% 
51-75% 
26-50% 
6-25% 
76-100% 
76-100% 
76-100% 
76-100% 
51-75% 
76-100% 
class II 
Pre-
0-5% 
0-5% 
0-5% 
0-5% 
0-5% 
26-50% 
51-75% 
0-5% 
0-5% 
0-5% 
cells' 
Post· 
0-5% 
0-5% 
0-5% 
0-5% 
0-5% 
26-50% 
6-25% 
0-5% 
0-5% 
0-5% 
Pre-, pretreatment; post-, pojt-IL-2 treatment on day 18. 
* Numben corresponding to Table 1. 
' Grade of squamous-cell carcinoma, pretreatment; moderately differentiated. 
' Jakobson score. 
J
 -, no or only very few mononuclear cells; +. occasional patch; ++, patchy rim; •+•, continuous rim of 
infiltrating cells; n.i., not interpretable due to absence of tissue surrounding the tumor in the specimen. 
' Percentage of positive cells; results from MAb HC10 (HLA class I), and ano-HLA-DR serum (HLA class 
ID-
Discussion 
In 15 patients with nonpretreated locally advanced HNSCC, we did not observe tumor 
shrinkage after a 10-day treatment course with low doses of IL-2 injected 
perilymphatically. The observation period used to detect a response to IL-2 treatment was 
4 weeks, which is short. ID prior studies on this treatment modality [6,20], however, 
dinica] responses and histological changes occurred within 4 weeks after the start of 
treatment. Our findings are in contrast with Cortesina's results [6] with perilymphatic 
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injections of Jurkat-IL-2 in recurrent inoperable HNSCC, which might be partly explained 
by a difference in patient characteristic The current study concerned primary disease and 
the size of the tumor masses, as indicated by the TNM stage, was considerably larger than 
in Corrcsina's patients. 
Our histopathologic^ findings corresponded to the clinical results, since no changes were 
found after treatment. Furthermore, in the post-IL-2 biopsies, we did not find an increase 
in the mononuclear cell infiltrate, an eosinophilic infiltration, or necrosis of tumor cells, as 
described in responding patients in other series [20,21]. 
The low level of HLA class II antigen expression in HNSCC has been described before by 
Esteban et aL [22], and might be disadvantageous with regard to tumor control. HLA class 
II antigens are essential for antigen presentation to CD4-positive Τ cells, and a correlation 
between expression of HLA-DR antigens by tumor cells and a favorable response to IL-2-
based immunotherapy has been suggested [21,23]. In HNSCC Esteban et aL [22] found a 
correlation between HLA class II antigen expression and a well-differentiated pattern and 
also a bener prognosis. The low frequency of expression by HNSCC lesions, however, 
limits the utility of HLA class II as a marker to predict the prognosis or the effect of 
immunotherapy. 
HLA class I antigen expression, on the other hand, was found in nine of the ten cases in 
the current study. This might suggest susceptibility to killing by CD8-positive cytotoxic 
lymphocytes, one of the supposed mechanisms of immunotherapy. Besides, a low 
expression of HLA class I antigens is associated with a poor prognosis in melanoma [24], 
and with a poor differentiation in HNSCC [22]. Despite the high HLA class I expression 
in our study, however, the prognosis was poor. 
Further studies are required to establish the true value of locoregional treatment with low 
doses of IL-2 in HNSCC. Our findings illustrate the feasibility of repeated representative 
histological tumor analysis in this kind of cancer, which might provide more relevant 
information about the mechanisms of action of immunotherapy and factors predictive ol 
prognosis. 
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Chapter 5 
Recombinant interleukin-2 and PEG-interleukin-2 
in locoregional immunotherapy 
of established guinea-pig line-10 tumors 
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Mattijssen V, De Mulder PHM, Balemans LTM, Steerenberg PA. Efficacy of polyethylene 
glycol-modified interleukin-2 in locoregional immunotherapy of guinea-pig tumors. Proc 
AACR 1992; 33:329 (abstract). 
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Summary 
Background: Polyethylene glycol-modified imerieukin-2 (PEG-IL-2) represents a cytokine 
with prolonged circulatory half-life and increased antitumor activity as compared to 
unmodified IL-2 after systemic administration. We studied whether PEG-IL-2 would also 
be advantageous in locoregional immunotherapy of established tumors. 
Methods: The syngeneic guinea-pig line· 10 tumor model was used, characterized by 
progressive local tumor growth following intradermal inoculation, and regional lymph-
node metastases within 7 days. Intratumoral and/or perilymphatic injections with IL-2 or 
PEG-IL-2 were started on day 7 after inoculation, in animals with palpable tumors. 
Treatment groups consisted of 5-6 animals. 
Results: Combined intratumoral and perilymphatic injections with PEG-IL-2 caused signifi-
cant growth inhibition of both the primary tumor and che regional lymph-node metastases 
at lower doses and with less frequent administration than IL-2. The best schedule for 
PEG-IL-2 included 3 injections a week for 5 weeks, resulting in cure of 4/17 and 5/5 
(jxO.Ol) animals at the 2 most efficient dose levels tested (60,000 and 200,000 U, res-
pectively). Subsequent experiments indicated that the intratumoral and not the peri-
lymphatic injection route was essential for the obtained antitumor effect. Moreover, 12/12 
animals cured after PEG-IL-2 treatment rejected a rechallenge with line-10 tumor cells. 
No cures were seen after IL-2 treatment. 
Conclusion: Intratumoral PEG-IL-2 injections can cure guinea-pigs with palpable 
experimental rumors and regional lymph-node micrometastases, and induce protective 
systemic antitumor activity, without signs of toxicity. 
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Introduction 
Interleukin-2 (IL-2), a cytokine produced by activated Τ cells, is significant for the growth 
and function of a variety of immune ceib [1-5]. Endogenous IL-2 mediates ics effect 
locally at the cell-cell interaction level, and its activity is not normally detectable in human 
serum. Since recombinant human IL-2 has become available, its potential as an immune 
stimulant in anticancer immunotherapy has been studied on a large scale. Most studies 
concern intravenous (i.V.), i.e. systemic, administration of IL-2 either alone or in 
combination with other cytokines, or adoptive cellular therapy. The very short circulatory 
half-life, being 13 min initially after i.v. bolus injection followed by a slower phase with a 
half-life of 85 min, is well documented [6]. Using high doses and long-term i.v. admi­
nistration, antitumor effects are obtained with IL-2-based therapy especially in metastatic 
malignant melanoma and renal-cell carcinoma [7]. However, the number of responding 
patients in this and other trials is limited and the treatment is accompanied by serious 
toxicity. Although subcutaneous (s.c) administration, resulting in lower but fairly constant 
serum IL-2 levels for about 8 h [6], may reduce toxicity [8], a widely applicable regimen 
for treating cancer patients has not yet been realized. Furthermore, the mechanisms by 
which IL-2 mediates antitumor effects in vivo, i.e. activation of a circulating cell 
population such as lymphokine-activated killer cells, or stimulation of immune reactions 
directly at the rumor site, are largely unknown. Meanwhile it is questionable whether high-
dose i.v. or s.c IL-2 administration is always the most beneficial approach. Alternative 
administration routes are being explored, such as IL-2 injections inrralymphatically on the 
dorsum of the foot [9] or into the splenic or hepatic artery [10] in an attempt to enhance 
immunostimulation in vivo. On the other hand, locoregional IL-2 application should be 
considered in certain malignancies with local tumor spread. This might, in contrast to 
systemic administration, promote a more physiological immune activation, providing a 
higher IL-2 concentration at the tumor site to stimulate infiltrating immune cells, and 
avoiding systemic toxicity [11]. The efficacy of repeated injections with fairly low doses of 
natural IL-2 or recombinant IL-2 into or next to the tumor lesion, or around the tumor-
draining lymph nodes, has been described in several syngeneic animal tumor models [12-
14], in spontaneous bovine ocular carcinoma [15], in human bladder cancer [16], and 
head and neck squamous-cell carcinoma [17]. In addition, intracavitary application was 
studied in patients with malignancies limited to the peritoneal cavity [18]. 
Recently, chemical modification of IL-2 with the water-soluble polymer polyethylene 
glycol resulted in a substance with enhanced solubility and a 10- to 20-fold prolonged 
circulatory half-life [19,20]. The in vitro specific activity of PEG-IL-2 is qualitatively 
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unchanged, bue quantitatively 2- to 3-fold lower than that of unmodified IL-2. However, 
this does not correlate with its in vivo activity, which may be related to the duration of 
exposure. In 3 murine tumors i.v. administered PEG-IL-2 showed a significantly higher 
antitumor activity than IL-2. and a less frequent administration schedule proved to be 
sufficient [21]. So гаг. no data arc available on locoregional PEG-IL-2 application in 
animal studies or patients. 
We have investigated in a syngeneic guinea-pig tumor model whether PEG-IL-2 would be 
particularly advantageous in locoregional immunotherapy as well. The objectives of this 
study were: 1. to compare the antitumor activity of IL-2 and PEG-IL-2 when injected 
intratumorally and perilymphatically in established tumors; 2. to determine the optimal 
administration route and schedule for locoregional PEG-IL-2 therapy; and 3. to observe 
the development of systemic antitumor activity after locoregional PEG-IL-2 application. 
Matcriab and methods 
Anitmds 
Female Sewall-Wright inbred strain-2 guinea-pigs were obtained from the National Cancer 
Institute-Frederick Cancer Research Facility, Frederick, MD. The animals were caged in 
groups of 6 or less and fed guinea-pig rations and water ad libitum. They were used when 
2 to 3 months old, weighing 400 to 600 g. 
Tumor 
Line-10 tumor cells, syngeneic to strain-2 guinea-pigs, were kindly provided by Dr. H.J. 
Rapp and Dr. B. Zbar (National Cancer Institute, Bethesda, MO). This hepatocellular 
carcinoma was, as one in a series of tumors, induced by oral administration of 
diethylnitrosamine [22], and converted to the ascites form. Intradermal inoculation of 
lxlO6 tumor cells in the anterior flank led to progressive local tumor growth, development 
of regional axillary lymph-node metastases within 1 week, and lung metastases resulting in 
death after 60-90 days [23]· The tumor was weakly immunogenic. The tumor-cell line was 
maintained as frozen stock, and propagated intrapcritoncally. Tumor cells were used in 
their 12th passage. 
6] 
Tbtrapeutict 
Highly purified recombinant IL-2 (Proleukin) and PEG-IL-2 were provided by Eurocctus, 
Amsterdam, The Netherlands. The PEG-IL-2 used has a degree of modification equivalent 
to 2-3 PEG M, 7,000 molecules/IL-2 molecule. The apparent average molecular weight of 
this species was M, 160,000 by size-exclusion chromatography [19]. The specific activities 
of the IL-2 and PEG-IL-2 were 18.0x10e and 9.4x10* U/mg IL-2 protein, respectively. 
Stock concentrates of 1x10* U/ml were prepared from lyophilized IL-2 and PEG-IL-2 by 
reconstitution in sterile water and dilution in phosphate-buffered saline (PBS) containing 
1% (w/v) bovine serum albumin (BSA), and stored at -20°C. Before use IL-2 and PEG-
IL-2 were further diluted in PBS containing 0.1% (w/v) BSA. 
Treatment schedules 
Guinea-pigs were injected inuadermally in the left anterior flank with 1x10* line-10 tumor 
cells. After 7 days the animals, bearing established tumors, were randomly divided into 
treatment groups of 5-6 animals, and 0.2-ml injections with IL-2 or PEG-IL-2 were 
started. In the first series of experiments both intratumoral and perilymphatic injections 
were given at différent schedules and dose levels. The perilymphatic injection was 
administered between the tumor inoculation site and the tumor-draining axillary lymph 
nodes. In subsequent experiments the influence of the injection site was evaluated by 
treating animals cither intratumorally or perilymphatically. Control animals received 
injections with PBS containing 0.1% (w/v) BSA in a similar way, or no injections at all. 
To evaluate the effect of PEG on tumor growth, one separate group received injections 
with PEG Mr 6,000 (Merck, Darmstadt, Germany) in PBS without IL-2. The tumors on 
the flank were measured weekly from day 7 with calipers in 3 directions and the volume 
was calculated. The incidence of palpable axillary lymph-node metastases was recorded. 
The animals were observed until the diameter of the axillary lymph-node mass exceeded 
25 mm, at which time they were killed. 
Treated animals without signs of tumor growth on day 49 received a second challenge 
with 1x10* line-10 tumor cells intradermally in the contralateral (right) flank to test the 
development of systemic antitumor activity. As a control, untreated animals were 
inoculated at the same time. Tumor growth was measured weekly. 
Treated animals were considered to be cured if tumor-free on day 84 after tumor-cell 
inoculation. 
S2 
Statistical analysis 
Students' í-test was used to determine significant differences in tumor growth between 
treatment and control groups of animals. In case of insufficient homogeneity of variances, 
die Welch correction with respect to the degrees of freedom was applied. Differences in 
survival between control and treatment groups were evaluated by Fisher's exact test. 
Results 
Daily intratumorat and perilymphatic administration ofIL-2 or PEG-IL-2 
The activity of IL-2 and PEG-IL-2 in locorcgional immunotherapy was compared first in 
ι daily administration schedule. A combined intratumoral and perilymphatic approach was 
chosen, because in the model used microscopic axillary lymph-node m et is tases have 
il ready developed before day 7 [23]. 
On day 7 after line-10 tumor inoculation, animals had established tumors on the flank 
with a diameter of 6-8 mm. In control animals the tumor always showed progressive 
growth with disruption of the skin and ulceration, while axillary lymph-node metastases 
became palpable on day 21 to 28 and reached a diameter of approximately 25 mm on day 
42. No differences in tumor growth were observed between nontreated animals and those 
receiving PBS+BSA control injections (Fig. 1). The observation period in the Figures up to 
lay 42 marks the point at which the control animals had to be killed because of extensive 
regional lymph-node metastases. 
Figure 1 shows the results of an experiment comparing the effects of 8 daily IL-2 and 
PEG-IL-2 injections, with doses ranging from 3,000 to 60,000 U per injection site, on the 
intradermal growth of line-10. Treatment with IL-2 resulted in a significant inhibition of 
tumor growth at the dose level of 60,000 U (Fig. la, /xO.01). With PEG-IL-2, however, a 
similar inhibition was achieved at a dose level of 9,000 U (Fig.lb, /xO.01). This was 
confirmed in a similar experiment (tumor-growth curves not shown). 
Table I summarizes the data on lymph-node metastases of all experiments performed. 
When daily treatment schedules were used, the incidence of palpable axillary lymph nodes 
was delayed by 14 days or more in 4/26 (15%) of the IL-2-treated animals and in 33/50 
(66%) of the animals injected with PEG-IL-2 (Table 1, treatment groups 1-4 and 7-10, 
respectively). Only 1 animal, treated with 60,000 U PEG-IL-2, was cured (Table 1, group 
10). 
63 
2500 г 
m 
" 1250 
о 
a: rlL-2 
7 14 
A m А А Л A A A 
21 2 8 3 5 
ι 
4 2 
days after tLmor cell inoculation 
2 5 0 0 
* 1250 
о 
b:PEG-IL-2 
21 2 8 35 4 2 0 7 14 
A A ^ χ Φ Φ Ψ ^ 
days after tumor cell inoculation 
Figure 1. Growth of intradermal line-10 tumors following daily (day 7-14) intratumoral and 
perilymphatic injections with 11^ -2 (a) or PEG-IL-2 (b). The doses indicated are per injection site, 
per day. •, Control PBS+BSA; D, control untreated; Δ. 3,000 U; A, 9,000 U; O, 30,000 U; · , 
60,000 U. Arrows, treatment days. Points, mean values of 5 animals; bars, SEM. Statistically 
significant différences compared to the untreated group are indicated: *, fxO.05; **, /κθ.01; ***, 
/xO.OOl. 
Tabic 1. Metastatic growth and survival after loeoregional IL-2 or PEG-IL-2 treatment of established 
intradermal line-10 tumors in guinea-pigs'. 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
16. 
Treatment* 
Dose and schedule 
IL-2 
3,000 U, daily, day 7-14 
9,000 U, daily, day 7-14 
30,000 U, daily, day 7-14 
60,000 U, daily, day 7-14 
60,000 U, 2*/wk, for 5 wks 
60,000 U, Зх/wk, for 5 wks 
PEG-IL-2 
3,000 U, daily, day 7-14 
9,000 U, daily, day 7-14 
30,000 U, daily, day 7-14 
60,000 U, daily, day 7-14 
60,000 U, 2x/wk, for 5 wks 
60,000 U, Зх/wk, for 5 wks 
200,000 U, Зх/wk, for 5 wks 
60,000 U, Зх/wk, for 5 wks 
60,000 U, Зх/wk, for 5 wks 
60.000 U, Зх/wk, for 5 wks 
Site 
i.t.+p.l. 
i.t.+p.l. 
i.t.+p.l. 
i.t.+p.l. 
i.t.+p.l. 
i.t.+p.l. 
i.t.+p.l. 
i.t.+p.l. 
i.t.+p.l. 
i.t.+p.l. 
i.t.+p.l. 
i.t.+p.l. 
i.t.+p.l. 
ix 
p.l. 
p.l.' 
Develo 
lymph-
0 
3/5 
1/5 
1/11 
5/6 
676 
2/11 
1/17 
1/6 
1/6 
6/6 
pment of | palpable axillary 
node metastases; delay 
in days' 
7 
2/5 
4/5 
4/5 
7/11 
8/11 
3/11 
3/17 
2/6 
1/6 
3/6 
14 
1/5 
1/11 
1/6 
1/11 
5/11 
9/11 
9/17 
3/6 
2/17 
2/6 
¿21 
2/11 
3/11 
2/11 
4/17 
15/17 
5/5 
4/6 
1/6 
Tumor-free/ 
number treated 
(%) on day 84 
0/5 
0/5 
0/5 
0/11 
0/6 
0/6 
0/11 
0/11 
0/11 
1/17(6) 
0/6 
4/17 (24) 
5/5 (WO)·1 
2/6 (33) 
0/6 
0/6 
Summary of 5 separate experiments. 
Treatment with intratumoral (i.t.) and/or perilymphatic (p.l.) IL-2 or PEG-IL-2 injections was always 
started on day 7 after intradermal inoculation with 1x10* linc-10 tumor cells in the flank. Dose indicated 
in U per injection day, and per injection site. Treatment regimens 4,7,8,9,10 and 12 were tested in more 
than one experiment. 
Delay as compared to the control group of animals in the individual experiment, indicated as 
number/total treated. Control groups of animals were scored positive when ¿80% of animals had palpable 
axillary lymph nodes (¿6 mm). In the separate experiments this was on day 21, 28, or 35. 
Significant difference as compared to control group (/κθ.01). 
After excision of the tumor on the flank on day 7. 
65 
Intermittent intratMmoral and perilymphatic administration ofIL-2 or PEG-IL-2 
To test the schedule dependency, in another experiment the daily treatment course was 
compared to schedules with less frequent, but more prolonged, administration. Injections 
were given intratumorally and perilymphaticalry at a dose level of 60,000 U per injection 
site per day. PEG-IL-2 injected twice weekly (tumor-growth curve not shown) or 3 times 
weekly for 5 weeks (Fig. 2) had a significant tumor-growth-inhibiting effect (/κθ.05 and 
/κθ.01 respectively), while IL-2 using these schedules had no significant effect on the 
intradermal tumor (Fig. 2), nor on the lymph-node metastases (Table 1, treatment group 
5-6). Treatment with 3 PEG-IL-2 injections per week was equal to 8 daily 60,000 U 
PEG-IL-2 injections with regard to inhibition of the intradermal tumor growth (curve of 
daily treatment not shown in Fig. 2). Summarizing the results of the different experiments, 
however, the former schedule gave a more pronounced delay in development of palpable 
lymph nodes (Table 1, group 12 and 10 respectively). With the 3-times-weekly schedule a 
delay of at least 21 days was observed in 15/17 (88%) animals. Moreover, 4/17 (24%) 
animals in group 12 were cured. 
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days after txmor cell inoculation 
Figure 2. Growth of intradermal li ne-10 rumors following 3-times-weekly treatment with IL-2 or 
PEG-IL-2. Intratumoral and perilymphatic injections with IL-2 ( · ) or PEG-IL-2 (O) were given 3 
times weekly for 5 weeks (arrows) at a dose of 60,000 U per injection site, per day. •, Control, 
untreated; points, mean values of 6 animals; bars, SEM. Statistically significant differences 
compared to the control group are indicated: **, /xO.OI; ***, ^<0.001. 
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Relevance of injection site 
The relevance of the injection site was evaluated by treating animals either intratumorally 
or perilymphatically or at both locations with the optimal schedule so rar, i.e. PEG-IL-2 
injections (60,000 U) 3 times weekly. In addition, in one group only perilymphatic 
injections were given after the intradermal tumor was excised under general anaesthesia on 
day 7. Int га tumoral injections alone, like combined intratumoral and perilymphatic 
injections, suppressed intradermal tumor growth (Fig. 3). Furthermore, the development of 
lymph-node metastases was delayed for at least 21 days in 4/6 (67%) animals, and 2/6 
(33%) animals were cured (Table 1, group 14). Perilymphatic treatment, on the other 
hand, had no effect at all on the intradermal tumor on the flank (Fig. 3), and did not 
suppress the lymph-node metastases (Table 1, group 15). Even after excision of the 
primary tumor on day 7, the perilymphatic injections resulted in a variable, but mostly 
(5/6 animals) only 7- to 14- day delay in the growth of the axillary lymph-node metastases 
(Table 1, group 16). 
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Figure 3. Growth of intradermal line-10 cu more following treatment wich PEG-IL-2 ar diffèrent 
injection sites. PEG-IL-2 injections were given 3 times weekly for 5 weeks (arrows) ar a dose of 
60,000 U per injection sice per day. • , Control, PBS+BSA; O, intratumoral and perilymphatic; · , 
intratumoral; Δ, perilymphatic. Points, mean values of 6 animals; ban, SEM. Statistically 
significant differences compared to che concrol group are indicated: *, ƒx0.05; **, /κθ.01; ***, 
/xO.OOl. 
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Optimizing the PEG-IL-2 dote 
So far, the results obtained with doses ranging from 3,000 to 60.000 U showed a dose-
response relation for locoregional PEG-IL-2 treatment, and application 3 times weekly-
proved to be the best schedule. To further improve the efficacy the PEG-IL-2 dose was 
ucalated to 200,000 U. The results of this experiment are shown in Figure 4. In 5/5 
mimais no tumor was palpable on day 28, and no lymph-node metastases developed 
[Table 1, group 13). All 5 animals were cured (/κθ.01). 
In all experiments in this study, including the highest dose level of 200,000 U PEG-IL-2, 
therapy was well tolerated by the guinea-pigs. No adverse effects were seen at the injection 
site, and no premature deaths occurred. 
days after tumor cell inoculation 
Figure 4. Growth of intradermal line-10 tumors following treatment with PEG-IL-2 at different 
dose levels. Intratumoral and perilymphatic PEG-IL-2 injections were given 3 times weekly for 5 
weeks (arrows) at a dose of 60,000 U ( · ) or 200,000 U (O) per injection site per day. •, Control, 
PBS+BSA. Points, mean values of 5 animals; bars, SEM. t, death. Statistically significant 
differences compared to the control group are indicated: *, ^e0.05; **, ^<0.01; ***, /κθ.001. 
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Retballenge with line-ΙΟ tumor ceUs 
In total, 16 PEG-IL-2-treated animals (5 treated daily and 11 treated 3 times weekly; 
Table 2) showed no signs of tumor growth on day 49 in the individual experiments, and 
were given a second challenge with 1x10* viable line-10 tumor cells in the contralateral 
(right) flank. Three out of the 5 animals undergoing daily treatment (groups 8 and 10) 
rejected the rechallenge, however 2 of these 3 ultimately showed tumor growth at the 
primary inoculation side, and only 1 proved to be cured. All 11 animals receiving a 
rechallenge after PEG-IL-2 treatment 3 times weekly (group 12-14) were resistant to the 
line-10 tumor, and remained tumor-free. The nonprctreated control animals challenged at 
the same time all showed progressive tumor growth. None of the IL-2-treated animals was 
eligible for a second tumor challenge on day 49, because all had palpable lymph-node 
metastases. 
Table 2. Second challenge with lxl(f line-10 tumor ceto in guinea-pip following locoregianal PEG-
IL-2 treatment. 
V 
10 
12 
13 
14 
PEG-IL-2 treatment 
Dose and schedule 
9.000 U, daily, day 7-14 
60.000 U. daily, day 7-14 
60.000 U, 3»/wk, for 5 wb 
200,000 U, 3x/wk, for 5 wks 
60,000 U, Зк/wk, for 5 wks 
Site 
i.t.+p.l. 
i.t.+p.l. 
i.t.+p.l. 
i.t.+p.l. 
i.t. 
Number resistent*/ 
number challenged 
1/3 
2/2 
4/4 
5/5 
2/2 
Tumor-free* on 
day 84/number 
challenged 
0/3 
1/2 
4/4 
5/5 
2/2 
Animals without signs of tumor growth or lymph-node metastases after locoregional PEG-IL-2 treatment 
were rcchallengcd in the contralateral (right) flank on dag 49 after tumor inoculation. 
' Resistent to second tumor challenge in right Rank. 
* Tumor-free on original inoculation (left) side on day 84 after this inoculation. 
' Numbers corresponding to Table 1. 
Discussion 
In the present study PEG-IL-2 proved to have clear advantages in locoregional anticancer 
immunotherapy as compared to unmodified IL-2. PEG-IL-2 showed significant tumor-
growth-inhibiting effects, regarding both the primary tumor and the regional lymph-node 
metastases, at lower doses and with less frequent administration than IL-2. The best results 
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were obtained with PEG-IL-2 injected 3 times weekly, while IL-2 showed a tumor-
growth-inhibiting effect only if administered daily. This finding is in concordance with 
optimal treatment schedules for i.v. IL-2 or PEG-IL-2 administration [21]. Schedules with 
less frequent administration provide practical advantages in patient treatment. More 
important, however, is the fact that locoregional PEG-IL-2 treatment resulted in cure of 
guinea-pigs with established tumors. Furthermore, cured animals rejected rechallenges with 
viable tumor cells, which suggests the development of systemic immunity. From the 
schedules tested, the best results (5/5 cured) were obtained with 200,000 U PEG-IL-2 
injected both intratumorally and perilymphatically 3 times weekly for 5 weeks. The total 
dose received by these animals was 4x10s U/day, or 12x10' U/wk. This is about 8x10s 
U/kg/day, or 24x10' U/kg/wk, which was tolerated by the guinea-pigs without any sign of 
toxicity. 
The tumor model used in this study is a suitable experimental model for locoregional 
immunotherapy for several reasons. The syngeneic guinea-pigs are immunologically 
competent hosts. Line-10 is an undifferentiated carcinoma, characterized by progressive 
local tumor growth at the inoculation site, and fast development of regional lymph-node 
metastases. In this respect it resembles human head and neck squamous-cell carcinoma, 
which is a good candidate for locoregional IL-2 immunotherapy [17]. To obtain a 
reasonable reflection of clinical practice, treatment protocols in this study were always 
started in animals with established tumors on day 7, when microscopic axillary lymph-
node metastases have already developed [23]. This was actually confirmed in the 
experiment with surgical removal of the intradermal tumor on day 7. In spite of 
perilymphatic treatment, large axillary lymph-node metastases developed in 5/6 animals. 
Whereas Vaage [14] found a relation between responsiveness to local IL-2 immunotherapy 
and strong immunogenicity in mouse mammary tumors, the line-10 tumor is only weakly 
antigenic Following a challenge with irradiated tumor cells, a very weak DTH 
responsiveness is observed [24]. Spontaneous regression, or rejection of a second challenge 
after surgical resection of a 1-cm primary tumor, is never observed. 
The increased antitumor activity in vivo of locally administered PEG-IL-2 as compared to 
IL-2 can probably be explained by a prolonged exposure time. Therapeutic effects of 
sustained peritumoral IL-2 release were previously described by Buben Ik et aL [25], using 
IL-2-producing lymphoid cells transformed by IL-2 cDNA, and by Vaage and Mayhew 
[26], using IL-2 liposome-gel preparations. PEG itself has no antitumor effects, as we 
demonstrated in the line-10 model by injecting PEG without IL-2 according to the 3-
times-weekly schedule (data not shown). 
No cure was obtained with IL-2 treatment in this studv. nor has anv cure of the line-10 
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tumor with IL-2 treatment been reported [27]. Although it cannot be excluded that 
locoregional IL-2 application with increased frequency and at higher doses might cure 
guinea-pigs with established tumors, this would not undermine the superiority of PEG-IL-
2. A very successful local immunotherapy approach in the line-10 guinea-pig tumor has 
been described before using Bacillus Calmette-Gucnn (BCG). One intratu.noral BCG 
injection on day 7 completely inhibited tumor growth, and resulted in protecting systemic 
anti-line-10 immunity from 1 week after BCG injection [28]. 
An important finding in this study is the significance of the intratumoral injection route. 
As on day 7 tumor cells are present both at the inoculation site and in the regional lymph 
nodes, in the first experiments both sites were treated. However, subsequent tests indicated 
that the intratumoral PEG-IL-2 injection was principally, and maybe even completely, 
responsible for the antitumor effect. There is a tendency for the combination of 
intratumoral and perilymphatic PEG-IL-2 administration to suppress lymph-node 
metastases more efficiently (compare treatment groups 12 and 14, Table 1); this point 
certainly deserves further investigation. On the other hand, it was clearly proven that 
merely perilymphatic PEG-IL-2 administration is of no benefit in this model, even after 
surgical resection of the primary tumor. The advantage of the intratumoral administration 
route is difficult to explain. IL-2-stimulated tumor recognition by the host immune system 
directly at the tumor site might play a role [29]. However, the regional lymph nodes also 
contained tumor cells when treatment was started. On the other hand, the intratumoral 
route might provide an efficient way of reaching the draining lymph nodes. This is 
suggested by the very fast transport of blue dye to the regional lymph nodes after 
intratumoral injection of Patent Blue V (personal observation, in head and neck cancer 
patients). Our finding concerning the injection site agrees with that of Vaage [14,26] who 
found that therapeutic effects resulted from IL-2 alone or IL-2 liposome-gel preparations 
injected directly next to, but not 2-3 cm from, the tumor. However, it is inconsistent with 
the clinical results of Conesina et al. [17], who described effects of perilymphatic IL-2 
injections in recurrent head and neck cancer, which we could not confirm in patients with 
primary advanced disease [30]. 
In conclusion, PEG-IL-2 appears to be a valuable substance for intratumoral 
immunotherapy. Repeated injections given 3 times weekly at intermediate doses result in 
cure of established tumors with micrometastases in guinea-pigs, without signs of toxicity. 
A role for additional perilymphatic injections cannot be totally excluded and therefore 
deserves further study. Even so, the capacity of intratumoral PEG-IL-2 therapy started at 
later stages of disease has to be evaluated. The present results should be considered in the 
development of clinical studies, for example in head and neck cancer. 
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Histological and immunohistochemical analysis 
of line-10 tumor regression induced by 
intratumoral PEG-interleukin-2 therapy 
Submitted for publication as: 
Mattijssen V, Balemans LTM, Ruiter DJ, Van Swaaij-Elgersma A, Schalkwijk L, De 
Mulder PHM, Steerenberg PA. Histological and immunohistochemical analysis of line-10 
tumor regression induced by intratumoral PEG-interleukin-2 therapy. 
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Summary 
Background: Guinea-pigs with palpable line-10 tumors on the flank and regional lymph-
node micrometastases were cured by intrarumoral injections of polyethylene glycol-
modified interleukin-2 (PEG-IL-2), and developed protective systemic antitumor activity. 
Metboa: To explore the working mechanisms involved serial histological and immunohis-
tochemical analysis of tumors and tumor-draining lymph nodes from PEG-IL-2-treated 
and control animals was performed. 
Remits: Before starting treatment CD4* Τ cells were observed in close contact with the 
tumor. Apparently gradual tumor regression was accompanied by an intense inflammatory 
reaction with Τ cells, eosinophils, macrophages, and fibroblasts, surrounding and com­
partmentalizing the tumor. During treatment CD8-like CT6* Τ cells infiltrated into the 
substance of the tumor. Expression of major histocompatibility (MHC) class I molecules 
by the tumor cells as detected with immunohistochemical methods was low. 
Conclusions: This study docs not permit certain conclusions about the working mechanism 
of intrarumoral PEG-IL-2 therapy. An antitumor immune response might be elicited by 
direct activation of the CD4* Τ cells at the tumor site by the injected PEG-IL-2. The 
infiltration of CD8-Iike CT6* Τ cells into the tumor suggests a cytotoxic Τ cell effector 
function. In this respect the observed low MHC class I expression by the tumor is discor­
dant. The role of the eosinophils, macrophages and fibroblasts remains speculative. A 
concerted action of different types of immune-competent and inflammatory cells might be 
responsible for the obtained antitumor reaction. 
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Introduction 
Intcrleukin-2 (IL-2) is naturally secreted by Τ cells upon antigenic activation and has an 
essential role in the generation of an immune response [1]. Pcritumoral supply of IL-2 in 
experimental tumors from the moment of subcutaneous inoculation was shown to elicit an 
antitumor immune response, which resulted in suppression of tumor growth [2-6]. Functi­
onal analysis indicated that both specific Τ cells and aspecifk immune mechanisms were 
involved in this response [4-7]. We studied the therapeutic effects of locoregional 
injections with IL-2 or polyethylene glycol-modified IL-2 (PEG-IL-2) in established 
malignant disease. For this purpose guinea-pigs with palpable intradermal line-10 tumors 
and micrometastases in the tumor-draining lymph nodes were used [8,9]. We previously 
described that cure of these animals could be obtained with PEG-IL-2 injections, in which 
the ¡ntratumoral administration route was obligatory [9]. Repeated experiments indicated 
that intratumoral injections with 200,000 U of PEG-IL-2, given 3 times a week for 5 
weeks, caused complete tumor regression with suppression of metastatic lymph-node 
growth and long-lasting disease-free survival in 80% and 40% of the animals, when 
therapy was started on day 7 or day 14-28 after tumor-cell inoculation, respectively. Cured 
animals had protective immunity against line-10 rechallcngc [9], which was transferable to 
naive guinea-pigs by spleen lymphocytes [10]. Furthermore, the PEG-IL-2-induced antitu-
mor effect was completely abrogated by pretreatment of the animals with anti-thymocyte 
serum. This suggests that Τ lymphocytes are involved in the antitumor effect However, 
we could not demonstrate anti-line-10 cytotoxicity of lymphocytes isolated from the 
tumor, tumor-draining lymph node, or spleen of PEG-IL-2-treated animals in vitro [10]. 
In this paper we describe serial histological and immunohistochemical analysis of regressing 
line-10 tumors and lymph-node metastases. This study was performed to shed more light 
on the starting-point and the mechanism of effective intratumoral PEG-IL-2 therapy. 
Immune-cellular infiltration at the tumor site was studied with emphasis on Τ lym­
phocytes. As these cells interact with other cells in a major histocompatibility complex 
(MHC)-depcndent way, also MHC expression on the tumor cells was determined. 
Materiab and methods 
AnimaL· 
Female Sewall-Wright inbred strain-2 guinea-pigs were obtained from the National Cancer 
Institute-Frederick Cancer Research Facility, Frederick, MD, and used when 2 to 3 
months old, weighing 400 to 600 g. 
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Tumor 
The line-10 tumor is syngeneic co strain-2 guinea-pigs. This hepatocellular carcinoma was 
originally induced by oral administration of diethylnitrosamine, and converted to the 
ascites form [8,11]. The tumor-cell line was maintained as frozen stock, and propagated 
intraperitoneally. Intradermal inoculation with 1x10* cells on the flank results in local 
tumor growth, axillary lymph-node metastases within 7 days, and lung metastases later on. 
Tumor cells were used in their 12th passage. 
Therapeutics 
Recombinant human IL-2 modified by the covatene attachment of 2-3 PEG M, 7,000 
molecules per IL-2 molecule (PEG-IL-2) was provided by Eurocetus, Amsterdam, The 
Netherlands. PEG-IL-2 has a higher molecular weight, comparable in vitro activity, and a 
plasma clearance that is 10-fold lower than that of rIL-2 [12]. The specific activity of 
PEG-IL-2 was 9.4x10* U/mg IL-2 protein. Solutions containing 1x10* U/ml were 
prepared from lyophilized PEG-IL-2 by reconstitution in sterile water and dilution in 
phosphate-buffered saline (PBS) containing 0.1% (w/v) bovine serum albumin (BSA), and 
stored at -20°C until use. 
Experimental design 
Guinea-pigs were injected intradermally in the left anterior flank with 1x10* line-10 tumor 
cells on day 0. Intratumoral injections with 200,000 U PEG-IL-2 were started on day 7, 
and given 3 rimes weekly for 5 weeks. Control animals received injections with PBS 
containing 0.1% (w/v) BSA. Tumors and first tumor-draining axillary lymph nodes were 
obtained from guinea-pigs killed prior to treatment (day 7), and on days 14, 28 and 42 
during PEG-IL-2 or PBS+BSA treatment (n=4 per group). One half of each tumor and 
lymph node was fixed in formalin and embedded in paraffin, and the other half was 
frozen immediately into liquid nitrogen. As a control for tumor-independent PEG-IL-2-
induccd changes, injection sites and regional lymph nodes from 4 nonrumor-bearing 
guinea-pigs, given intradermal 200,000 U PEG-IL-2 injections on the flank 3 times 
weekly fot 3 weeks, were excised. 
Intmunobistocbemistry 
Cryostat tumor sections were stained with a 2-step ¡mmunoperoxidase procedure as 
described before [13], using the following monoclonal antibodies (MAbs): anti-guinea-pig 
CD4 rat MAb HI55 [14], recognizing helper Τ cells; the putative anti-guinea-pig 
cytotoxic/suppressor Τ cell mouse MAb CT6 [15,16]; mouse MAb MR1 [17], reactive 
with Euinea-pie monocytes and macrophages, but not with Lanecrhans' cells in the skin; 
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mouse МАЬ MSgp4, reactive with guinea-pig MHC class I [18]; mouse MAb 27E7, reac­
tive with guinea-pig MHC class II [19]; anti-human keratin 5/8 MAb OVTL 12-5, reac­
tive with all line-10 tumor cells [20]. All MAbs were kind girts of the originating 
laboratories. As secondar/ antibodies in the immunoperoxidase procedure peroxidase-con-
jugated rabbit-anti-mouse Ig and rabbit-anti-rat Ig were used. The peroxidase label was 
visualized by incubation with a 3,3'diaminobenzidine tetrahydrochloride solution as a 
substrate. PEG-IL-2-trcated tumors on days 28 and 42 showed marked staining due to 
endogenous peroxidase activity of infiltrating eosinophils. For this reason an immuno-
alkalinc phosphatase method was used on these sections as well. After incubation with 
alkaline phosphatase-conjugated rabbit-anti-mouse Ig or rabbit-anti-rat Ig as the secondary 
antibody, the alkaline phosphatase label was visualized by incubation with Fast Red 
substrate solution. Negative controls were obtained by incubation with PBS+BSA without 
the primary antibody. Positive controls included normal spleen and lymph-node sections. 
Evaluation 
Histopathological analysis on routinely fixed paraffin sections included pathological 
diagnosis, growth pattern, mean number of mitotic figures per high power field (HPF, 
400x), lymphatic vessel invasion, necrosis, and vascularization. At the tumor site, overall 
intensity of leukocytic infiltrate, and intensity of eosinophils (HE-stained paraffin sections), 
and intensity of Τ lymphocytes and macrophages (immunohistochemically stained frozen 
sections) were scored according to the following scales: (1) tumor-surrounding tissue: -, no 
or only very few cells; +, scattered cells; ++, cells in groups; +++, cells in a continuous rim 
surrounding tumor islets; and (2) within the tumor substance: -, no or only very few cells; 
+, scattered cells all over the tumor mass; ++, strong intensity of infiltrating cells. Expres­
sion of MHC class I and II antigens on tumor cells was estimated as percentage of the 
total number of tumor cells in the slide, and scored in 1 of 5 categories: 0-5%; 6-25%; 
26-50%; 51-75%; and 76-100%. MHC class II expression was not useful as an activation 
marker for lymphocytes, because of the constitutively high expression on guinea-pig Τ 
cells, as described before [16]. 
Results 
Histology of primary tumors 
Histopathological analysis of the intradermal growing line-10 tumor on HE-stained 
paraffin sections showed a pleomorphic undifferentiated malignant tumor with a high (10-
20/HPF) mitotic frequency (Fig. 1). On day 7, prior to therapy, small tumor cell nests in 
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che deep dermis and subcutaneous fat were intermingled with an intense, predominantly 
lymphocytic infíltrate. 
In the PBS+BSA-treated guinea-pigs a massive layer of tumor cells with a mean diameter 
of 8 mm had developed on day 14. Lymphatic vessel invasion was observed. The tumors 
«vere separated from the skin muscle by a narrow but continuous border of mononuclear 
cells. On day 28 the tumors had expanded laterally in the subcutaneous fat, and invaded 
the tendinous sheet along the skin muscle. Deep infiltration in the skin muscle was 
observed on day 42, when the tumor area had reached a size of about 13x5 mm. The 
tumor stroma then contained few leukocytes (+) and large blood vessels. Nevertheless, 
Focal central ischemic necrosis occurred. 
In the PEG-IL-2-rreated tumors on the other hand, an impressive inflammatory reaction 
developed. While on day 14 the tumor area was comparable to the PBS+BSA treated 
tumors, the border of mononuclear cells along the skin muscle was 2-3 times as broad, 
uid contained lymphocytes, histiocytes, eosinophils, and fibroblasts. On day 28 the rumor 
irea was compartmentalized by sheets of fibrous stroma, containing mononuclear in-
flammatory cells with a granulomatous aspect. Besides many histiocytes and eosinophils 
[++/+++, Table 1), also fibroblasts, multinucleated giant cells, and neutrophilic granulo-
cytes were observed, while lymphocytes were identified only sparsely in the HE-stained 
sections (Fig. 1). This inflammatory reaction widely spread through the dermis, and within 
and beyond the skin muscle. On day 42 also phagocytic cells with large vacuoles were 
observed in the tumor-surrounding stroma. The tumor area in the PEG-IL-2-treated 
rumors had decreased on day 28, and on day 42 in 3 samples 1-4 small islets (<1 mm2 
each; Fig. 2a) with tumor cells remained, while in the fourth sample no tumor cells could 
be detected, neither on HE-stained sections, nor with OVTL 12-5 MAb staining. In the 
regressing tumors, individual tumor cell death was observed along the borders of the 
tumor cell islets, especially on day 42 (Fig. 2a,b). In the sample from day 28 with the lar-
gest tumor area, more extensive tumor decline was observed with subtotal central tumor 
necrosis, leaving less than 10% viable tumor cells along the borders. The necrotic area in 
this tumor was heavily infiltrated by neutrophilic granulocytes. Changes in blood vessels 
such as occlusion, clotting or endothelial swelling were not observed. The frequencies of 
mitotic figures in PEG-IL-2- and PBS+BSA-treated tumors were comparable, except for 
day 42, when the tumor areas in the PEG-IL-2-treated tumors, however, we.-e too small 
for adequate comparison. 
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Table 1. Intensity cf tumor-surrounding cosinopbUs, macrophages, and Τ ceüs in PEG-IL-2-treated and 
control intradermal growing line-10 guinea-pig tumors. 
Intensity 
Eosinophils* Macrophages* 
day 7 14 28 42 day 7 14 28 42 
· · 
00 
0000 it 00 00 
· · · 
• 
ooo 
0 
0000 К 00 00 0000 
Intensity 
Cytotoxic/suppressor Τ cells' Helper Τ cells' 
day 7 14 28 42 day 7 14 28 42 
· · 
0000 8*0 000 0000 
8 
0000 8? 
00 
· · 
о 
So 
· · 
0000 
Detected in HE-staincd paraffin sections', or frozen sections stained with МАЫ MR1', CT6', or HI 55' 
0, control tumor, · , PEG-II^2-trcatcd tumor, I, PEG-II^2-treatcd sample, in which no tumor cells could 
be detected. 
On day 28, only 3 frozen samples per group were available. 
Intensity scored as: -, no or only very few positive cells; +, scattered positive cells; ++, positive cells in 
groups; +++, positive cells in a continuous rim surrounding tumor islets. 
Figure 1. Peripheral area of a PEG-II^-treated line-10 tumor on day 28 after inoculation, HE-
stained paraffin section. T, tumor mass, with mitotic figures (arrows); S, tumor-surrounding 
stroma, containing histiocytes (arrowheads) and fibroblasts (*). Bar = 25 μπι. 
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Figure 2. Paraffin sections of PEG-IL-2-treated line-10 tumors on day 42 after inoculation 
showing a small tumor islet (T) completely surrounded by stroma (S) with inflammatory reaction. 
(a) Bar =100 pm, (¿) Bar = 50 pm. A rim of necrotic tumor cells is observed at the edge of the 
tumor (arrowheads). The stroma shows fibrosis (F), and the May-Griinwald-Giemsa staining used 
highlights the large number of eosinophils (arrows). 
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Regional fympb nodes 
Table 2 shows size and metastatic load of the tumor-draining lymph nodes, assessed on 
ЫЕ-stained paraffin sections, and frozen sections sained with MAb OVTL 12-5· Tumor 
xlls were seen in the marginal sinus from day 7. In PBS+BSA-treated animals large 
netastases developed, almost completely replacing lymphatic tissue on day 42. 
η comparison with the PBS+BSA-treated animals no dear cortical or paracortical 
ïyperplasia occurred in the lymph nodes of PEG-IL-2-treated animals. However, these 
ytnph nodes became diffusely infiltrated with eosinophils, and showed a remarkable 
•eaction on the edge. The lymph-node capsules became broadened, which culminated on 
lay 28 in a wide lymph-node-surrounding zone containing mainly eosinophils and 
Table 2. Regional lymph-node metastases from intradermal line-10 tumors in PEG-IL-2-treated and 
•ontrol guinea-pigs. 
>100 
51-100 
26-50 
13-25 
512 
Lymph-
day? 
0 
0 0 0 
node area 
M 
0 
· · · · 
000 
(nun2)· 
28 
0 0 
· · · 
0 0 
• 
42 
0 0 0 0 
· · 
· · 
+++ 
++ 
+ 
± 
-
Metastatic load' 
day 7 
0 
0 0 0 
14 
• 
0000 
· · 
• 
28 
0 
0 0 0 
• 
· · 
• 
42 
0000 
· ' 
t 
· · 
>, control tumor, · , PEG-IL-2-ucated tumor. 
Multiplication of largest diameters on section, not including the perilymphatic inflammation observed in 
PEG-IL-2-treated animals. 
Based on histopathological analysis of HE-stained paraffin and frozen sections, and on frozen sections 
stained with MAb OVTL 12-5. —, no tumor cells; ±, tumor cells identified on OVTL 12-5 stained 
sections only (<10 cells per slide); +, invasion of marginal sinus and/or few tumor cells scattered in lymph 
node; ++. tumor involves 25-75% of the lymph-node area; +++, tumor involves >75% of lymph-node 
area. 
Excludine 90% tumor necrosis. 
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histiocytes (Fig. 3), and tesembling the inflammatoiy reaction induced in the stroma of 
the intradermal tumor. No specific reaction was observed in the immediate vicinity of the 
viable micrometastases within the lymph nodes of PEG-IL-2-treated animals on days 14 
and 28. On day 42, lymph nodes from 2 PEG-IL-2-treated animals were small, and one 
of these contained few tumor cells. The remaining 2 were clearly enlarged (26-50 mm2, 
Table 2). One showed a large metastasis, which, unlike in PBS+BSA-treated animals, 
contained 90% dead tumor cells. The other did not show tumor cells, but large fields of 
histiocytes with centrally some necrosis. 
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Immunobistocbemical analysis of the mononuclear cell infiltrate 
The intensity of Τ cell infiltration in the tumor-surrounding stroma as scored with MAbs 
CT6 and HI55 is represented in Table 1. The lymphocytic infiltrate on day 7 mainly 
consisted of helper Τ cells. In the PEG-IL-2-treated tumors the stroma surrounding the 
tumor islets on days 28 and 42 proved to contain considerably more Τ lymphocytes than 
identified in the HE-stained sections, with helper Τ cells (HI55*) and cytotoxic/suppressor 
Τ (CT6*) cells in about equal numbers. Adjacent tissues, including the skin muscle, were 
diffusely infiltrated with Τ cells (mainly CT6*) as well. Within the tumor mass (Table 3), 
on days 7 and 14 HI55* and CT6* cells were sparse (scored as -) . On day 28, however, 
within the РЕС-^2-ігеаг«1 tumors Τ cells were scattered all over the tumor (Fig. 4), 
with CT6* cells outnumbering Η155* cells. 
From day 7 MR1*, MHC class II-expressing (27E7*), dendritic cells were evenly spread 
within the tumor (+/++, data not shown). The tumor-surrounding stroma also contained a 
considerable number of MR1* macrophages (+), that increased during treatment (++, 
Table 1). The vacuolized phagocytic cells observed around PEG-IL-2-treated tumors on 
day 42 were MR1*. 
Table 3. Intensity of Τ cell infiltrate within the tumor substance in PEG-IL-2-treated and control 
intradermal line-ΙΟ guinea-pig tumors. 
Intensity 
++ 
+ 
-
Cytotoxic/suppressor 
day 7 14 
0000 8SSS 
Τ cells' 
28 
· · 
• 
0 0 0 
42 
· · 
0000 
Helper Τ cells' 
day 7 14 
0000 Woo 
28 
· · 
8oo 
42 
S8oo 
Immunohisrochemically detected in frozen sections with MAbs CT6' and HI55'. 
0, control tumor, · , VÏ.G-\h-2-xitisai tumor. On day 28, only 3 frozen samples per group were available. 
On day 42, no tumor was found in the frozen sections from 2 PEG-IL-2-treated animals, whereas scoring is 
based on a very small residual tumor area in the other 2. 
-, no or almost no positive cells; +, scattered positive cells all over the tumor mass; ++, strong intensity of 
infiltrating cells. 
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Figure 4. Immunoperoxidase staining with MAb CT6 directed against cytotoxic/suppressor Τ cells 
on frozen sections of line-10 tumors on day 28 after inoculation. In the PEG-IL-2-treated tumor 
(a) an intense infiltration of stained cells is observed both in the tumor-surrounding stroma (S) 
and within the substance of the tumor (T). In the PBS+BSA-treated tumor (b) few stained cells are 
seen in the stroma only. Bar = 50 ц т . 
МНС expression on tumor celò 
The immunohistochcmically detected expression of MHC class I and II antigens on linc-
io tumor cells was low. In most tumors 6-25% of the cells, situated in the periphery of 
the tumor, showed weak to moderate staining with anti-МНС class I MAb MSgp4 (data 
not shown). This percentage appeared to increase in the PEG-IL-2-treated tumors on day 
28. However, it was almost impossible to differentiate between the strongly MHC class I-
positive infiltrating cells, penetrating into the tumor, and the tumor cells themselves. 
Expression of MHC class II as recognized by МЛЬ 27E7 was not observed (<5% of cells), 
although the borders of PEG-IL-2-treated tumors were not interpretable on days 28 and 
42 because of the strongly positive tumor-surrounding inflammatory cells. 
Effects of PEG-IL-2 in nontumor-bearing guinea-pip 
Intradermal PEG-IL-2 injections in nontumor-bearing animals for 3 weeks (comparable to 
day 28 in PEG-IL-2 treated tumor-bearing animals) resulted in disturbance of the normal 
subcutaneous fat by intense infiltration with eosinophils (++) and histiocytes (++). 
Phagocytic cells with large vacuoles were seen, and also some multinucleated cells and 
fibroblasts. Immunoperoxidase-stained frozen sections showed scattered (+) CT6* and 
H155* Τ cells at the PEG-IL-2 injection site. In contrast, no (-) CT6* and Η155* cells 
were observed in the normal, noninjected guinea-pig deep dermis and subcutaneous fat. 
The regional lymph nodes from PEG-IL-2-injected nontumor-bearing guinea-pigs were 
not enlarged (<Λ2 mm2), and a minor capsular reaction with eosinophils and histiocytes 
was observed (data not shown). 
Discussion 
The antitumor mechanisms induced by either systemic or locoregional IL-2 administration 
in vivo arc incompletely understood. Experimental studies on locoregional IL-2 supply 
mosdy concerned growth inhibition of tumor-cell inoculations [2-7]. In contrast, the linc­
io tumor used in this study provides a model with palpable tumors, and regional 
micrometastases, in which 80% cure was obtained with intratumoral administration of 
PEG-modified IL-2. The present histological and immunohistochemical study indicates 
that this therapeutical effect is accompanied by an intense inflammatory reaction of mixed 
composition, surrounding and compartmentalizing the tumor area. Such analysis in one 
tumor model docs not allow conclusions on the working mechanism of IL-2 in vivo. The 
shortage of suitable monoclonal antibodies for immunohistochemical analysis of guinea-pig 
tissues constitute a special limitation of this model. Nevertheless, a study like this may 
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provide background information for the interpretation of therapeutical and functional 
immunological studies, and leads for further research. Several aspeas will be discussed in 
detail. 
We and others found that the peri- or intratumoral administration route was necessary to 
cure tumor-bearing animals with IL-2 and to induce immune memory [2,3.9]. Analysis of 
the line-10 tumor site prior to stirring PEG-IL-2 therapy showed tumor cells in dose 
contact with Τ cells which were predominantly CD4\ It is conceivable that PEG-IL-2 
directly activated these tumor-sensitized helper Τ cells to initiate an immune response and 
to induce immune memory. Requirement of lymphocytes at the tumor site for locoregio-
nal IL-2 therapy to be effective was also described in other models [2,3]. In studies on the 
in vivo growth of tumor cells engineered to produce IL-2 by IL-2 gene transfection, it was 
shown that CD4* Τ cells were essential for the induction of immune memory [5], whereas 
CD8* Τ cells were required for tumor rejection [4-6]. That CD8* Τ cells were involved in 
PEG-IL-2-induced tumor regression in our model as well, was suggested by the observed 
infiltration of CD8-like CT6* cytotoxic/suppressor guinea-pig Τ cells into the regressing 
tumors. No other inflammatory cells penetrated within the substance of the tumor as 
deeply as these cells did. On the other hand, the immunohistochemically low MHC class I 
expression on line-10 tumor cells is not in favor of interaction with MHC class I-restricted 
CD8' Τ cells. The absence of in vitro aná-line-10 cytolytic activity of tumor-, lymph-
node-, and spleen lymphocytes from PEG-IL-2-treatcd animals, described earlier [10], in 
itself does not exclude a role for CD8* Τ cells, as others showed that also noncytolytic 
CD8* tumor-infiltrating lymphocytes mediated tumor regression in vivo [21]. 
Besides lymphocytes, an intense inflammatory reaction with eosinophils, macrophages and 
fibroblasts, both in the tumor-surrounding stroma and around the tumor-draining lymph 
node, accompanied the PEG-IL-2-induced line-10 regression. A similar but less intense 
reaction was observed after intradermal PEG-IL-2 injections in nontumor-bearing animals. 
The question arises whether these eosinophils, macrophages and fibroblasts contribute to 
the PEG-IL-2-induced therapeutical enea. The local inflammatory reaction probably is 
not specific for PEG-IL-2. In humans intradermal injections w'th unmodified IL-2 
induced local infiltration of CD4* and CD8* Τ cells, and monocytes, reminiscent of a 
dclayed-type hypersensitivity (DTH) reaction to antigen [22]. Infiltration of eosinophils 
[7] and macrophages [4,23] at the tumor site following local supply of IL-2 was also 
described before. IL-2 was shown to display direct chemoattractant effects on eosinophils, 
which express functional IL-2 receptors [24]. On the other hand, the peripheral-blood 
eosinophilia described in patients receiving systemic IL-2 therapy [25], was found to be 
mediated by IL-5 release from IL-2-stimulated Τ lymphocytes [26,27]. Recently, Rivoltini 
et al. [28] described in vivo IL-2-activated peripheral-blood eosinophils of cancer patients 
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η possess direct cytotoxicity and antibody-dependent cytotoxicity (ADCC) against 
dlogeneic tumor cells in vitro. Tepper et αϊ [29] found IL-4-induced antitumor effects to 
ye dependent on local eosinophil infiltration. Otherwise, IL-5-induced eosinophilic in-
iltrarion at the tumor site in itself did not induce an antitumor response [30]. In a 
iifferent model, an antitumor effector role for eosinophils in co-operation with neutrop-
lils. macrophages and lymphocytes was suggested in an electron-microscopic study on IL-
(-induced rejection [31], since these inflammatory cells were observed in dose contact 
with the tumor cells and with each other. The latter is in contrast to our results, as we 
>bserved eosinophils in the tumor-surrounding stroma and tissues, but not directly adja-
xnt to the tumor cell islets. Eosinophils may interact with other immune cells by cytokine 
production, and MHC dass II-dependent antigen presentation to CD4* Τ cells [32]. 
[be accumulation of macrophages around the tumor islets we observed, together with Τ 
xUs and the peritumoral fibrotic reaction, resembles the fibrous tumor encapsulation 
lescribed by Steerenberg et al. [13] in line-10 tumor regression induced by intratumoral 
Bacillus Calmette-Guérin (BCG) injection, and also by Vaage [23] in local IL-2 therapy of 
nouse mammary carcinomas. Macrophages, triggered by lymphokines from helper Τ cells, 
an produce cytokines which induce fibroblast proliferation and collagen synthesis [2333]. 
Such immunologically enhanced fibrous encapsulation in itself might be beneficial by con-
rolling tumor growth [34]. The macrophages we observed around regressing tumor-cell 
lests, and in large fields within one of the lymph nodes of day 28, suggested a role in the 
phagocytosis of tissue debris and scavenging. Direct tumoricidal activity was described in 
iL-2-stimulated monocytes [35]. 
η the present study, a gradual decrease of the line-10 tumor mass was observed, wich 
ndividual tumor-cell death along the borders of the tumor islets. In 2 samples out of the 
:otal group of tumors and lymph nodes analyzed, however, extensive central tumor cell 
leath was observed. This overwhdming reaction might be related to tumor-growth rate, as 
K>th samples contained a relatively large tumor area on day 28-42 after inoculation. 
Extensive IL-2-induced tumor necrosis was also described in the fast-growing mouse SL-2 
ymphoma [36]. 
[n this study it was shown chat cure of established line-10 guinea-pig tumors induced by 
intratumoral PEG-IL-2 injections is accompanied with an intense locoregional inflam­
matory reaction. The obtained results are compatible with a role for CD4* Τ cells in the 
induction phase of the immune response, and are suggestive for an effector function of 
CD8-like CT6' Τ cells. In the latter the low MHC dass I expression by the tumor is 
discordant. The role of eosinophils, macrophages and fibroblasts remains speculative, and 
deserves further analysis. A concerted action of different types of immune-competent and 
inflammatory cells might be responsible for the obtained antitumor reaction. 
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Chapter 7 
Intratumoral PEG-interleukin-2 therapy 
in patients with locoregionally recurrent 
head and neck squamous-cell carcinoma 
Submitted for publication as: 
Mactijssen V, De Mulder PHM, De Gracff A, Hupperets P, Joosten F, Ruiter DJ, Bier H, 
Palmer PA, Van den Brock P. Intratumoral PEG-interleukin-2 therapy in patients with 
locoregionally recurrent head and neck squamous-cell carcinoma. 
This study was presented at the 84ώ annual meeting of the American Association for 
Cancer Research, May 1993, Orlando, Florida {Proc AACR 1993; 34:218). 
Background. Immunotherapy with local supply of ¡nterleukin-2 (1L-2) has proven enhanced 
efficacy compared to systemic administration in several experimental tumor models. We 
previously showed that intratumoral injections with polyethylene glycol-modified IL-2 
(PEG-IL-2) could cure guinea-pigs with palpable tumors and regional micro metastases. In 
the present study we assessed the feasibility and antitumor effects of this PEG-IL-2 
treatment schedule in a clinical situation. 
Patients and methods: Nineteen patients with locoregionally recurrent head and neck 
squamous-cell carcinoma (HNSCC), not exceeding 8 centimeter as largest diameter, and 
for whom no curative treatment was available, were entered. Intratumoral injections with 
200,000 U of PEG-IL-2 were given 3 times weekly in courses of 4 weeks into 11 local 
and 11 regional tumor recurrences. 
Results: Treatment was given on an out-patient basis, and was well tolerated. Temporary 
regional swelling and redness developed in 8 patients. In 7 of these patients systemic 
eosinophilia was documented. Low-grade fever occurred in 1 patient Median duration of 
treatment was 4 weeks (range 2-14 weeks). Seventeen patients were évaluable for response. 
One complete response (CR; 6%; duration 91 weeks), and 6 stable diseases (SDs; duration 
8-57* weeks) were recorded. The CR and the 3 best SDs (23, 40, 57* weeks) occurred in 
patients with a single regional tumor recurrence of relatively small size. During treatment, 
all 4 developed locoregional edema and redness, and high levels of circulating eosinophils. 
Median survival was 23 weeks for the total patient group, and >45 weeks for the patients 
with SD. 
Conclusion: Intratumoral injection of PEG-IL-2 in patients with HNSCC is feasible. A 
local inflammatory reaction may contribute to the observed antitumor effect. This 
treatment appears beneficial for highly selected patients. The objective response rate is 
insufficient for wide clinical application. 
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Introduction 
In several experimental tumors the therapeutical effects of repeated locoregional injections 
with relatively low doses interleukin-2 (IL-2) have been described. Both suppression of 
tumor growth [1-Э]. and regression of established tumors [3,4] were reported. Besides 
these locoregional effects, this approach was shown to induce specific systemic antitumor 
immunity, resulting in rejection of tumor cells inoculated simultaneously at distant sites 
[3,4], or subsequent tumor rechallenges [1,5]. The peritumoral administration route 
appeared to be a prerequisite for these effects [1,4,6], as was the presence of lymphocytes 
at the tumor site [1,6], and an immunocompetent host [7]. It was hypothesized that host 
immune cells at the tumor site were activated by exogenous IL-2 to produce cytokines, 
and to recruit specific and nonspecific immune effector mechanisms [7]. 
Head and neck squamous-cell carcinoma (HNSCC) appears a suitable disease to evaluate 
the feasibility and efficacy of local IL-2 immunotherapy in man. The tumor is localized 
near the body surface, metastasizes primarily to the neck lymph nodes, and tends to recur 
locoregionally after primary surgery and/or radiotherapy. Primary tumors are generally 
infiltrated with Τ lymphocytes, which have been shown to obtain cytotoxic activity after 
activation by IL-2 in vitro [8]. Moreover, extensive submucosal and nodular lymphatic 
tissue is localized in the direct vicinity. Although locoregional, probably tumor-induced, 
immunosuppression in HNSCC is well-documented [9], cytotoxic Τ cells specific for 
HNSCC targets were obtained from tumor-draining lymph nodes be th by activation with 
IL-2 in vitro [10], and by locoregional IL-2 application in vivo [11]. 
The therapeutic effects of locoregional IL-2 administration in HNSCC have been studied 
in several ways. Perilymphatic injection (i.e., around the tumor-draining lymph nodes) was 
first described by Conesina et aL [12]. With 10 daily low-dose IL-2 injections, they 
initially obtained 3 complete responses (CR; duration 4-6 months) and 3 partial responses 
(PR) in 10 patients with locoregionally recurrent HNSCC [12]. This high rate of objective 
responses, however, was not confirmed by the same authors when enlarging their study 
group [13], nor by us in patients with locoregionally far-advanced primary disease [14]. 
PR were also described in studies using combined perilymphatic and intratumoral IL-2 
injections (2/36 patients) [15], intra-arrerial IL-2 infusion (2/12 patients) [16], and 
combined locoregional IL-2 and LAK cell administration (3/6 and 3/14 patients, 
respectively) [17,18]. 
In the syngeneic guinea-pig line-10 tumor model, characterized by fast-growing regional 
lymph-node metastases, we analyzed locoregional IL-2 therapy, using polyethylene-glycol-
modified IL-2 [19]. As compared to unmodified IL-2 this PEG-IL-2 has enhanced 
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solubility and plasma half-life [20,21], and increased in vive antitumor activity in 
experimental tumors after intravenous (i.v.) administration [20,22]. Applying PEG-IL-2 
locoregionaUy, 3 rimes weekly, we could cure guinea-pigs with palpable line-10 tumors on 
the flank and micrometastases in the regional lymph nodes. Furthermore, protective anti-
line-10 activity was induced [19]. Intratumoral, and not perilymphatic administration was 
a prerequisite for this effect. Based on these experimental results, we developed the present 
clinical study for patients with locoregionaUy recurrent HNSCC. The main aims were to 
evaluate the feasibility and the local antitumor effects of intratumoral PEG-IL-2 injections 
in HNSCC, in a schedule which we found to be optimal in the animal study. As patients 
with extended tumor growth were not likely to benefit from this approach, the tumor size 
was restricted arbitrarily. PEG-IL-2 has been applied before i.v. in cancer patients in phase 
I [21] and II [23] studies, and intradermaUy in human immunodeficiency virus (HIV)-
type 1-infected patients [24], but not locoregionaUy in cancer patients. To learn more 
about the locoregional effects, tumor biopsies were scheduled to be taken before and after 
PEG-IL-2 therapy whenever possible, to study the mononuclear cell infiltrate, and human 
leukocyte antigen (HLA) expression on the tumor cells. 
Materials and methods 
Patients 
Eligible patients met the following criteria: measurable, histologically or cytologically 
confirmed locoregional recurrence of HNSCC, for which no curative treatment was 
available, and newly occurring after previous surgery and/or radiotherapy. No more than 
two tumor sites were allowed. Tumor recurrences had to be accessible to injection, and 
should not exceed 8 cm as largest diameter. Furthermore, patients should have a 
Karnofsky performance status of 80% or more, an expected survival of 3 months at least, 
normal hematologic parameters, adequate hepatic, renal, and cardiac function, no other 
significant medical conditions requiring ongoing therapy, no organ allografts, and no 
distant metastases. Concurrent corticosteroid therapy was not permitted. Between 
November 1991 and May 1993, 19 patients gave their informed consent and were entered 
in this study, at the University Hospitals of Nijmegen (n-11), Utrecht (n=5), Maastricht 
(n=2), and Düsseldorf (n-1). Patient characteristics are oudined in Table 1. 
Table 1. Patient characteristics 
No. of patients enrolled 
Males/females 
Median age, yean (range) 
Karnorslcy Performance statu 
100% 
90% 
80% 
60% 
Primary tumor site 
Oral cavity 
Larynx 
Oropharynx 
Hypopharynx 
Vestibulum nasi 
Ear 
Prior therapy for HNSCC 
Radiotherapy 
Surgery primary tumor 
Neck lymph node dissection 
• unilateral 
- bilateral 
Chemotherapy 
Median time between finishing previous 
therapeutic intervention and diagnosis of 
current tumor recurrence, months 
Range: 1.5-4 months 
4.5-12 months 
12-24 months 
>24 months 
19 
13/6 
69 (46-83) 
4 
7 
7 
1' 
6* 
6 
4 
1 
1 
1 
19 
14 
6 
5 
4 
4 
10 
7 
0 
2 
' As this Karnorsky score was caused by decreased mobility due to a 
cerebrovascular accident years before, the patient was still accepted for this study. 
ь
 Including 2 patients with a history of multiple oral carcinomas. 
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Treatment 
Recombinant human IL-2 modified by the covalent attachment of 2-3 PEG M, 7,000 
molecules per IL-2 molecule (PEG-IL-2) was provided by Eurocetus, Amsterdam, The 
Netherlands. The PEG-IL-2 used had a specific activity of 85.7x10* (Lomo. LCP-920) or 
40.0ХІ05 (Lotno. LCP-039B) U/mg IL-2 protein. The treatment regimen involved 
intralesional injections with 200,000 U PEG-IL-2 in 0.5 ml normal saline containing 
0.1% human serum albumin. Injections were given 3 times a week (Monday, Wednesday, 
and Friday) for 4 weeks. If patients had 2 tumor recurrence sites, these were injected 
simultaneously with 200,000 U each. After 4 weeks, patients were evaluated for clinical 
response. Patients with progressive disease (PD) were removed from the study. In case of 
stable disease (SD) treatment was continued till 8 weeks. Objective responders were 
scheduled to receive 12 weeks of treatment without interruption, unless CR was achieved 
earlier. 
During therapy, changes in performance status and locoregional adverse effects were 
recorded every treatment day. Hematological parameters were assessed every 2 weeks, and 
biochemical parameters of hepatic and renal function every 4 weeks. A Chest X-ray was 
performed before and at the end of PEG-IL-2 treatment. 
Assessment of response 
During treatment, tumor sizes were measured every 4 weeks by physical examination, 
ultrasound, or CT scan, as appropriate. CR was defined as disappearance of all evidence of 
disease for at least 4 weeks, and PR as 50% or greater reduction of the product of the 
greatest perpendicular tumor diameters for at least 4 weeks. PD was defined as 25% or 
greater increase in the size of the tumor lesions, or the appearance of new lesions; SD as 
disease not meeting the criteria for either CR, PR, or PD. Duration of response was 
reported from the start of PEG-IL-2 treatment. After stopping treatment, patients with 
SD, PR, or CR were evaluated monthly during the first 6 months, bimonthly from 6-12 
months, and 3-monthly thereafter. Patient survival was determined from the start of PEG-
IL-2 treatment. 
Tissue specimen asid immunobistocbemical analysis 
Pre-treatment tumor samples were analyzed for histopathological grade, intensity of the 
mononuclear cdl infiltrate, and Η LA antigen expression. Post-treatment tumor samples 
were obtained in 4 patients. 
Η LA class I and II antigen expression on tumor cells was assessed with 
immunohistochemical methods on paraffin sections, usine anti-HLA class I MAb HC 10 
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and anti-HLA-DR serum, as described before [25]. The intensity of the mononuclear cell 
infiltrate in the tumor-surrounding tissue was assessed on HE-stained sections. In those 
tumors (rom which samples were obtained both before and 4 weeks after PEG-IL-2 
treatment, additional staining was performed with MAbs UCHL1 (anti-CD45RO, Τ 
cells), L26 (anti-CD-20. В cells), and KP1 (anti-CD68, macrophages). 
Anti-IL-2 antibodies 
Patient sera were obtained before, after 4 weeks, and at the end of PEG-IL-2 treatment, 
and deep frozen. Presence of 1L-2 binding-antibodies in these sera was studied by an 
Eniyme Linked Immunosorbent Assay (ELISA), as described before [26]. The ELISA titer 
was defined as the product of the highest serum dilution with an absorban« below 0.5 
and the actual absorbance value. ELISA titers exceeding 10 were defined as positive. 
Results 
Turner lesions and administration of PEG-IL-2 
Clinical characteristics of the treated lesions are represented in Table 2. Ten patients had 
recurrent disease at the site of the primary tumor, 8 had regionally recurrent disease, and 1 
had both. Regional tumor recurrences included lymph-node metastases, subcutaneous 
metastases in the neck after prior lymph-node dissection, and skin metastases. In total 22 
tumor recurrences were treated in 19 patients. Median time between diagnosing the 
current tumor recurrence and starting PEG-IL-2 treatment was 1 month (range 0.5-14 
months). In the 2 patients with the largest delay (6 and 14 months, in patient no. 13 and 
10, respectively) the current tumor recurrence was treated with palliative laser debulking 
and/or chemotherapy with methotrexate, before PEG-IL-2 was given. 
Treatment duration is shown in Table 2. More than 90% of the PEG-IL-2 injections were 
given in the out-patient clinic. In local tumor recurrences, preferably the vital borders, and 
not necrotic central parts were injected. In the larger tumor masses, variable sites were 
injected. Depending on the fragility of the tumor, leakage of fluid was sometimes 
observed. This appeared problematic in patient no. 15 only. For treatment of lymph-node 
metastases in patients nos. 2, 3. 8, 12, and 14, injection site and depth were determined, 
and controlled regularly, by ultrasound. 
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Table 2. HNSCC locortgwrud rtcurrtnca and intratumoral PEG-IL-2 treatment. 
Рас 
no. 
1 
2 
3 
4 
5 
б 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
Treated lesions 
Site· 
sube 
l.n. (2) 
l.n. 
sube 
prim, 
prim. 
prim. 
I.n.+prim. 
prim. 
prim. 
prim. 
Size (an7)* 
7.2 
3.1; 3.2 
4.3 
10.8 
3.8 
12.0 
1.5 
5.5; 5.3 
36.0 
42.0 
4.9 
l.n. 1.6 
prim, not measurable 
In. 
prim. 
l.n. 
prim-
skin (2) 
prim. 
20.0 
6 3 
234 
150 
3.6; 2.0 
6.0 
Total Response 
weeks of (duration, 
treatment wecb) 
8 
2 
8 
4 
6 
6 
8 
8 
2 
4 
4 
4 
14 
8 
4 
8 
4 
2 
4 
CR (91) 
Early Progression 
SD (40) 
PD 
PD 
PD 
SD (8) 
SD (8) 
Early Progression 
PD 
PD 
SD (57+) 
not measurable 
SD (23) 
PD 
SD (12) 
PD 
not évaluable 
PD 
Patient 
survival 
(weeks) 
102+ 
9 
59 
20 
23 
24 
39 
22 
14 
8 
8 
57+ 
31 
52+ 
38+ 
36+ 
11 
2 
6 
Locoregional Eosinophils, 
side max. level1 
effects (к IO4/!) 
swelling, redness 
swelling, redness 
swelling, redness, itching 
none 
swelling, redness 
enhanced tumor necrosis 
swelling, redness 
swelling, redness, mild pain 
none 
none 
none 
swelling, redness, itching 
swelling, redness 
swelling, redness, itching 
none 
mild pain 
none 
swelling, redness 
mild pain 
1140 
962 
2436 
320 
720 
231 
726 
710 
97 
186 
162 
3515 
688 
4653 
70 
99 
152 
n.m. 
260 
1
 sube, subcutaneous; l.n., lymph node; prim., primary tumor site. 
k
 Product of largest biperpendicular diameters. 
c
 Normal count <400xl0i/l. n.m., not measured. 
Response 
Tumor response and patient survival are shown in Table 2. Seventeen patients were 
évaluable for response. One CR (1/17, 6%) was obtained in a 69-year old man with a 
Karnofsky score of 80%, who previously had radiotherapy, laryngectomy, and bilateral 
lymph-node dissection for poorly differentiated SCC of the larynx (patient no. 1). He was 
treated with PEG-IL-2 for a nodular subcutaneous metastasis in the left neck. Shrinkage of 
this lesion was first observed after 3 weeks of treatment. After 8 weeks a flat superficial 
skin lesion remained, which could not be injected anymore. Treatment was stopped then, 
and 4 weeks later the lesion had disappeared completely (Fig. 1). The CR persisted for 91 
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reeks. Then a rumor recurrence occurred in the pharynx, which was nor accessible ro 
njecrion. Radiotherapy was starred. 
η 6 patients SD was recorded (duration 8-57* weeks). Five of them received 8 weeks of 
réarment, according to the protocol. One patient (no. 12) refused further treatment after 
ί weeks, because of emotional saess. The 3 best SDs, lasting 57°, 40, and 23 weeks, were 
»btaincd in patients with single lymph-node metastases (patients nos. 12, 3, and 14, 
espccdvely). In patient no. 3, treated for a lymph-node metastasis of a larynx carcinoma, 
¡O was accompanied with loss of contrast enhancement of the lesion on CT scan, and 
ibsence of neoplastic cells in an ultrasound-guided cytological puncture at the end of 
'EG-IL-2 treatment. 
'atients with progressive tumor growth at evaluation after 4 weeks, or before completing 
he next 4 weeks of treatment were recorded as PD. In patient no. 6, who was treated for 
ocally recurrent carcinoma of the oropharynx, an impressive enhancement of central 
umor necrosis occurred, with expectoration of an huge necrotic mass 6 weeks after 
topping treatment. Nevertheless, the outer tumor margins gradually increased. Ultrasound 
summation suggested progressive central tumor necrosis in 1 out of the 5 patients whose 
ymph-node metastases were evaluated that way (patient no. 8). 
Two patients were not évaluable for response. Patient no. 13 had unmeasurable disease, 
iecause of subjective improvement, PEG-IL-2 treatment was continued till 14 weeks, 
'atient no. 18, a 66-year old man, unexpectedly died during his sleep, about 36 hours 
iter the 5th PEG-IL-2 administration for 2 skin metastases on the check. Autopsy was 
tot allowed. The cause of death remained uncertain. 
η 5 patients (nos. 3,4,14,16, and 17) chemotherapy was given for progressive tumor 
;rowth during or after PEG-IL-2 therapy. This did not result in objective responses. 
Median survival from the start of PEG-IL-2 treatment was 23 weeks for the total group, 
ind also for the 17 évaluable patients, and >45 weeks for the 6 patients who achieved SD. 
Toxicity 
Ml patients were évaluable for toxicity. Treatment was well tolerated. Mild pain following 
njecrions was experienced by 3 patients. Except for low-grade fever in 1 patient (no. 19), 
io systemic toxicity was observed. Renal and hepatic function remained unchanged. In 1 
»tient (no. 8) treatment was interrupted 1 week because of an intercurrent respiratory 
nfection, and continued afterwards without problems. 
During treatment, a locoregional reaction with swelling and redness of the neck and/or 
ace on the side of injection developed in 10 patients (Table 2). Three of these patients 
amplained of locoregional itching as well. The swelling consisted of thickening of the 
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skin and subcutaneous edema, as was confirmed by ultrasound examination. This reaction 
generally started after 1 week of treatment, and decreased gradually from 1-2 weeks after 
stopping treatment. These locoregional side effects were most impressive in patients who 
received PEG-IL-2 into lymph-node metastases. 
Also because of this mild toxicity in general, a causative relation between PEG-IL-2 
treatment and the sudden unexpected death in patient no. 18, as described above, was felt 
unlikely. 
Hematological effect! 
Hematological blood counts revealed an increase in the number of eosinophils during 
treatment in 9 patients. Remarkably, these were the same patients who also developed 
regional swelling and redness during treatment (Table 2). In most patients (7 out of 9) the 
highest levels of eosinophils were observed after 2 weeks of PEG-IL-2 treatment. They 
returned to normal after stopping treatment. No consistent changes occurred in peripheral 
blood lymphocyte counts (data not shown). 
Anti-IL-2 antibodies 
In none of the 16 patients tested, anti-IL-2 serum antibodies could be detected. 
Immunobistocbemical analysis 
Histopathological results are represented in Table 3. Pretreatment tumor samples included 
biopsies from the current tumor lesion (n=9), and biopsies from previously treated tumor 
recurrences (n=5) or primary tumors (n=5). The latter 10 concerned patients in whom 
malignancy of the PEG-IL-2-treated lesion was confirmed cytologically. Most tumors were 
moderately differentiated squamous-cell carcinomas. A variable intensity of the 
mononuclear cell infiltrate was observed. HLA class I-expression by 25% of the tumor 
cells or less, was observed in 9 out of 18 in the respect evaluated pretreatment tumor 
samples, while HLA class II-expression was absent (£5% tumor cells stained) in 15 
pretreatment samples. Tumor biopsies after 4 weeks of PEG-IL-2 treatment were obtained 
in 3 patients with local tumor recurrences (nos. 5,6,7), who had either PD or short-term 
SD. The intensity of the mononuclear cell infiltrate before PEG-IL-2 treatment happened 
to be low in all 3. No differences were observed after PEG-IL-2 injections, neither with 
regard to the infiltrating cells, nor to HLA expression by tumor cells. In patient no. 10, 
enhanced HLA class II expression by tumor cells was observed in a tumor sample obtained 
at autopsy. 
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Table 3. Histopathologic^ evaluation and HLA antigen expression on tumor lesions from patients 
treated with intratumoral PEG-IL-2 injections became of ¡ocoregionalfy recurrent HNSCC 
Patient 
no. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
Evaluated 
tumor lesion* 
previous recurrence 
primary tumor 
primary tumor 
primary tumor 
before PEG-IL-2 
after PEG-IL-2 
before PEG-IL-2 
after PEG-IL-2 
before PEG-IL-2 
after PEG-IL-2 
previous recurrence 
previous recurrence 
previous recurrence 
autopsy 
previous recurrence 
primary tumor 
before PEG-IL-2 
primary tumor 
before PEG-IL-2 
before PEG-IL-2 
before PEG-IL-2 
before PEG-IL-2 
before PEG-IL-2 
Histopathol. 
grade* 
poorly 
moderately 
moderately 
moderately 
moderately 
moderately 
moderately 
moderately 
well 
well 
moderately 
poorly 
moderately 
moderately 
well 
moderately 
moderately 
poorly 
well 
well 
moderately 
poorly 
moderately 
Intensity of 
mononuclear 
cell infiltrate' 
++• 
++ 
-
+ 
n.i. 
+ 
+ 
++ 
+ 
+ 
++ 
+ 
+ 
+ 
+ 
+ 
++ 
HLA antigen expression 
by tumor cells' 
class I 
£5% 
76-100% 
6-25% 
51-75% 
51-75% 
51-75% 
51-75% 
51-75% 
6-25% 
6-25% 
51-75% 
£5% 
6-25% 
26-50% 
76-100% 
6-25% 
6-25% 
6-25% 
n.d. 
26-50% 
26-50% 
£5% 
51-75% 
class II 
£5% 
51-75% 
£5% 
6-25% 
26-50% 
26-50% 
£5% 
£5% 
55% 
55% 
£5% 
£5% 
£5% 
26-50% 
£5% 
£5% 
£5% 
£5% 
n.d. 
£5% 
£5% 
£5% 
£5% 
Numbers corresponding to Table 2. 
Pretreatment tumor samples included biopsies from the current tumor recurrence (before PEG-IL-2), from 
the primary tumor, or from a previous tumor recurrence which was treated with surgery or radiotherapy. 
Posrtreatment tumor samples were obtained immediately after 4 weeks of PEG-IL-2 treatment, or at 
autopsy. 
Grade of squamous cell carcinoma. 
-, no or only very few mononuclear cells; +, occasional patch; ++, patchy rim; +++, continuous rim of 
infiltrating cells; n.i., not interpretable due to absence of tissue surrounding the tumor in the specimen. 
Immunohistochcmically detected with anti-HLA doss I MAb HC10, or anti-HLA-DR rabbit serum on 
paraffin sections. Expression of antigens by the tumor cells was estimated as a percentage of the total 
number of tumor cells in the slide, and scored in 1 out of 5 categories, n.d., not done. 
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Figure 1. Nodular subcutaneous tumor recurrence (30x24 mm, cytologically confirmed squamous-
cell carcinoma, with documented progressive growth) in the upper jugular region of the left neck, 
in a 69-year old man who was previously treated with radiotherapy, laryngectomy, and bilateral 
neck lymph-node dissection for poorly differentiated squamous-cell carcinoma of the larynx, a, 
before Ρ Ε ϋ - ^ 2 treatment, b, complete response, 4 weeks after stopping treatment with 3 times 
weekly 200,000 U РЕС-ІЬ2 injections for 8 weeks. 
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Discussion 
From this study we can conclude that intratumoral injection of PEG-IL-2, 3 times weekly 
at intermediate doses, in patients with HNSCC is feasible. Treatment was applicable in 
the out-patient clinic, and toxicity was mild. The response rate obtained in a selected 
group of patients with locoregionally recurrent disease was low, as 1 objective response was 
recorded in 17 évaluable patients (6%). Nevertheless, the longlasting CR, in a patient for 
whom no other treatment was available anymore, indicates that a highly effective 
antitumor mechanism can be induced in certain circumstances. In addition, 3 patients 
achieved SD of substantial duration. 
Considering the present and previous studies [13,14,18] on locorcgional IL-2-bascd 
therapy in HNSCC, a tumor response in patients with large or very fast-growing tumors 
appears unlikely. While it has been suggested that responses occurred at the primary tumor 
site only [13,18], in our study, the patient with the CR and the 3 with the best SDs all 
had a single regional tumor recurrence, of relatively small size. These 4 patients developed 
locorcgional edema, and induration and redness of the skin, as well as 6 other patients. 
Temporary regional edema has also been described during local IL-2 therapy in HNSCC 
patients [11,16,18]. This local reaction might be related to increased microvascular 
permeability at the site of IL-2 application, as was demonstrated in an experimental 
situation [27]. After subcutaneous or intradermal IL-2 [28] or PEG-IL-2 [24] injection in 
humans a local indurative and erythematous reaction, resembling a delayed-typc 
hypersensitivity (DTH) reaction, was described to consist of mononuclear cell infiltration, 
and to increase with the dose of PEG-IL-2 [24]. It is tempting to say that this local 
inflammatory reaction might contribute to the antitumor effect of intratumoral PEG-IL-2 
therapy. 
Systemic eosinophilia is well described in cancer patients treated with systemic IL-2 
therapy, and has been shown to be mediated by IL-5, produced by IL-2-activated Τ cells 
[29]. Remarkably, in the present study eosinophilia occurred in the patients who 
developed therapy-induced locorcgional swelling only, while the highest levels were found 
in the patient with the CR, and the 3 best SDs. An association between eosinophilia and a 
favorable tumor response was found before by Atzpodien et aL [23] in cancer patients 
receiving subcutaneous IL-2 and IFNa therapy. In the line-10 guinea-pig tumor, in which 
we evaluated intratumoral PEG-IL-2 therapy before [19], an intense inflammatory reaction 
with eosinophils, and also Τ lymphocytes, macrophages and fibroblasts was observed at the 
site of regressing tumors [30]. This suggests that eosinophils play a role in the PEG-IL-2-
induced antitumor effect. Evidence for eosinophil-mediated tumor-cell killing in vivo was 
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provided by Tepper et al [31], who reported IL-4-induced antitumor effects to be 
dependent on local eosinophil infiltration. Independent of immunotherapy, the grade of 
tumor-infiltrating eosinophils was found to be a prognostic marker in HNSCC [32]. In 
the present study, no sufficient material could be obtained for histopathologic^ analysis of 
PEG-IL-2-induced antitumor reactions. Postrxeatment biopsies from local tumor 
recurrences in 4 non-responding patients did not show infiltration of eosinophils, nor 
other histopathological changes. For thorough histological and immunohistochemical 
analysis of PEG-IL-2-induced locoregional reactions, possibly contributing to the 
antitumor effect, an alternative study design, with intratumoral injections prior to tumor 
resection and regional lymph-node dissection, appears more appropriate. 
Cytotoxic CD8* Τ cells recognize antigens when presented together with Η LA class I 
antigens. We evaluated the level of HLA class I antigen expression by the HNSCCs in this 
study with immunohistochemical methods. A previous tumor recurrence of the patient 
with the CR (Table 3, no. 1) and the primary tumors of the 3 patients with the best SDs 
(Table 3, nos. 3,12, and 14) all had a low level (£25%) of HLA dass I expression. Since 
we are not informed about the HLA class I expression of the PEG-IL-2-treated lesions in 
these patients, nor about any therapy-induced changes in HLA class I expression, no 
certain conclusions are allowed. Remarkably, however, the PEG-IL-2-responsive line-10 
guinea-pig tumor immunohistochemically also showed low expression of major 
histocompatibility (MHC) class I antigens [30]. These findings do not support a major 
role for CD8* Τ cell-mediated cytotoxicity in the antitumor effect induced by intratumoral 
PEG-IL-2 injections. 
Sacchi et aL [33] (bund that the growth of HNSCC xenografts in nude mice with 
eliminated NK activity was inhibited by local IL-2 administration, and suggested that this 
was a direct effect of IL-2 itself. This was supported by the demonstration of functional 
intermediate-affinity and high-affinity IL-2 receptors on some HNSCC cell lines [34]. 
Moreover, growth of these tumor-cell lines, and not normal keratinocytes, was inhibited 
by IL-2 in vitro [34]. Fresh tumor samples, necessary for immunohistochemical analysis of 
IL-2 receptor expression, were not available in the present study. However, this possible 
mechanism for IL-2-induced tumor regression in HNSCC certainly deserves further 
attention in prospective clinical studies. 
In rabbits and mice, PEG-IL-2 was demonstrated to be less immunogenic than IL-2 [35]. 
We did not find anti-IL-2-anribody production following intratumoral PEG-IL-2 
administration in the HNSCC patients within this study. The relevance of this finding is 
uncertain. 
In the present study, a single, intermediate dose-level for PEG-IL-2 was chosen. This dose 
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was based on our experimental results with intratumoral PEG-IL-2 in the fast-growing 
line-10 tumor, where a dose-response relationship was found for low to intermediate dose 
levels. It is uncertain whether the present dose is optimal for HNSCC. In previous studies 
with locorcgional IL-2 administration in HNSCC, however, no indications were round for 
high IL-2 doses to give better results [15,16]. In contrast, most objective clinical responses 
were obtained especially with daily locorcgional administration of relatively low doses 
(200-30,000 U) of IL-2 [13,15.16]. 
In conclusion, a minority of patients with locoregionally recurrent HNSCC appears to 
benefit from intratumoral PEG-IL-2 injections. Therapy is well tolerated. The antitumor 
mechanism is unknown. Both a locoregionally induced inflammatory-like reaction, 
eosinophils, and a direct effect via binding to IL-2 receptors on HNSCC tumor cells 
might be involved. Increased knowledge on the underlying mechanism would enable 
identification of patients susceptible to this kind of locorcgional immunotherapy. 
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Chapter 8 
Biodistribution of interleukin-2 and PEG-interleukin-2 
in the guinea-pig following intratumoral injection 
Submitted for publication as: 
Mattijssen V, Boerman OC, Balemans LTM, Stcerenberg PA, (Dorstens FHM, De Mulder 
PHM. Biodistribution of intcrleukin-2 and PEG-interleukin-2 in the guinea-pig following 
intratumoral injection. 
по 
Summary 
Background: Intcrleukin-2 (IL-2) is rapidly cleared from the circulation. In several 
experimental studies on immunotherapy with IL-2 local administration was found a prere­
quisite for the induction of an effective host antitumor immune response. In the line-10 
guinea-pig tumor enhanced efficacy was demonstrated when polyethylene glycol (PEG)-
modiRed IL-2 was used. We examined whether the difference in efficacy of intratumorally 
injected IL-2 and PEG-IL-2 was related to the duration of retention at the site of the 
tumor and/or the tumor-draining lymph nodes. 
Methods: IL-2 and PEG-IL-2 were radioiodinated with 1 2 5I and , M I , respectively. A mixture 
of both compounds was injected intratumorally into line-10 guinea-pig tumors. At several 
intervals groups of 4 animals were killed. Selective organs were removed and radioactivity 
was measured. 
Results: A gradual decrease of activity in the tumor was observed for both mI-IL-2 and 
131I-PEG-IL-2 following incratumoral injection. Uptake of both labeled compounds was 
found in the tumor-draining lymph node. Blood levels for "4-PEG-IL-2 were significantly 
higher than for 125I-IL-2 (JKO.007) from 3 h up to 48 h after intratumoral injection. 
Conclusion: No evidence was found for prolonged retention of PEG-IL-2 as compared to 
IL-2 in the tumor or the regional lymph node to explain the enhanced efficacy of 
intratumoral PEG-IL-2 administration. The higher blood levels for ,31I-PEG-IL-2 suggest 
that circulatory activity might contribute to the antitumor effect of intratumoral IL-2-
based therapy. 
Ill 
Introduction 
The 15-Kd protein ¡nterleukin-2 (IL-2) is a produa of Τ lymphocytes which plays an 
essential role in the generation of the immune response and the clonal expansion of 
lymphocytes [1]. Endogenous IL-2 mediates its effect locally in a paracrine and/or 
autocrine fashion by binding to IL-2-specific cell-surface receptors. Since several yean 
recombinant IL-2 has been studied as an immune-stimulant in anticancer therapy [2]. IL-2 
is rapidly cleared from the circulation. After i.v. bolus injection in humans a high serum 
peak-level is obtained, decreasing initially with a half-life of 6-13 min (ta), followed by а 
slower elimination phase with a half-life of 70-85 min (tß) [3,4]. Subcutaneous (s.c) 
injection and 30-min intraperitoneal (i.p.) infusion result in much lower but fairly 
constant serum levels for about 8 h [4]. Renal filtration appears the major route of 
clearance [4]. Because of its rapid clearance IL-2 is mostly administered by repeated high-
dose i.v. bolus [5], continuous infusion [6] or s.c injections [7] in order to obtain lasting 
serum levels at an assumed therapeutic level. With all schedules mentioned objective 
responses were obtained in selected patient groups. However, which serum levels are most 
beneficial is not clear [8]. Moreover, it is not known where IL-2 generates its antitumor 
effect, i.e. in the circulation, at the site of the tumor, or in some specific organ. After i.v. 
bolus injection of radioiodinated IL-2, specific accumulation has been demonstrated in the 
liver and to a lesser extent in the spleen [9,10]. After i.p. administration, on the other 
hand, no organ-specific uptake was found [9]. Whether there is uptake of IL-2 into 
tumors following systemic administration is not known. 
We previously studied the antitumor effects of locoregionally injected IL-2 and polyethy-
lene glycol-modified IL-2 (PEG-IL-2) in the line-10 guinea-pig tumor, and found PEG-
IL-2 to be superior to IL-2, at less frequent administration [11]. The inuatumoral ad-
ministration route was obligatory for the obtained effect [11]. PEG-IL-2 has enhanced 
solubility and a 10- to 20-fold prolonged circulatory half-life as compared to IL-2 [12]. 
The latter is supposed to explain the higher antitumor activity of PEG-IL-2 compared to 
IL-2 after i.v. administration [12,13]. We hypothesized that prolonged locoregional 
retention of PEG-IL-2 might be responsible for the enhanced antitumor activity as 
compared to IL-2 after intratumoral injection. In the present study we investigated the 
distribution over time of radioiodinated IL-2 and PEG-IL-2 in guinea-pigs after 
intratumoral injection, with special emphasis on the tumor and the tumor-draining lymph 
nodes. Knowledge on this distribution might contribute to the elucidation of the working 
mechanism of intratumoral IL-2 therapy in general, and might be relevant for application 
of experimental data in the human situation. 
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Materiab and methods 
Animal tumor model 
Sewall-Wright inbred strain-2 guinea-pigs were obtained from the National Cancer 
Institute-Frederick Cancer Research Facility, Frederick, MD, and used when 2 to 3 
months old, weighing about 500 g. Line-10 hepatocellular carcinoma cells, syngeneic to 
strain-2 guinea-pigs, were maintained as frozen stock, and propagated intraperitoneally. 
Tumor cells were used in their 12th passage. Intradermal inoculation of 1x10* tumor cells 
in the anterior left flank was performed on day 0. In previous experiments this led to pro-
gressive local tumor growth and development of regional axillary lymph node metastases 
within one week [11]. 
Radioiodination ofIL-2 and PEG-IL-2 
Recombinant human IL-2 (Proleukin, Eurocetus, Amsterdam, The Netherlands; specific 
activity 18.0x10* U/mg) was radiolabeled with 1MI using the glucoseoxidase-lactoperoxidasc 
method, essentially according to the manufacturer's instructions. Briefly, 1 mg lyophilized 
IL-2 was reconstituted in 230 ul distilled water. IL-2 (350 pg) was incubated with 50 ul 
enzymobead suspension (Biorad, Richmond CA) and 7.0 mCi Na'"l (Amersham 
International, Amersham, UK) in 0.15 M phosphate buffer, pH 7.4. The reaction was 
initiated by adding D(+)glucose to the final concentration of 4 mg/ml. After 30 min the 
enzymobeads were spun down (2,000xg, 5 min), and the supernatant was eluted with 
phosphate buffered saline on a Sephadex G-25 column (PD-10; Pharmacia, Uppsala, 
Sweden) to separate the labeled IL-2 from the free I25I. The void fractions containing 6% 
of the radioactivity, were pooled and sterilized through a 0.2 pm filter. 
Recombinant human IL-2 modified by the • covalent attachment of 2-3 PEG M, 7,000 
molecules per IL-2 molecule (PEG-IL-2; specific activity 5.5x10* U/mg IL-2 protein) was 
provided by Eurocetus, Amsterdam, The Netherlands. PEG-IL-2 was labeled with 131I 
according to the enzymobead method as described above. PEG-IL-2 (5.5x10* U) was 
incubated with 50 ul enzymobead suspension and 1.8 mCi Na131I (Medgenix, Fleurus, 
Belgium) in 0.15 M phosphate buffer, pH 7.4. The reaction was initiated as described 
above. Gclfiltration indicated a labeling efficiency of 85%. 
Experimental design 
Twenty-eight guinea-pigs with 10-day old palpable line-10 tumors on the flank (diameter 
10-12 mm) were divided into 7 equal groups. Animals received an intratumoral injection 
with 0.2 ml of the injection mixture, containing 14 pCi I25I-IL-2 (200,000 U) and 28 pCi 
из 
"4-PEG-IL-2 (100,000 U). At 5 min and 1, 3, 6, 12, 24, and 48 h after injection groups 
of 4 animals were given an intracardial injection of pentobarbital (60 mg) and were bled. 
Selective tissues, including the tumor and the first tumor-draining axillary lymph node, 
were dissected, weighed and counted in a well-type gamma counter (Pharmacia-LKB, 
Sweden) along with injection standards to correa for physical decay. Data were 
represented as percent of the injected dose per dissected tissue (% ID; for tumors and 
thyroid glands), or per gram organ weight (%ID/g) for I2'I-IL-2 and 13II-PEG-IL-2 
separately. 
Statistical analysis 
For each time point mean values ± SD were calculated for the group of 4 animals, 
separate for 125I-IL-2 and 131I-PEG-IL-2. After log-transformation Students' «est for 
paired differences was used for comparison between values of 125I-IL-2 and 131I-PEG-IL-2 
at each time point. This was done separately for tumor, lymph node and blood. The 
Bonferroni-correction was used for testing on each of the multiple time points. A 
difference was called statistically significant if the resulting /rvalue of the ¿-test is <0.007 
(<0.05/7). 
Results 
The intratumoral activity of 125I-IL-2 and 131I-PEG-IL-2 over time is represented in Fig. 1. 
At 5 min after injection about half of the injected dose of both labeled compounds was 
found in the tumor. The intratumoral levels of both compounds decreased rapidly to 
about 10% of the injected doses at 3 h, and then more slowly to about 3% at 24 h after 
injection. Significant (jxO.007) higher values for 13lI-PEG-IL-2 were found at lh and 3h 
after injection. At 24h and 48h the values for 125I-IL-2 were significantly higher, although 
absolute intratumoral levels were very low for both compounds then. 
Biodistribution data for intratumorally injected 125I-IL-2 and 13II-PEG-IL-2 are shown in 
Table 1. Uptake of both labeled compounds in the tumor-draining lymph node (indicated 
as % ID/gram organ weight) was clearly higher than in any other organ studied. Although 
the uptake of 131I-PEG-IL-2 in the tumor-draining lymph node appeared higher than that 
of l2,I-IL-2, no significant differences were found. The uptake values of both labeled 
compounds for liver and spleen were very low, as were those for lung, intestine and 
muscle (data not shown). 
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hours post Injection 
Figure 1. Intratumoral levels (in % ID/tumor) of ' " 1 - ^ 2 ( · ) and 13,I-PEG-IL-2 (O) following 
simultaneous intratumoral injection into 10-day old intradermal line-10 guinea-pig tumors. Points, 
mean values of 4 animals; ban, SD. Time-points at which statistically significant differences were 
obtained (ƒx0.007) are indicated with *. 
Φ > 
β 
0.40 г 
0.30 
0.20 
0.10 
0.00 
hours post Injection 
Figure 2. Blood levels (in % ID/g blood) of ,2,I-IL-2 ( · ) and "Ч-РЕС-ІЬ2 (О) following simul­
taneous intratumoral injection into 10-day old intradermal line-10 guinea-pig tumors. Points, 
mean values of 4 animals; bars, SD. Time-points at which statistically significant differences were 
obtained (jxO.007) are indicated with *. 
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Table 1. Biodittribution of wI-!L-2 (Λ) end '3'I-PEG-IL-2 (B) in guinea-pip following mixed 
intratumoral injection. 
5 min 1 h 
% ID/organ; mean of 4 animals ± SD 
Time post injection 
3 h 6 h 12 h 24 h 
5 min 1 h 
% ID/g organ weight; mean of 4 animals * SD 
Time post injection 
3 h 6h 12 h 24 h 
48 h 
Tumor 
Λ 4l.03i4.96 
В 46.20*6.37 
Thyroid 
A 0.07*0.03 
В 0.02*0.01 
17.88t 1.40 
27.89*3.36 
0.36*0.05 
0.07±0.01 
8.29*1.55 
12.33*2.89 
1.07±0.21 
0.27*0.06 
4.80*0.56 
8.11*342 
1.30*0.29 
0.47±0.12 
4.30±0.19 
4.75±2.24 
1.74*0.92 
0.91*0.48 
3.06*0.66 
0.69*0.48 
3.21*1.48 
2.27*1.05 
0.85*0.43 
0.15*0.06 
3.19*0.74 
2.81*0.72 
48 h 
Lymph node 
A 10.37*4.01 
В 10.66*3.42 
Blood 
A 0.17*0.02 
В 0.14*0.06 
Liver 
A 0.09*0.01 
В 0.05*0.01 
Spleen 
A 0.09*0.02 
В 0.03*0.01 
Kidney 
A 0.49*0.18 
В 0.14*0.07 
4.57*0.73 
6.34*1.19 
0.17*0.03 
0.20*0.04 
0.09*0.02 
0.06*0.03 
0.12*0.02 
0.05*0.01 
1.24*0.16 
0.43*008 
1.54*1.17 
4.06*2.57 
0.17*0.03 
0.31*0.06 
0.09*0.02 
0.11*0.03 
0.08*0.02 
0.09*0.04 
0.53*0.13 
0.72*0.08 
0.87*0.40 
2.40*0.52 
0.08*0.01 
0.25*0.05 
0.04*0.01 
0.07*0.02 
0.04*0.01 
0.06*0.02 
0.16*0.03 
0.56*0.06 
0.45*0.30 
0.91*0.36 
0.06*0.01 
0.23*0.01 
0.03*0.01 
0.06*0.01 
0.03*0.01 
0.07*0.01 
0.08*0.01 
0.41*0.06 
0.20*0.19 
0.21*0.02 
0.03*0.01 
0.11*0.03 
0.01*0.01 
0.03*0.01 
0.01*0.01 
0.03*0.01 
0.03*0.01 
0.14*0.04 
0.14*0.08 
0.04*0.01 
0.01*0 
0.04*0.01 
0.01*0.01 
0.01*0.01 
0.01*0.01 
0.01*0.01 
0.01*0.01 
0.04*0.01 
A mixture of ,2,I-IL-2 and "'I-PEG-II^2 was injected intratumorally into 10-day old intradcrmally growing 
line-10 guinea-pig tumors. At the indicated time-points following injection animals were killed and tissues 
were obtained for measurement of radioactivity. 
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Blood levels are shown in Fig. 2. From 3 h after injection, when I51I-PEG-IL-2 reached a 
peak blood level, till the end of the experiment blood levels of 131I-PEG-IL-2 were 
significantly higher (jxO.007) than the levels of l2'I-IL-2. 
The experiment, including the labeling procedure, was performed twice. Essentially the 
same results were obtained (data not shown). 
Discussion 
In several experimental tumor models evidence was obtained that repeated local, and not 
systemic, administration of IL-2 could elicit an effective antitumor immune response [14-
17]. It was suggested that locally supplied IL-2 direcdy activated tumor-sensitized immune 
cells at the tumor site, thus bypassing an otherwise failing helper Τ cell function [18]. We 
previously described that guinea-pigs with palpable line-10 rumors on the flank and 
regional lymph-node micrometastases could be cured, and developed systemic anti-linc-10 
immunity, by 3-times weekly intratumoral PEG-IL-2 injections, whereas IL-2 caused 
tumor-growth inhibition only [11]. The obligatory intratumoral injection route [11] 
suggested that the antitumor effect of PEG-IL-2 was generated at the tumor site. We 
hypothesized that intratumoral injection of PEG-IL-2 resulted in more prolonged retention 
at the site of the tumor and/or the tumor-draining lymph-nodes than IL-2. This was 
supported by the observation in humans that PEG-IL-2 following intradermal or subcuta­
neous injection showed a greater local indurative and erythematous reaction with longer 
duration than IL-2 [19]. The results of the present study, however, do not confirm our 
hypothesis. Although from 1 to 3 h after injection higher tumor values were found for 
"4-PEG-IL-2, protracted retention in the tumor, and uptake into the tumor-draining 
lymph node following intratumoral injection were comparable for PEG-IL-2 and IL-2. 
The unexpected sustained locoregional levels of '"I-IL-2 might be partly explained by 
limited denaturation of I2'I-IL-2, since analysis of the l25I-IL-2 preparation by sodium-
dodccyl sulphate (SDS) Polyacrylamide gclclectrophoresis indicated that 90% migrated as a 
15-Kd compound, while 10% migrated as a high molecular weight compound (>100 Kd; 
data not shown). 
Uptake of both labeled compounds in liver and spleen was very low, and probably of no 
relevance. Kidney values were somewhat higher, which is concordant with the renal 
excretion mechanism. Thyroid uptake (in % ID/thyroid) represents dehalogenated 125I and 
131I. 
A dear différence in biodistribution of 12,I-IL-2 and l31I-PEG-IL-2 was observed at the 
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circulatory level. Intratumoral administration proved to result in significantly higher blood 
levels for 131I-PEG-IL-2 than for 125I-IL-2. This probably is related to the higher circulato-
ry half-life of PEG-IL-2 as compared to IL-2 [12]. Only radioactivity, and no bioactivity 
was measured in this study. Yet, it should be considered that the circulatory levels 
following intratumoral PEG-IL-2 injection in the present model might have contributed to 
the obtained antitumor effect by activation of host immune mechanisms [11]. The 
experiments of Forni et al [14,20] abo suggested that local IL-2 immunotherapy encom-
passed more than a purely local reaction. They found that the antitumor response induced 
by peritumoral IL-2 injections in mice challenged with tumor cells admixed with lym-
phocytes was abrogated in immunosuppressed animals. The circulatory PEG-IL-2 levels in 
the guinea-pigs might be high enough to activate intermediate-affinity IL-2 receptors from 
natural killer (NK) cells. Other investigators found evidence that these cells are involved in 
the antitumor response induced by local IL-2 supply as well [18,20]. 
If circulatory levels of (PEG-)IL-2 are relevant for the effect of intratumoral (PEG)-IL-2 
therapy, this has important consequences for application of the experimental data in 
humans, since equal intratumoral doses in guinea-pigs and man might provide comparable 
levels at the injection site, but much lower circulatory levels in humans. 
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Chapter 9 
Summary and general discussion 
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Interleukin-2 (IL-2) 'к one of the most extensively studied immune-stimulants in antican­
cer immunotherapy. Natural IL-2 has a central role in the generation of the immune 
response, and enhances proliferation and activity of both specific and non-specific 
immune-competent cells. In therapeutical studies generally high-dose systemic ad­
ministration is used. This way, remarkable tumor responses have been obtained in a small 
percentage of cancer patients, by a still incompletely understood working mechanism. 
Considering the biological and pharmacological characteristics of IL-2, and the potential 
antitumor effects of tumor-infiltrating lymphocytes, however, locoregional administration, 
i.e. at the site of the tumor, might be preferable. Moreover, in several experimental tumor 
models enhanced efficacy of IL-2 after locoregional application, including the generation 
of a specific antitumor immune response, has been demonstrated. The background and 
experimental data which formed the basis for further exploring the value of locoregional 
immunotherapy with IL-2 are described in detail in chapter 2. 
Head and neck squamous-cell carcinoma (HNSCC) appeared suitable to locoregional IL-2 
administration because of its predominantly locoregional rumor spread, accessibility to 
injection, and localization close to extensive submucosal and nodal lymphatic tissue. We 
studied the effects of 10 daily low-dose IL-2 injections in patients with locoregionally far-
advanced non-pretreated HNSCC (chapter 4). Injections were given perilymphatically, i.e. 
around the tumor-draining lymph nodes, as was described previously in HNSCC by Cor-
tesina et al (Cancer 1988). In contrast to them we did not observe tumor responses in 15 
patients treated. Furthermore, histopathological evaluation of pre- and post-treatment 
tumor biopsies from 10 patients revealed no treatment-induced changes. The absence of 
any effect might be related to the large tumor masses in our patient group. 
To obtain more information on the optimal dose and route for locoregionally adminis­
tered IL-2 in established malignant disease, we performed a series of experiments in the 
line-10 guinea-pig tumor (chapter 5). Next to IL-2, polyethylene-glycol modified IL-2 
(PEG-IL-2) was used. PEG-IL-2 had enhanced solubility and prolonged circulatory half-
life, eventually permitting less frequent administration. Data on locoregional application of 
this formulation were not available so far. We found that guinea-pigs with palpable tumors 
on the flank and micrometastases in the regional lymph nodes could be cured by repeated 
intratumoral injections with PEG-IL-2. Moreover, these animals had developed systemic 
anti-line-10 immunity, protecting them against line-10 tumor rechallenges on the other 
flank. PEG-IL-2 was superior to IL-2 since higher efficacy was obtained at less frequent 
administration. The intratumoral administration route was obligatory for the antitumor 
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effect. This was in concordance with previous experimental results from other investigators 
with IL-2, and strongly suggested that the antitumor effect was generated at the site of the 
tumor. 
Subsequendy, the in the experimental setting optimal PEG-IL-2 schedule was applied in 
HNSCC patients to study the feasibility and the antitumor efficacy (chapter 7). Nineteen 
patients with locoregionally recurrent HNSCC, for whom no curative treatment was 
available, were treated with 3-times weekly intratumoral injections with 200,000 IU of 
PEG-IL-2, in courses of 4 weeks. Systemic toxicity, well known from high-dose systemic 
IL-2 therapy, did not occur. Within 17 évaluable patients, 1 complete response (CR; 
duration 91 weeks) and 6 stable diseases (SD; duration 8-57* weeks) were observed. The 
CR and the 3 best SDs occurred in patients with a single regional tumor recurrence of 
relatively small size. These 4 patients, besides 4 others, developed temporary regional 
swelling and redness, and high levels of circulating eosinophils. 
Knowledge on the working mechanism of intratumoral PEG-IL-2 immunotherapy might 
contribute to optimizing treatment schedules and identification of patients susceptible to 
this kind of treatment. In the line-10 guinea-pig tumor histological and immunohis-
tochcmical analysis revealed that PEG-IL-2-induced tumor regression was accompanied by 
in intense peritumoral inflammatory reaction of strikingly mixed composition (chapter 6). 
Involvement of Τ lymphocytes in the induced antitumor effect was suggested by the 
infiltration of CD8*-like Τ lymphocytes into the substance of the tumor. Furthermore, the 
PEG-IL-2-induced antitumor effect was completely abrogated by pretreatment of the 
animals with antithymocyte serum, and the obtained anti-line-10 immunity could be 
transferred to naive animals by spleen lymphocytes (Balemans et al, Cancer Immunol 
Immunother 1993). Whether the temporary locoregional swelling and redness during 
PEG-IL-2 treatment in 8 HNSCC patients was caused by a similar inflammatory reaction 
remains speculative, since it appeared very difficult to obtain sufficient material for his­
tological and immunohistochemical analysis in these patients (chapter 7). In chapter 6 the 
possible role for other infiltrating cells observed in PEG-IL-2-treated line-10 tumors is 
discussed. Especially eosinophils might be important since these cells were observed in high 
numbers at the site of PEG-IL-2-treated guinea-pig tumors (chapter 6), and also at high 
circulatory levels in the HNSCC patients with the CR and the 3 best SDs after PEG-IL-2 
therapy (chapter 7). 
Because Τ lymphocytes are МНС-restricted in their interaction with other cells, we 
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studied with immunohistochemical methods the expression of MHC molecules on 
HNSCC and also on the line-10 guinea-pig tumor. If cytotoxic CD8* Τ lymphocytes are 
involved in the PEG-IL-2-induced antitumor effect, like suggested above, then high MHC 
class I expression by the tumor would be favorable. In primary HNSCCs of various sites a 
relatively high MHC dass I expression was round, especially in tumors from the oral 
cavity (chapter 3). In view of the observed antitumor efficacy, a surprisingly low MHC 
class I expression was observed in the PEG-IL-2-treated line-10 guinea-pig tumor (chapter 
6). In the 4 patients with the most favorable course after PEG-IL-2 therapy also a low 
MHC class I expression was found in their primary tumors or previous recurrences 
(chapter 7). Although the latter only provides indirect evidence, these findings do not 
support a major role for CD8* Τ cell-mediated tumor cell lysis. We did not observe 
changes in MHC class I or II expression by tumor cells induced by locoregional IL-2 
(chapter 4) or PEG-IL-2 (chapters 6,7) administration. 
The necessity to administer IL-2 and PEG-IL-2 directly at the tumor site to induce an 
effective host antitumor immune response, as demonstrated in this (chapter 5) and 
previous experimental studies, suggested that the effect was generated at the tumor site. 
This was the main reason for applying PEG-IL-2 intratumorally in patients in the same 
dose as found optimal in guinea-pigs. There are no arguments to suppose that the working 
mechanism of PEG-IL-2 is basically different from that of IL-2. The enhanced efficacy in 
the line-10 tumor was assumed to be related to differences in kinetics. To confirm this, 
radiolabeled IL-2 and PEG-IL-2 were injected intratumorally in guinea-pigs and the 
radioactivity at several sites was measured over time (chapter 8). No evidence was found 
for prolonged retention of PEG-IL-2 in the tumor or the regional lymph nodes. The 
blood levels for PEG-IL-2, however, were higher. This raises questions about the 
contribution of circulating, systemic IL-2 activity to the antitumor effect of locally injected 
(PEG-)IL-2. 
Reviewing these and previous investigations (chapter 2) on anticancer immunotherapy with 
IL-2 it can be concluded that a host immune response towards the tumor can be elicited 
in experimental models by protracted peri- or intratumoral application of IL-2. In 
established disease PEG-IL-2 might be more effective than IL-2. This immune response 
can mediate local and distant tumor regression, and may encompass protective immune 
memory. Both T-cell mediated and non-specific mechanisms appear to be involved in this 
therapeutic effect Production of interferon-γ has been shown to play a role. Immunohis-
tochemically detectable MHC class I expression by the tumor cells appears not to be 
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necessary. In several animal studies a dose-response relation has been observed in the low 
to intermediate IL-2 dose range. 
Whether a systemic immune response can be elicited by intra- or peritumoral IL-2 
administration in cancer patients is not known. Occasionally, HNSCC patients with 
limited local or regional disease appear to benefit from locoregional IL-2 or PEG-IL-2 
therapy. Local tumor regression has been observed. The therapy is well tolerated. So rar, 
there is no evidence in HNSCC patients that high doses of locally administered IL-2 are 
more effective than low doses. 
The mechanism of local IL-2 immunotherapy is still incompletely understood, as are the 
prerequisites for a favorable response. Most experimental studies have been performed in 
early-stage disease, while advanced disease is common in the clinical situation. Depressed 
host immune responsiveness, as demonstrated in advanced tumor-bearing hosts, might 
contribute to the presently observed restricted efficacy of local IL-2 therapy in cancer 
patients. Local IL-2 therapy might be more appropriate for patients with minimal disease, 
as an adjuvant to conventional therapy. 
Possible targets for future research include: 
1. Factors related to tumor-host interaction: tumor-induced immune suppression 
(depressed Τ cell responsiveness), tumor-specific antigens, antigen presentation, co-
stimulatory signals (B7/CD28), tumor micro-environment (antigen-presenting cells). 
2. Better understanding of the mechanisms triggered by local IL-2: involved immune-
competent or inflammatory cells, secondary cytokines, systemic effects, IL-2 receptor 
expression by tumor cells. 
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Samenvatting 
De behandeling van kanker steunt op drie pijlers, te weten chirurgie, radiotherapie 
(bestraling) en chemotherapie (toediening van tumorcel-dodende medicijnen). Oe laatste 
10 jaren is immunothérapie in ontwikkeling als een potentiële vierde behan-
delingsmogelijkheid van kanker. Bij immunothérapie wordt beoogd het lichaamseigen 
afweersysteem (immuunsysteem) aan te zetten kankercellen als zodanig te herkennen en af 
te breken. In het immuunsysteem werken een groot aantal cellen (meest witte bloedcellen) 
samen, zoals: Τ lymfbcytcn, В lymfocyten, NK (natura! killer) cellen, monocyten, 
macrofagen en granulocytcn. Deze cellen kunnen elkaar signalen geven door middel van 
eiwitten die ze zelf maken, zogenaamde cytokinen. 
Interleukine-2 (IL-2) is een dergelijk cytokine dat gemaakt wordt door Τ lymfocyten en 
dat van nature een belangrijke rol speelt bij het in gang zetten van een immunologische 
(afweer) reactie. Tevens blijkt IL-2 in staat om Τ lymfocyten en NK cellen aan te zetten 
tot tumorcel-dodende (cytotoxische) activiteit. Sinds IL-2 in het laboratorium 
geproduceerd kan worden door middel van de zogenaamde recombinant DNA techniek is 
het uitgebreid onderzocht op zijn waarde voor de behandeling van patiënten met kanker. 
Doorgaans wordt het in hoge doses met een infuus in de bloedbaan toegediend. Hiermee 
zijn opmerkelijke resultaten bereikt, alhoewel slechts bij een klein deel van de patiënten 
(met name met melanomen en niercelkanker) en ten koste van ernstige bijwerkingen. Het 
precieze werkingsmechanisme van deze behandeling is niet bekend. 
Dit proefschrift handelt over immunothérapie met lokale IL-2 toediening, dat wil zeggen 
toediening direct op de plaats van de tumor. Het onderzoek is met name gericht op 
toepassing van IL-2 bij patiënten met plaveiselcelcarcinomen van het hoofd-halsgebied. Dit 
zijn tumoren die ontstaan uit de slijmvliezen van mond- of keelholte. Door de oppervlak-
kige lokalisatie, de voornamelijk lokale en regionale tumor-uitbreiding en de nabijheid van 
lymfatisch weefsel lijken deze tumoren relatief goed geschikt voor lokale immunothérapie. 
In hoofdstuk 2 wordt nader ingegaan op de redenen om IL-2 lokaal toe te dienen in plaats 
van systemisch (in de bloedbaan). Van nature werkt IL-2 over een hele kleine afstand, 
namelijk op de plaats waar het ook gemaakt wordt en komt het niet in grote hoeveelheden 
in het bloed. Als het in de bloedbaan wordt toegediend wordt het daaruit ook weer snel 
door de nieren verwijderd. Bij lokale toediening van IL-2 zou met een lagere dosis volstaan 
kunnen worden, hetgeen de bijwerkingen van de behandeling belangrijk zou kunnen 
verminderen. Daarnaast zijn in veel tumoren lymfocyten aanwezig waarvan in het 
laboratorium is aangetoond dat ze een potentieel hogere anti-tumor activiteit hebben dan 
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lymfocyten uit de bloedbaan. Deze tumor-infiltrerende lymfocyten (of TIL cellen) zouden 
door lokaal toegediend IL-2 rechtstreeks geactiveerd kunnen worden. Verder is door 
verschillende onderzoekers aangetoond dat bij dieren met tumoren in een vroeg stadium 
een specifieke, tegen de tumor gerichte, immunologische reactie opgewekt kan worden 
door aanwezigheid van IL-2 op de plaats van de tumor. 
In hoofdstuk 3 wordt een zijpad bewandeld. Bij lokale immunothérapie met IL-2 spelen Τ 
lymfocyten mogelijk een belangrijke rol. Een voorwaarde voor interactie tussen Τ 
lymfocyten en tumorcellen is dat de tumorcellen zogenaamde MHC moleculen (bij de 
mens: HLA antigenen) op hun oppervlak tot expressie brengen. Het is bekend dat 
tumorcellen wat betreft HLA expressie vaak afwijken vari normale cellen. Door middel van 
een immunohistochemische kleurmethode en microscopisch onderzoek hebben wij de HLA 
expressie van hoofd-halscarcinomen onderzocht. Er werd een hoge HLA klasse I expressie 
gevonden, met name in tumoren uitgaande van de mondholte. Dit suggereert dat deze 
tumoren gevoelig zouden kunnen zijn voor cel-dodende (cytotoxische CD8') Τ lym­
focyten. De hier beschreven techniek is later toegepast op tumorweefsel van patiënten 
behandeld met IL-2. 
In hoofdstuk 4 wordt een studie beschreven met perilymfatisene injecties met een hele lage 
dosis IL-2 bij patiënten met hoofd-halscarcinomen. Perilymfatische IL-2 injectie wil zeggen 
toediening rondom de lymfeklieren die gelegen zijn in de buurt van de tumor en is gericht 
op activering van lymfocyten in die lymfeklieren. Het gebruikte behandelschema was 
gebaseerd op een eerder gepubliceerd kleinschalig onderzoek, waarbij positieve resultaten 
waren bereikt. Vijftien nog niet eerder behandelde patiënten met zeer grote en daardoor 
niet te genezen hoofd-halstumoren kregen, nadat zij daarvoor toestemming gegeven 
hadden, gedurende 10 dagen een perilymfatische IL-2 injectie. Uitwendig was er géén 
effect op de tumor en ook microscopisch onderzoek van weefselstukjes (biopten) uit de 
tumor toonde geen verschil ten opzichte van de situatie voorafgaande aan de behandeling. 
Er traden geen bijwerkingen van de behandeling op. Het verschil in resultaat ten opzichte 
van de eerder gepubliceerde studie heeft waarschijnlijk te maken met de grootte van de 
tumoren. 
In hoofdstuk 5 worden een aantal experimenten beschreven verricht bij cavia's met tumoren 
op de flank (line-10 tumoren). Het doel van deze studies was meer informatie te krijgen 
over de optimale dosis en toedieningsweg van IL-2 bij lokale immunothérapie. Behalve IL-
2 werd ook PEG-IL-2 getest. Dit is IL-2 waaraan lange ketens van de stof polyethyleen 
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glycol zijn gekoppeld, die zorgen voor een betere oplosbaarheid en een tragere verwijdering 
van de stof uit de bloedbaan. Het bleek dat cavia's met uitwendig voelbare tumoren op de 
flank en microscopisch waarneembare uitzaaiingen in de regionale lymfeklieren genezen 
konden worden met herhaalde injecties met PEG-IL-2, rechtstreeks toegediend in de 
tumor (¡ntratumoraal). Ab deze dieren vervolgens op de andere flank opnieuw line-10 
tumorcellen ingespoten kregen, dan werden die afgestoten. Dit geeft aan dat beschermende 
immuniteit tegen de tumor was ontwikkeld. PEG-IL-2 was sterker werkzaam dan IL-2 en 
hoefde minder vaak toegediend te worden. Intratumorale toediening was essentieel voor 
een goed effect. 
In hoofdstuk 6 wordt verslag gedaan van een microscopisch onderzoek van de cavia-
tumoren in verschillende fasen van behandeling met intratumorale PEG-IL-2 injecties in 
vergelijking met niet-behanddde tumoren. Voor de start van de behandeling waren er 
lymfbcyten in de directe omgeving van de tumor aanwezig. Bij een immunohistochemische 
kleuring bleek het met name te gaan om CD4* Τ lymfbcyten. Mogelijk is de gunstige 
reactie opgwekt door de PEG-IL-2 injecties een gevolg van activering van deze lymfocyten. 
Tijdens de PEG-^2 behandeling ontwikkelde zich een uitgebreide ontstekingsreactie met 
Τ lymfocyten, eosinofilie granulocyten, macrofagen en fibroblasten rondom tumor en 
regionale lymfeklieren. Met name CD8* Τ lymfocyten drongen daarbij door tot in de 
tumor, hetgeen suggereert dat cytotoxische Τ lymfocyten een rol spelen bij het opruimen 
van de tumor. De door ons waargenomen lage MHC klasse I expressie op de line-10 
tumorcellen is hiermee echter in tegenspraak, aangezien MHC klasse I expressie op de 
tumorcellen noodzakelijk is voor herkenning door CDS* Τ lymfocyten. 
Het behandelschema waarmee optimale resultaten werden behaald bij de cavia's is 
vervolgens onderzocht in de patiëntenstudie die beschreven is in hoofdstuk 7. Hiervoor 
werden patiënten geselecteerd bij wie na een aanvankelijk succesvolle behandeling met 
operatie en/of bestraling de tumor in het hoofd-halsgebied opnieuw was teruggekomen en 
voor wie er geen uitzicht meer was op genezing. Negentien patiënten gaven hun toestem-
ming voor deelname aan dit onderzoek en kregen 3 maal per week een injectie met een 
middelmatige dosis PEG-IL-2 rechtstreeks in de tumor, in kuren van 4 weken. De 
behandeling werd poliklinisch gegeven en werd goed verdragen. Er traden geen algemene 
ziekteverschijnselen op. Wel kregen 8 patiënten tijdelijk een zwelling met roodheid van het 
gelaat en/of de hals aan de kant van de injecties. Bij 7 van deze 8 patiënten werd tevens 
een tijdelijke stijging van het aantal eosinofide granulocyten in het bloed waargenomen. 
Het resultaat van de behandeling bestond eruit dat bij 1 patiënt de tumor volledig 
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verdween. Deze patiënt bleef 91 weken vrij van tekenen van ziekte. Bij 3 patiënten werd 
gedurende enige tijd (23 tot meer dan 57 weken) stilstand in de tumorgroei waargenomen. 
Deze 4 patiënten hadden allen één enkele tumorlokalisatie in de hals die van een beperkte 
omvang was. Opvallend was dat bij alle 4 de patiënten tijdens behandeling de boven-
genoemde lokale zwelling en roodheid optrad en dat zij de allerhoogste aantallen 
eosinofiele granulocytcn in het bloed vertoonden. 
Wij veronderstelden dat PEG-IL-2 na intratumorale toediening langer in de tumor en/of 
de regionale lymfeklieren aanwezig bleef dan IL-2. Om dit nader te onderzoeken werd een 
biodistributie studie uitgevoerd bij cavia's. Deze studie is beschreven in hoofibtuk 8. IL-2 
en PEG-IL-2 werden hiervoor radioactief gemerkt en intratumoraal ingespoten in line-10 
cavia-tumoren. Vervolgens werd op verschillende tijdstippen vastgesteld hoeveel activiteit 
aanwezig was in diverse weefsels. De uitkomsten leverden geen steun op voor de boven-
genoemde veronderstelling. Wel bleek PEG-IL-2 na intratumorale toediening hogere 
concentraties in het bloed op te leveren dan IL-2. De vraag is in hoeverre dit bijdraagt aan 
de sterkere anti-tumor werking van PEG-IL-2 dan van IL-2 na intratumorale toediening. 
In hoofdstuk 9 worden nog eens kon de resultaten van de hier beschreven en door anderen 
gepubliceerde onderzoeken met betrekking tot immunothérapie met IL-2 bediscussieerd. 
Geconcludeerd wordt dat door IL-2 op de plaats van de tumor te brengen in experimen-
tele dierentumoren een immunologische reactie gericht tegen de tumor opgewekt kan 
worden, die zowel lokaal als op afstand kan leiden tot afbraak van tumor. Zowel Τ 
lymfbcyten als andere, niet-specifieke immuuncellen lijken betrokken bij dit effect. In reeds 
uitgegroeide tumoren lijkt PEG-IL-2 effectiever dan IL-2. Of een dergelijke effectieve 
systemische immunologische reame ook bij kankerpatiënten opgewekt kan worden door 
intratumorale IL-2 toediening is nog de vraag. Patiënten met hoofd-halscarcinomen van 
beperkte omvang blijken in een enkel geval voordeel te hebben van lokale (PEG-)IL-2 
behandeling. Deze behandeling wordt goed verdragen. Er zijn tot nu toe geen aanwijzin-
gen verkregen in patiëntenstudies dat hogere doses lokaal toegediend IL-2 tot betere 
resultaten leiden. Het precieze werkingsmechanisme van lokale immunothérapie met IL-2 
in nog niet bekend. Dierexperimenten hebben meestal betrekking op tumoren in een heel 
vroeg stadium, terwijl er bij patiënten altijd sprake is van voortgeschreden ziekte. Een 
onderdrukt immuunsysteem, zoals beschreven bij kwaadaardige ziekten in een gevorderd 
stadium, zou mede verantwoordelijk kunnen zijn voor de beperkte effectiviteit van lokale 
IL-2 therapie bij patiënten met kanker. 
Appendix 
Jakobsson score, 
histopathological grading scheme for squamous-cell carcinoma1 
Histopathologic parameter Score 
Cytoplasmic keratinization 1 High degree, well-formed pearls 
2 Moderate, 20-S0% of cells, attempts at pearl formation 
3 Poor, 5-20% of cells with suggestion of keratinization 
4 No evidence of keratinization 
Nuclear differentiation 1 Few enlarged nuclei, >75% mature appearing 
2 50-75% mature appearing nuclei 
3 Considerable nuclear pleomorphem, 25% mature ap-
pearing 
4 Anaplastic tumor 
Mitosis, average number/HPF 1 0-1 
2 2-3 
3 4-5 
4 >5 
Inflammatory response 1 Continuous rim 
2 Pitchy rim 
3 Occasional patch 
4 None 
Vascular/lymphatic invasion 1 Not identified 
4 Identified 
Pattern of invasion 1 Pushing borden 
2 Solid cords 
3 Thin irregular cords 
4 Single cells 
HPF. high power field, 40x. 
1
 Crisman et al, Cancer 1984; 54:2995-3001. 
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Dankwoord 
Het dankwoord is ¿én van de best gelezen delen van een proefschrift, zoals u als lezer 
wellicht kunt beamen. Een goede zaak, want het doet recht aan de inspanning van de vele 
medewerkers die een promotie-onderzoek doorgaans kent. Zo ook dit onderzoek, dat tot 
stand is gekomen door samenwerking van diverse afdelingen, deels binnen en deels buiten 
het Academisch Ziekenhuis Nijmegen (AZN). Graag wil ik allen danken die hieraan 
hebben bijgedragen: 
Medewerken afdeling Medische Oncologie, AZN, 
met name Pieter de Mulder, die de initiator was van dit onderzoek en in de moeilijke 
fasen steeds een rots in de branding bleek. Riet Verstraten heeft steeds actief meegezocht 
naar oplossingen voor mijn vragen en mij veel uitleg en praktische ondersteuning gegeven. 
Prof. Wagener ben ik erkentelijk voor de mogelijkheid die mij werd geboden op zijn 
afdeling onderzoek te verrichten. Kees Punt dank ik voor het kritisch lezen van een deel 
van het manuscript. 
Medewerkers afdeling Pathologie, AZN, 
jullie afdeling was 4 jaar lang mijn "tweede thuis" binnen het AZN. Prof. Dirk Ruiter wil 
ik graag danken voor zijn stimulerende begeleiding, heldere commentaren en leerzame 
onderricht achter de microscoop. Lia Schalkwijk dank ik hartelijk voor het deskundige en 
nauwgezette immunohistochemische werk, maar vooral ook voor haar vriendschap. 
Medewerkers Laboratorium voor Pathologie, RIVM, Bilthoven, 
met name Peter Steerenberg en Lianne Balemans: jullie enthousiaste en daadkrachtige inzet 
bij het plannen en uitvoeren van de dier-experimenten heeft een onmiskenbare impuls 
gevormd voor het gehele project. 
L·den Nijmeegse Werkgroep voor Hoofd-Hahtumoren, 
Prof. Paul van den Broek en Ingolf Bruaset, als vertegenwoordigers van de secties KNO en 
Mond-Kaakchirurgie, dank ik voor de medewerking van beide afdelingen waarop ik steeds 
kon rekenen. Prof. Hans Manni wil ik graag danken voor zijn actieve participatie in de 
klinische en histologische studies en voor het screenen van de KNO-literatuur op rurnor-
immunologischc artikelen. De hulp van Frank Joosten bij de echografisch ondersteunde 
injecties en evaluaties heb ík zeer gewaardeerd. 
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Oncologen en KNO artsen van de andere participerende ziekenhuizen, 
zonder hen hadden de twee klinische studies niet voltooid kunnen worden. Met name wil 
ik noemen: Alexander De Gracff, Ac?demisch Ziekenhuis Utrecht, Pierre Hupperets, 
Academisch Ziekenhuis Maastricht, Jan Schornagel, destijds Academisch Ziekenhuis 
Utrecht en Jaap Verweij, Dr. Daniel den Hoed Kliniek Rotterdam. 
Medewerkers aftUling Nucleaire Geneeskunde, AZN, 
het biodistributie-vraagstuk was bij hen in zeer deskundige handen. Prof. Corstens bood de 
mogelijkheid dit deel van het onderzoek te realiseren. Otto Boerman dank ik voor zijn 
actieve betrokkenheid tot het allerlaatste moment. 
Medewerkers afdeling Klinische Farmacie, AZN, 
zij hebben de vele interleukine injecties steeds weer op tijd klaargemaakt, waarvoor ik hen 
hartelijk dank. 
Medewerkers "afdeling transmurale zorg", 
Bart Berden, manager thuiszorg, dankzij jouw inspanningen kan dit werk met recht deel 2 
in onze serie heten. De room-service van mijn altijd toegewijde ouders en de aangename 
afleiding waarvoor mijn vrienden zorg droegen, completeerden een werkbare situatie. 
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Curriculum vitae 
Ven Mattijssen werd op 27 januari I960 te Bern mei geboren. In 1978 behaalde zij het 
Gymnasium-ß diploma aan het Katholiek Gelders Lyceum te Arnhem. Aansluitend 
studeerde zij Geneeskunde aan de Katholieke Universiteit te Nijmegen. Het artsexamen 
werd behaald in januari 1986. Vanaf 1 februari 1986 was zij werkzaam als arts-assistent in 
opleiding tot internist, aanvankelijk in het St. Maartens Gasthuis te Venlo (opleider Dr. 
JJ . Mattousch) en vanaf 1 februari 1988 op de afdeling Inwendige Ziekten van het St. 
Radboudziekenhuis te Nijmegen (opleiders: Prof. Dr. A. Van 't Laar en Prof. Dr. J.W.M. 
Van der Meer). Van 1 juni 1989 tot 1 juni 1993 werd de opleiding onderbroken en 
werkte zij op de afdeling Medische Oncologie van het St Radboudziekenhuis (hoofd: Prof. 
Dr. D.J.Th. Wagener). In die periode werden onder meer de onderzoeken verricht die 
beschreven zijn in dit proefschrift. In mei 1991 bezocht zij het Massachusetts General 
Hospital te Boston (USA) in het kader van een uitwisselingsprogramma voor arts-assisten-
ten. De opleiding tot internist zal worden afgerond op 1 augustus 1994. 
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Stellingen 
behorende bij het proefschrift 
Locoregional immunotherapy with interleukin-2 
in head and neck squamous-cell carcinoma 
Preclinical and clinical studies 
Vera Mattijssen, 10 mei 1994 
1. In diverse experimentele tumormodellen is de werkzaamheid 
aangetoond van intra- of peritumorale toediening van relatief lage 
doses IL-2 aangaande het opwekken van een effectieve antitumor 
immuunrespons. 
2. Herhaalde intratumorale injectie van PEG-IL-2 kan cavia's met een 
palpabele line-10 tumor op de flank en micromctastasen in de 
regionale lymfklieren genezen. 
3. Histologische analyse van line-10 tumorregressie onder invloed 
van intratumorale PEG-IL-2 toediening suggereert dat een complex 
van immuuncompetente cellen betrokken is bij dit antitumor effect. 
4. Op basis van de mogelijkheid tot interactie met CD8+ Τ lymfo-
cyten lijkt expressie van MHC klasse I door tumorcellen van 
belang bij (locale) immunothérapie met IL-2. Met immunohisto-
chemisch onderzoek is hiervoor in therapie-experimenten evenwel 
nog geen duidelijke bevestiging gevonden. 
5. Als circulerend IL-2 bijdraagt aan het antitumor effect van 
intratumorale (PEG-)IL-2 therapie dan heeft dat consequenties 
voor de vertaling van dierexperimentele behandelschema's naar de 
humane situatie. 
6. Het "garbage effect" in experimentele immunothérapie ("the obser-
vation that if a procedure can make animals sick enough, even 
their tumors will suffer") is niet van toepassing op locale IL-2 
therapie. 
J. Vaage, Immunol Lett 1989; 21:275. 
7. Een hoog percentage tumorcellen met membraneuze expressie van 
het epitheliale adhesiemolecuul E-cadherine is gerelateerd aan een 
gunstig klinisch beloop bij hoofd-hals plaveiselcelcarcinomen. 
8. Herhaling van instructie in primaire reanimatie om de zes maanden 
houdt de vaardigheden op een adequaat niveau. 
Bart Berden et ai, BMJ 1993; 306:1576-7. 
9. De voortschrijdende (sub)specialisatie stelt hogere eisen aan de 
communicatie tussen specialist en huisarts, zowel algemeen vak-
inhoudelijk als ook toegespitst op de individuele patiënt. In de 
opleiding tot specialist dient hieraan bijzondere aandacht te worden 
besteed. 
10. Opleiding van vrouwen is het beste anti-conceptiemiddel. 
Margaret Catley-Carlson, voorzitter Population Council. 
11. Het in het huidige Nederlandse bestel gelijkstellen van 
economische groei aan groei van welvaart getuigt van onvoldoende 
begrip voor mens en milieu. 
12. De wijze waarop in proefschriften partners doorgaans worden 
bedankt voor hun schijnbaar onvoorwaardelijke steun en begrip 
doet vrezen voor een verengd bewustzijn van promovendi ten tijde 
van de afronding van hun onderzoek. 



